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   SUMMARY 
 Zonulae Occludens (ZO) or tight junctions (TJ) are specialized plasma membrane 
domains that regulate the paracellular transepithelial permeability and prevent the inter-
mixing of apical and basolateral plasma membrane components. TJs consist of integral 
membrane proteins such as claudin, occludin and JAM proteins that are linked via 
cytoplasmic peripheral proteins e.g. ZO-1, -2 and -3 to the actin cytoskeleton. 
 This study identifies the roles of zonula occludens (ZO) proteins and characterizes 
their interacting partners. Novel proteins that interact with ZO-1 were identified using a 
yeast-two-hybrid screen. A gap junction protein, Connexin 45, and a member of p120 
catenin family, Armadillo velo-cardio facial syndrome (ARVCF), were identified and the 
functional significances of their interaction were analyzed. In the second part, TJ integral 
membrane protein, claudin-16, was shown to interact with ZO-1 and its role in TJ barrier 
function was analyzed. Mutations in claudin-16 have been linked to familial 
hypomagnesaemia with hypercalciuria and nephrocalcinosis (FHHNC), where affected 
individuals excrete excessive magnesium and calcium in the urine, leading to kidney 
stones and end-stage renal failure. The molecular mechanisms by which these mutations 
affect CLDN16 function were determined by analyzing their effect on intracellular 
transport and paracellular Mg2+ and Ca2+ transport. Interestingly, mutations associated 
with FHHNC could affect either the correct intracellular transport of CLDN16, or its 
function in paracellular ion transport. Chemical chaperones restored surface transport of 
some of the CLDN16 mutants analyzed, thus providing a possible therapeutic 
intervention for FHNNC.  
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CHAPTER 1: INTRODUCTION 
 Multi-cellular organisms are composed of organs and tissues with 
compositionally distinct and specialized fluid compartments that are important for 
development and functional maintenance of the organism.  Various cellular sheets that 
delineate these compartments function as barriers to maintain the distinct internal 
environment of each compartment. For example, blood vessels, renal tubules and 
peritoneal cavity are lined with endothelial, epithelial and mesothelial cells respectively. 
Each cell is mechanically linked with adjacent cells to maintain the integrity of the 
cellular sheet and to prevent the unregulated diffusion of molecules through the 
intercellular space.  
 Epithelial cells are polarized cells that have apical and basolateral plasma 
membrane domains and they adhere to each other through junctional complexes. These 
cells can have different types of intercellular junctions including tight junctions (TJ, 
zonal occludentes), adherens junctions (AJ, zonulae adherentes) and desmosomes 
(maculae adherentes) (Fig. 1). TJ and AJ make up the so-called junctional complex. TJs 
in epithelial cells encircle the apical border of the lateral membrane. They form an 
intracellular seal that acts as a barrier and fence to prevent paracellular diffusion and 
intermixing of proteins and lipids between the apical and basolateral plasma membrane 
domains, respectively. AJs and desmosomes are mechanically linked to AJ and 
desmosomes on neighboring cells as well as to the actin and intermediate filament 
cytoskeleton, respectively, providing strength and rigidity to the entire tissue. AJs can be 
localized to the vicinity of TJs (to form the so-called apical adhesion complex) or be 
distributed along the lateral membrane (reviewed by Matter and Balda, 2003 and Tsukita 
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et al., 2001). Gap junctions form intercellular pores that allow the diffusion of small 
hydrophilic molecules and ions to pass between cells. Desmosomes and gap junctions can 
be found along the lateral membrane, but in some tissues they are intercalated with TJs 
(Giepmans and Moolenaar, 1998; Navarro et al., 2005; Schluter et al., 2004; Toyofuku et 
al., 1998). Each of these specialized adhesion complexes communicate within each other 















































Fig. 1: Junctional complexes. (A) Schematic diagram of junctional complexes found in 
epithelial cells. Tight junctions are located in the apical most part of the lateral membrane 
Figure reproduced with permission from Macmillan Magazines Ltd (Tsukita et al., 2001). 
(B) Polarized epithelial cells such as ciliated pseudostratified columnar epithelium of the 
bronchus have distinct apical and basolateral plasma membrane domains with 
characteristic morphology, protein and lipid compositions and functions. Figure 





1.1: TIGHT JUNCTIONS 
1.1.1: Tight junction structure and morphology 
Tight junctions (TJ) or zonulae occludens are specialized plasma membrane 
domains that regulate the transepithelial permeability barrier of the paracellular pathway. 
Farquhar and Palade (1963) originally described TJs as the apical most junctional 
complex in a variety of epithelial and endothelial tissues.  
 In electron micrographs of ultra-thin sections, TJs can be viewed as a series of 
apparent fusion points between the outer leaflets of the plasma membrane of adjacent cell 
(Fig. 2A, B and C). At these “kissing points” the intercellular space is completely 
abolished (Stevenson et al., 1986), whereas in adherens junction and desmosomes the 
apposing membranes remain 15-20 nm apart (Tsukita et al., 2001). The movement of 
electron dense tracers is restricted by these points of membrane contact (Farquhar and 
Palade, 1963; Friend and Gilula, 1972). The morphology of TJs has been analyzed by 
freeze-fracture electron microscopy. Where a fracture occurs through the hydrophobic 
core of the lipid bilayer, TJs are seen as a complex network of fibrils that encircle each 
cell, with cell-cell contacts occurring between fibrils from adjacent cells (Stevenson and 
Goodenough, 1984)(Fig. 2D).  These observations led to the model where each TJ strand 
within a plasma membrane laterally and tightly associates in trans with another TJ-strand 
in the apposing membrane of an adjacent cell to form a paired strand completely 
obliterating the intercellular space (Fig. 2C). The number of TJ strands as well as the 
frequency of their ramification vary from one cell type to another and are likely of 









Fig. 2: Structure of Tight junctions. (A) Electron micrographs of a junctional complex 
of mouse intestinal epithelial cells with the TJ circled. (B) Ultra thin sectional view of 
TJs. The “kissing points” where intercellular space is completely obliterated, are marked 
as arrowheads. Scale bar, 50 nm. (C) Schematic three-dimensional structure of TJs. Each 
TJ strand within the plasma membrane tightly associates in trans with another TJ strand 
from the apposing membrane of an adjacent cell to form a paired TJ strand. (D) Freeze-
fracture electron micrographs showing complex network of TJ fibrils (arrowheads). The 
abbreviations TJ, AJ, DS, Mv, Ap and Bl stand for tight junction, adherens junction, 
desmosomes, microvilli, apical and basolateral membrane, respectively. Figure 







1.2: Functions of Tight Junctions 
 
 Tight junctions function as selective permeability barriers that restrict the free 
diffusion of molecules through the paracellular space between adjacent cells (Fig. 3). 
Selected molecules can cross the epithelial or endothelial barriers via two highly 
regulated and selective pathways, the transcellular and paracellular routes. The barrier 
function of TJ can be demonstrated by the inability of lanthanum hydroxide (a high MW 
electron dense colloid) injected into pancreatic blood vessel of experimental animals or 
added to the basolateral sides of epithelial cell monolayers in culture to penetrate past the 
TJ (Contreras et al., 1992). Similarly, horseradish peroxidase, added either to the apical 
















Fig. 3: Transcellular and Paracellular pathways. Transcellular transport occurs 
through cells and is an active process that is dependent on channels and pumps, or 
receptors. Paracellular transport is a passive process that occurs between cells and is 
driven by electrochemical gradients and regulated by TJs (Figure adapted from Tsukita et 
al., 2001). 
  
Tight junctions also function to prevent the diffusion of outer leaflet lipids and 
proteins between apical and basolateral domains, thus acting as a fence in the plane of 
plasma membrane. If two types of fluorescently labeled lipids were inserted into either 
apical or basolateral membranes, they fail to mix freely and are retained at the level of 
tight junction (Fig. 4C). If the TJ integrity is disturbed, for instance by chelating Ca2+ 
from the media, the fluorescent lipids in the apical surface will diffuse to the basolateral 
surface and vice versa. 
Cell-cell junctions have been shown to be involved in a number of signaling 
processes that regulate and maintain cellular functions. TJs also have roles in signal 
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transduction processes that regulate gene expression, proliferation and differentiation 




























Fig. 4: Barrier and Fence function of tight junctions. (A) and (B) illustrate the barrier 
function of TJ, where horseradish peroxidase is added either to the apical (A) or 
basolateral (B) side of epithelial monolayers and it is unable to diffuse beyond the tight 
junction. (C) Fence function of MDCK monolayers. Different fluorescent lipids were 
inserted in the apical or basolateral sides of MDCK monolayer. Diffusion of the different 






1.3: Models of Tight Junctions 
 Two types of models have been proposed to explain the features of TJ strands 
seen in freeze fractures (Fig. 5). TJ strands were proposed to be composed of either 
proteins (Cereijido et al., 1978; Chalcroft and Bullivant, 1970; Griepp et al., 1983; Polak-
Charcon et al., 1978) or lipids (Kachar and Reese, 1982; Kan, 1993; Pinto and Kachar, 
1982). In the ‘protein model’, TJ strands represent integral membrane proteins that 
polymerize linearly within the lipid bilayer with their extracellular domain contacting that 
of proteins in strands on adjacent cells (Fig. 5A). The ‘lipid model’, in contrast, depicts 
strands as cylindrical micelles with the polar head groups of the lipids directed inward 
and the hydrophobic tail immersed in the lipid matrix of the plasma membrane of both 
the contacting cells (Fig. 5B). However, the observation that fluorescently labeled lipids 
cannot diffuse from one cell to the next via TJs does not favour the lipid model (van 
Meer et al., 1986). In addition, modifying the length and degree of saturation of fatty 
acids in lipids had no effect on the TJ gate function (Schneeberger et al., 1988) and 
changing systemically the polar groups, the hydrophobic chain length, as well as 
cholesterol and sphingomyelin content had no influence on the transepithelial electric 
resistance (TER), the freeze-fracture morphology, the fence function or the distribution of 
the TJ protein occludin in MDCK (Madin Darby Canine Kidney) cell monolayers 
(Calderon et al., 1998). In support of the lipid model are FRET experiments, where 
photobleaching large areas of the cell membrane of MDCK cells that were previously 
loaded with a fluorescent lipid probe showed that the probes diffuse not only in the plane 
of the membrane of the same cell, but also to neighboring cells provided the temperature 
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is kept above the melting point of the hydrophobic side chains (Grebenkamper and Galla, 
1994).   
 An increasing body of evidence supports the notion that TJ strands are primarily 
made up of proteins. Protein synthesis inhibition was found to prevent TJ assembly in 
freshly trypsinzed cells (Griepp et al., 1983; Hoi et al., 1979) and TJ fibrils were resistant 
to detergent extraction (Stevenson and Goodenough, 1984). With the recent identification 
of TJ integral and peripheral proteins, the ‘protein model’ gained additional support. In 
particular, the identification of the TJ integral proteins, occludin and claudin, and the 
observation that overexpression of these proteins in MDCK cells increases TER of 
MDCK cell monolayers (Balda et al., 1996; Van Itallie et al., 2001) strongly implicate a 
central role for proteins in TJ function. However, the role of specific lipids in TJ strand 
formation cannot be totally excluded and indeed, it was recently shown that TJs share 
properties with lipid rafts (Nusrat et al., 2000b; Stankewich et al., 1996). Lipids could 
also serve as a source of second messenger such as diaglycerol is required for TJ 
assembly (Balda and Anderson, 1993). 
 
 
Fig. 5: Proposed protein and lipid models of TJs. The protein model (A) involves 
integral membrane proteins that polymerize within the lipid bilayers and interacts with 
proteins on neighboring cells. The lipid model (B) involves inverted lipid cylindrical 
micelles, which constitute TJ strands. Figure reproduced with permission from 




1.4: Protein components of TJ 
The protein components of TJ can be divided in at least four main groups based on 
their structure and/or function (Fig. 6): (1) Transmembrane proteins, e.g. occludins, 
claudins and Junction Adhesion Molecules (JAMs), (2) Peripherally associated 
scaffolding or adaptor proteins, e.g. ZO-1, -2, -3, MAGI-1, -2, -3 (Membrane associated 
guanylate kinase inverted), PAR3/6, cingulin, Pals-1 (Protein-associated with Lin Seven), 
PATJ (Pals-associated tight junction protein) and MUPP1 (Multiple PDZ Domain 
containing protein-1), (3) Signaling or regulatory proteins, e.g. Rab13, Rab3B, Sec6/8, 
aPKC, PP2A and PTEN, and (4) Transcriptional and post-transcriptional regulators, e.g. 
symplekin, ZONAB and HuASH.  
 
 
Fig. 6: The composition of tight junctions. Tight junction proteins are composed of 
integral membrane proteins that are linked to the actin cytoskeleton via peripheral 
membrane proteins (Figure reprinted from Johnson et al., 2005 with permission from 
Elsevier). 
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1.4.1: TJ transmembrane proteins  
 Several integral membrane proteins have been identified in recent years and only 
three classes of integral membrane proteins, namely occludin, claudin and JAM proteins 
(Fig. 7), will be discussed here. Claudins and JAMs are protein families, with individual 
members showing distinct tissue distributions and functions, thus adding to the 
complexity and uniqueness of tight junctions in particular tissues. Other integral 
membrane proteins that have been identified but will not be discussed here in more detail 
include peripheral myelin protein (PMP22) (Notterpek et al., 2001), coxsackievirus and 
adenovirus receptors (CAR) (Cohen et al., 2001) and Protein O (P0) (D'Urso et al., 1999). 
 
   
 
Fig. 7: Integral membrane proteins of tight junctions. A schematic representation of 
the structure and membrane orientation of occludin, claudins and JAMs. Figure 







 Occludin was the first integral membrane protein to be identified by biochemical 
fractionation of TJ enriched from chicken liver (Furuse et al., 1993). The name of the 
protein is derived from the Latin word “occludere”, which means to occlude. Occludin is 
predominantly expressed in epithelial and endothelial cells, but can also be found in 
astrocytes and neurons (Barber et al., 2000; Bauer et al., 1999) and in dendritic cells 
(Rescigno et al., 2001).  
 
1.4.1.1.1: Occludin as a structural and functional component of TJ 
 Occludin was initially postulated to be involved in the formation of TJ fibrils and 
TJ function. Several lines of evidence contributed to this line of thinking. 
Immunostaining with antibodies against occludin in chick intestinal epithelia showed that 
it exclusively localized to the TJs (Furuse et al., 1993). Overexpression of chicken 
occludin in MDCK cells resulted in an increase TER and freeze fracture analysis showed 
that it was incorporated into TJ fibrils (Balda et al., 1996; McCarthy et al., 1996).  
The cDNA sequence of chicken occludin has an open reading frame coding for a 
protein 504 amino acids with a molecular weight of 60 kDa. Hydrophobicity plots of 
occludin predict that it spans the lipid bilayer four times and has two extracellular loops 
(Fig. 7). Occludin cDNAs from human, rat, mouse and canine have been cloned and the 
sequence between the species is well conserved (Ando-Akatsuka et al., 1996). There are 
two alternatively spliced variants, namely, occludin 1A and 1B, where 1B contains a 
unique 156 amino terminal region that replaces the first 15 amino acids in occludin 1B 
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(Mankertz et al., 2002; Muresan et al., 2000). However, the functional implications for 
TJ containing one or the other splice form are unknown. 
 Structural and functional studies show that the cytoplasmic C-terminus has at 
least two sub-domains. The membrane distal sub domain is highly charged and conserved 
across species and binds directly to zonula occluden proteins (ZO) (to be described later) 
(Furuse et al., 1994; Haskins et al., 1998; Itoh et al., 1999b). Occludin mutants lacking 
the distal domain fail to target to the TJ (Furuse et al., 1994) and a connexin-occludin 
chimera containing the N-terminal and transmembrane domain of connexin fused to the 
C-terminus of occludin localizes to the TJ (Mitic et al., 1999), suggesting that the distal 
C-terminal domain is required and sufficient for TJ targeting. The second membrane 
proximal sub-domain is less charged and shows less conservation across species and is 
not known to interact with other proteins (Ando-Akatsuka et al., 1996).  
 The extracellular domains of occludin have unusual amino acid compositions. 
The first loop lacks charged residues, has a high content in glycine (25 %) and tyrosine 
(36 %) residues, while the second loop has only a few amino acids with charged side 
chains.  The extracellular domains are thought to be involved in the interaction with 
occludin molecule on neighboring cells, creating a paracellular seal. However, targeting 
of occludin to the TJs could require pre-localized ZO-1 at the plasma membrane as 
overexpressing occludin in mouse L-cells, which lack TJ and AJ, did not localize to the 
plasma membrane. Whereas, in NRK and Rat-1 cells, which have plasma membrane 
localized ZO-1, overexpressed occludin localizes to the plasma membrane (Van Itallie 
and Anderson, 1997). This data is in contrast to that from two other studies, where 
occludin lacking the ZO-1 binding motif did not affect its localization to TJs in MDCK 
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cells, possibly due to the presence of endogenous occludin in these cells (Balda et al., 
1996). In addition, in ZO-1 null EpH4 cells, occludin recruitment to TJs was unaffected, 
possibly due to the presence of other ZO isoforms, e.g. ZO-2 and ZO-3, which might 
have some redundant roles (Umeda et al., 2004). 
 While there are several studies to implicate occludin as a functional component of 
TJ, embryonic stem cells (ES) lacking occludin and the occludin knockout mouse 
generated by Tsukita’s group had surprising results concerning the role of occludin in the 
complexity and function of TJ. Visceral endoderms differentiated from ES cells carrying 
a disrupted occludin gene had well-developed TJ strands (Saitou et al., 1998). This 
conclusively indicated that other unidentified molecules were responsible for TJ fibril 
formation. In addition, similar observations were made in occludin-null mice. The 
morphology of intestinal epithelial cells in 6-week old occludin null mice exhibited 
normal TJ strands and their barrier function was unaffected (Saitou et al., 2000). 
Occludin null mice had complex phenotypes like postnatal growth retardation and 
histological abnormalities in several tissues, for example chronic inflammation and 
hyperplasia of the gastric epithelium, calcification in the brain, testicular atrophy, loss of 
cytoplasic granules in striated duct cells of the salivary gland and thinning of the compact 
bone (Saitou et al., 2000). Using the same occludin null mice, another study showed that 
gastric acid secretion was almost abolished in these occludin null mice and this was 
paralleled by a dramatic change in gastric morphology with mucus cell hyperplasia and 
loss of parietal cells, suggesting that occludin might be involved in gastric epithelial 
differentiation (Schulzke et al., 2005). These results suggest that occludin probably has 
more complex roles than previously thought. More importantly, the presence of well-
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developed TJ strands and the largely unaffected barrier function in these occludin null 
mice indicate that other molecules are responsible for the TJ strand formation and barrier 
formation.  
 
1.4.1.1.2: Protein-protein interactions of occludin 
 Occludin is thought to be involved in signaling functions rather than playing 
structural roles at the TJ. Recently occludin was found to interact with TGF-β receptor I 
(Barrios-Rodiles et al., 2005). The C-terminus of occludin is capable of interacting 
directly with the actin cytoskeleton (Wittchen et al., 1999), a property that is not shared 
with other TJ integral membrane proteins. Occludin also interacts directly via its C-
terminal with TJ scaffolding proteins, ZO-1, -2 and -3 (Furuse et al., 1994; Haskins et al., 
1998; Itoh et al., 1999b; Wittchen et al., 1999). Using the last 150 amino acids, which 
form α-helical coiled-coil structure, as bait peptide, it was shown that occludin interacts 
with itself through this domain (Nusrat et al., 2000a). Additionally, this region interacts 
with protein kinase C-ζ (PKC-ζ) and non-receptor tyrosine kinase c-Yes (Nusrat et al., 
2000a). The N-terminus of occludin has a type 1 WW binding motif (PPYP) that interacts 
with four WW motifs present in Itch, a E3 ubiquitin protein ligase that is involved in 











 The conclusion that there exist TJ proteins other than occludin responsible for the 
formation of TJ fibrils led to the identification of another class of integral membrane TJ 
proteins, Claudins. The word Claudin is derived from the Latin word Claudere, meaning 
‘to close’. Biochemical fractionation of a junction enriched chick liver preparation led to 
the isolation of claudin-1 and –2, which co-purified with occludin (Furuse et al., 1998a). 
Peptide microsequencing permitted the cloning of the cDNA for both proteins from a 
mouse cDNA library. Additional claudins were later identified. Claudin-3 and -4 had 
previously been identified and cloned as RVP1 (Briehl and Miesfeld, 1991) and CPE-R, 
respectively, and were found to be homologous to claudin-1 and -2.  
Claudins are a multi-gene family with 24 isoforms identified in humans to date. 
Fig. 7 and 8 shows the topology of claudins. Similar to occludin, claudins span the 
membrane four times and have two extracellular loops. They have a molecular mass of 
~23 kDa and the cytoplasmic regions and the second extracellular loop are considerably 
shorter than in occludin. The first extracellular loop of claudin is larger than the second 
and is thought to be involved in the homophilic interactions implicated in TJ formation. 
The WWCC motif (W-X (17-22)-W-X (2)-C-X (8-10)-C) within the first loop is 
conserved among all claudins (Fig 8). The C-terminal cytosolic tail varies in sequence 
among claudins and has putative phosphorylations sites. Except for claudins-12, -22 and 
–23, all other claudins have a C-terminal PDZ-binding motifs that interacts directly with 
PDZ domain containing proteins such as, ZO-1, -2 and -3 (Itoh et al., 1999a), PATJ (Roh 




Claudin genes show a varied expression pattern among tissues and cells (Table 1), 
with some claudins showing a very restricted tissue and cell type specific expression. 
Claudin-16, for example, is exclusively expressed in kidney (Simon et al., 1999) and 
claudin-11 in oligodentrocytes and Sertoli cells (Gow et al., 1999). 
 
   
  
Fig 8: Schematic representation of the structure and the membrane topology of 
claudins. The WWCC motif is conserved in all claudins. The first extracellular loop is 
longer than the second. Most claudins have a PDZ-binding motif in their cytosolic C-
terminal tail (Figure reproduced from Turksen and Troy, 2004 with permission from 











Table 1: Claudin gene family.  
 
 
(Table adapted from Tsukita et al., 2001) 
 
Claudin orthologues have been reported in mouse (Morita et al., 1999), rat (Briehl 
and Miesfeld, 1991), fly, frog (Behr et al., 2003), worm (Asano et al., 2003; Simske et 
al., 2003) and zebra fish (Kollmar et al., 2001). In the teleost Fugu rubripes genome, 56 
claudin genes have been annotated, of which 35 have been assigned to 17 mammalian 
genes and the remaining 21 are specific to the fish lineage, with many of the genes 
having a tissue or developmental specific expression (Loh et al., 2004). In addition, 
Tepass et al., 2003 and Anderson et al., 2004 updated on the claudins orthologues found 
throughout animal phyla. In Drosophila, the epithelial barrier is associated with the 
septate junction and the claudin homologs Megatrachea (Mega) (Behr et al., 2003) and 
Sinuous (Sinu) (Wu et al., 2004) are required for septate junction formation and barrier 
function. In C. elegans, five claudin-like genes CLC-1, -2, -3 and -4 (Asano et al., 2003) 
and VAB-9 (Simske et al., 2003), which resembles members of PMP-22 family (Simske 
et al., 2003), have been identified.  
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1.4.1.2.1:  Claudins as structural and functional components of TJs 
 Several studies indicate that claudins are the structural and functional components 
of TJs. Tagged claudins expressed in MDCK cells, which possess TJs, are selectively 
targeted and incorporated into pre-existing TJ strands (Furuse et al., 1998b). In L-
fibroblasts, which lack TJs, exogenously expressed claudin-1 and -2 were concentrated in 
sites of cell-cell contact and formed well-developed networks of the TJ strands. To 
further clarify the function of claudins, Clostridum perfringens enterotoxin (CPE) was 
used as claudin-4 was previously identified as a CPE-receptor (Katahira et al., 1997; 
Sonoda et al., 1999). The C-terminal half of the toxin (C-CPE) binds to claudin-4 and 
increased the membrane permeability by forming pores in the plasma membrane. MDCK 
I cells incubated with C-CPE caused claudin-4 to be selectively removed from TJs and 
degraded. After a 4 hr incubation with C-CPE, TJ strands disintegrated and their number 
and complexity were markedly decreased in a dosage-dependent manner. These findings 
provided the first evidence for a direct involvement of claudins in the barrier function of 
TJs (Sonoda et al., 1999).  
 Disassociation and re-aggregations assays of claudin-1 expressing L-cells 
revealed that claudins have Ca2+-independent adhesive activity. In contrast, occludin 
failed to have any adhesive activity in these assays. This showed that claudins are major 
adhesion molecules with adhesive activity in vivo (Kubota et al., 1999). TJs are not rigid 
structures, but rather the paired claudins strands within apposing membranes exhibit 
dynamic behaviour (Sasaki et al., 2003). In claudin-transfected L-cells, which lack 
endogenous claudins, the claudin paired strands are continually reorganized in the plane 
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of membrane, breaking and reassociating in an end-to-side and side-to-side fashion 
within minutes, always maintaining the integrity of the TJ (Sasaki et al., 2003). 
 Claudins can interact with each other in cis to form TJ paired strands and in trans 
with other claudin molecules of a strand from an adjacent cell to establish cell adhesion 
and form a seal (Fig. 9). However, in contrast to what the name TJ might implies, this 
seal is not absolutely tight but represents an aqueous pore. The emerging model is that 
claudins create charge selective pores in TJs through electrostatic properties of charged 
amino acids in their extracellular domains. The extracellular charges among the different 
claudins are highly variable, with isoelectric points ranging from 4.05 to 10.50 (Mitic et 
al., 2001). 
Significant evidence for the role of claudins as ion selective pores was provided 
when positional cloning identified paracellin-1 or claudin-16 as the gene responsible for 
familial hypomagnesaemia and hypercalciuria and nephrocalcinosis (FHHNC) (Simon et 
al., 1999). Patients suffering from FHHNC have compromised renal Mg2+ reabsorption, 
which occurs via a paracellular pathway and the identification of mutations in the 
claudin-16 gene directly implicates it as a paracellular Mg2+ selective pore or channel. 
With 24 claudins identified, each claudin probably has a unique charge and size 




    
Fig. 9: Creating a paracellular seal. Extracellular loops of a claudin associate with 
those of another claudin molecule from an adjacent cell to create a paracellular seal. 
Occludin molecules can likewise associate in trans (Figure reproduced from Van Itallie et 





















Indeed, several studies have recently confirmed that claudin pores are ion-and 
size-selective. Replacement of negative for positive charges in the first extracellular loop 
of claudin-15 converts claudin-15 pores from a cation to an anion selective channel 
(Colegio et al., 2002). Further evidence came from experiments using two strains of 
MDCK (Madin Darby Canine kidney) cells. MDCK I cells have a high transepithelial 
resistance (TER > 1000 Ω.cm2) than MDCK II cells (TER < 100 Ω.cm2) but analysis of 
TJ fibrils showed no difference between the two strains (Stevenson et al., 1988). 
However, when MDCK I cells, which lack claudin-2, were transfected with a claudin-2 
cDNA, the TER decreased to the level as that of MDCK II cells (Furuse et al., 2001). 
This finding supports the notion that the differential expression of claudins and the 
claudin repertoire may determine the known differences in paracellular permeability of 
different tissues.   
Claudin pores also discriminate by size and reported size-cutoffs range from 4-40 
Å (Diamond, 1978). Claudin-5 and -12 are expressed in brain endothelia and claudin-5 
null mice die within several hours of birth (Nitta et al., 2003). Despite the lack of 
claudin-5 in TJ strands in endothelial cells, these cells exhibited morphologically normal 
blood vessels with claudin-12 based TJ strands. Tracer and MRI experiments; however 
revealed that the blood brain barrier (BBB) was severally compromised for small (~ 800 
kDa) but not larger molecules. Thus, the claudin-5 knockout mice had BBB that acted as 








1.4.1.2.2: Model for claudins in ion- and solute permeability 
 How can the TJ barrier behave differentially towards ion and solute permeability? 
A current model is that charged-selective claudin pores form the barriers. If the net 
charge on the extracellular domains of claudins is negative, then cations gain entry 
through the TJ (Fig. 10a). However, non-charged solute permeability might occur by a 
different mechanism (Fig. 10b). Since it has been showed that TJ strands can dynamically 
break and reseal (Sasaki et al., 2003), non-charged solutes might cross TJs through 
temporary gaps formed during this dynamic process. If that is the case, it can be 
postulated that paracellular transport of charged and uncharged solutes should occur with 
different kinetics (Anderson et al., 2004). 
 
   
 
Fig. 10: Proposed model of ion and size discriminations and flux of charged and 
non-charged molecules. (Figure reprinted from Anderson et al., 2004 with permission 
from Elsevier).  
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1.4.1.3: Junction Adhesion Molecule (JAM) 
  The junction adhesion molecule, JAM (Fig. 7) is the first immunoglobin-like (Ig) 
molecule identified at TJs (Martin-Padura et al., 1998). It was originally characterized as 
the F11 platelet receptor for a stimulatory anti-platelet antibody (Kornecki et al., 1990); 
(Naik et al., 1995). It can be found at TJs of endothelial and epithelial cells and in a 
variety of circulating leukocytes including monocytes, neutrophills and B- and T-
lymphocytes (Liu et al., 2000; Williams and Rizzolo, 1997). There are four isoforms of 
JAM, namely, JAM -A, -B, -C and -D. JAM has a signal peptide and three distinct 
structural domains: an extracellular region that contains two variable Ig-like domains (VH 
and C2-type); a single transmembrane domain and a short intracellular tail with a classical 
type II PDZ binding motif (Martin-Padura et al., 1998). JAM-B and -C (but not JAM-A 
and JAM-D) contain two extra cysteine residues in the C2 fold. JAM-D only shows about 
10-14 % homology to the other isoforms. It also carries a PDZ type I instead of the type 
II motif present in other JAM isoforms. Recently, two additional Ig-superfamily members 
have been identified at TJs, the coxsackie and adenovirus receptors (CAR) (Cohen et al., 
2001) and endothelial cell-selective adhesion molecule (ESAM) (Nasdala et al., 2002). 
Both proteins are structurally similar to JAM proteins. 
 What roles do JAM proteins have at TJs? In contrast to claudins, exogenous 
expression of JAM-A in L-cells does not induce TJ strand formation (Itoh et al., 2001). 
Evidence for a role of JAM proteins in the formation of TJ and cell polarity came from 
identifying proteins that interact with the C-terminus of JAM-A. Several PDZ-domain 
containing proteins such as ZO-1 (Bazzoni et al., 2000; Ebnet et al., 2000); Ebnet, et al., 
2003), AF-6/afadin (Yamamoto et al., 1999), Partitioning defective protein-3 (Par-3) 
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(Izumi et al., 1998) and Multi-PDZ domain protein-1 (MUPP1) (Hamazaki et al., 2002) 
were shown to interact with JAM-A and other JAM isoforms. Fig. 13 shows two of the 
major protein complexes that occur in TJs. Of the JAM-interacting proteins, Par-3 
strongly suggests a role for JAM in TJ formation since Par-3 is a component of the 
evolutionally conserved Par3-aPKC-Par6 polarity complex (Fig. 11). Dominant negative 
mutants of all the three components in the Par3-aPKC-Par6 complex were found to 
structurally alter the TJ, reduce the TER, redistribute other TJ proteins and induce a loss 
of cell polarity (Nagai-Tamai et al., 2002; Suzuki et al., 2001; Yamanaka et al., 2001), 
showing that this complex is an essential component of TJs. JAM-A, which in the early 
stages of junctional complexes formation is found together with E-cadherin and ZO-1 
(Ebnet et al., 2001; Suzuki et al., 2002) has been suggested to act as a docking point for 
the attachment of the Par-3-aPKC-Par-6 complex (Ebnet et al., 2004).     
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Fig. 11: Interaction of two of the major protein complexes in the TJs. JAM proteins 
are part of both complexes (Figure reproduced from Turksen and Troy, 2004 with 
permission from Company of Biologists Ltd). 
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1.4.2: Peripherally-associated scaffolding proteins 
 The first TJ protein to be identified from mouse hepatocytes membrane fraction 
enriched in ribbon-like remnants of junctions was the zonula occludens (ZO-1) protein 
(Stevenson and Goodenough, 1984). Monoclonal antibodies were raised specifically 
against components of the junction-enriched fraction and one of the clones, R26.4C, 
recognized a 225 kDa protein named ZO-1 (Stevenson et al., 1986). In 1991, Itoh et al. 
reported the cDNA sequence of ZO-1, which was found to have homology with 
postsynaptic density protein PSD95 and tumor suppressor disc large (Dlg). Other ZO 
isoforms, ZO-2 (Jesaitis and Goodenough, 1994) and ZO-3 (Haskins et al., 1998) were 
later isolated as proteins that co-immunoprecipitated with ZO-1. ZO-1, PSD95 and Dlg 
are the founding members of the MAGUK protein family (membrane associated 
guanylate kinase) (Fig. 12).  
MAGUK family is characterized by the presence of three PDZ domains, one SH3 
domain and a guanylate kinase (GUK) homology domain that lacks kinase activity. ZO 
proteins also contain an acidic module and a proline-rich C-terminus (Woods and Bryant, 
1993). In addition to ZO proteins, other MAGUK proteins at TJ include Par-3, Par-6 and 
PATJ, which are part of the Par3-Par6-aPKC complex and the Crumbs-Pals-PATJ 
complex. Both complexes are crucial for the establishment and maintenance of cell 
polarity (Tepass et al., 2001). Both complexes are also directly involved in TJ assembly 





Fig. 12: The ZO protein family in TJ that are part of MAGUK family. Schematic 
diagram of ZO isoforms at the TJs. MAGUK proteins are characterized by the presence 
of PDZ, SH3 and GUK domains. 
 
1.4.2.1: PDZ domains 
PDZ domains have a molecular mass of 80-90 kDa and were first recognized as a 
novel structural motif in the postsynaptic density protein (PSD-95), the Drosophila Disc-
Large (Dlg) septate junction protein and the tight junction protein ZO-1. Although they 
were originally referred to as GLGF (after a conserved Gly-Leu-Gly-Phe sequence found 
within the domain) or DHR motifs (after Disc-large homology regions), they are now 
known by an acronym representing these three PDZ containing proteins (PDZ: PSD-
95/Dlg/ZO-1). PDZ domain has been identified in over 200 proteins and can be present 
as single or multiple copies within a single protein. They are found throughout phylogeny 
in bacteria, yeast and vertebrates (Ponting et al., 1997) and are the most common protein 
domains represented in sequenced genomes. A large number of PDZ-containing proteins 
have been found to associate with the plasma membrane.  
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1.4.2.2: Mechanism of binding and specificity of PDZ domains   
 Observation that the C-terminal tail of Shaker K+ channel binds to the second 
PDZ domain of PSD-95 demonstrated that PDZ-domains are protein-binding motifs (Kim 
et al., 1995). Mutational analysis showed this interaction required the C-terminal region, 
in particular a S/TXV motif, where the serine and threonine are in position -2, X being 
any amino acid and valine in position 0. Table 2 shows the consensus sequence of four 
classes of PDZ ligands that interact with PDZ domains. 
 
Table 2: PDZ domain classes and examples of PDZ ligands.  
 
 
(Table adapted from Baruch et al., 2001) 
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1.4.2.3: Structure and function of PDZ domain 
 The structural basis for the PDZ domain binding specificity became more 
apparent with x-ray crystallography of PDZ domains with their cognate peptide ligands. 
The first crystal structure solved was the PDZ 3 domain of PSD-95 (Doyle et al., 1996). 
PDZ domains are relatively small (~90 amino acids) and form a globular fold with the N- 
and C-termini in close proximity in the folded structure. It comprises of six β-strands 
(βA-βF) and two α-helices (αA and αB), which fold into a six-stranded sandwich or β-
barrel (Fig. 13).  
 
 
Fig. 13: Structure of PDZ3 domain of PSD-95 with a peptide ligand. (A) Ribbon 
diagram of the PDZ3 domains and the peptide is depicted in yellow. The peptide lies in a 
groove created by βB strand and αB helix and the C-terminus of peptide ligand lies in a 
hydrophobic area created by βA-βB carboxylate loop. (B) Hydrogen bonds between 
residues of PDZ domain and peptide ligand. Presence of a conserved GLGF motif in all 
PDZ domains, hence PDZ domains were originally referred to as GLGF motifs. The 
residues involved in PDZ domain depicted as dashed white lines and as orange for 
peptide ligand (Figure reproduced from Doyle et al., 1996 with permission from 




C-terminal peptides bind in a hydrophobic groove created by the βB strand and 
the αB helix and the carboxylate loop connecting βA and βB strand. The βA-βB 
connecting loop has the conserved GLGF motif that is important for hydrogen bond 
coordination with the C-terminal carboxylate (COO-) group and this loop is also referred 
to as a carboxylate-binding loop.  The last four residues in the C-terminus of the peptide 
ligand interact directly with the peptide-binding groove. The main chain atoms of the βB 
strand form hydrogen bonds with the peptide ligand and stabilize the interaction, which 
does not mediate any sequence specificity. The recognition of the carboxylate group in 
the C-terminus of the ligand seems to be important for PDZ binding. In the case of the 
PDZ 3 domain of PSD-95, the highly conserved positively charged Arg 318 and the main 
chain amides of the GLGF motif form hydrogen bonds with the terminal carboxylate 
group (Doyle et al., 1996). The side chain of the residue at position 0 projects into a 
hydrophobic pocket, explaining why PDZ domains preferentially bind to sequences 
ending with a hydrophobic group (e.g. valine, isoleucine or leucine) (Table 2). The 
residue at position -1 points away from the interaction surface, explaining the sequence 
variability tolerated at this position.   
The interaction between the first residue of helix αB and the side chain of the 
residue at position -2 is a critical determinant of PDZ binding specificity and the basis of 
PDZ binding classification (Table 2). In Class 1 domains, the position -2 is usually 
occupied by Thr or Ser and the side chain hydroxyl group forms a hydrogen bond with 
the N-3 nitrogen residue of a His residue in αB1. In Class II domains, hydrophobic 
residues occupy the position -2 and the αB position of the PDZ domain. Class III 
domains prefer negatively charged residues at position –2, where the carboxylate group 
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forms hydrogen bonds with a hydroxyl side chain of a tyrosine residue in the αB1 
position. PDZ domains exhibit a restricted range in specificity and stringency. For 
example, a single PDZ domain can bind to ligands from Class I and II domains. While 
the position -2 is the key determinant in PDZ-ligand interaction, other more N-terminal 
residues may also contribute to specificity of the interaction. Based on crystallographic 
data (Doyle et al., 1996), residues in position -3 directly contact the peptide binding 
groove and residues up to position -8 may also play important roles (Songyang et al., 
1997).  
Besides binding to the C-terminus of interacting proteins, PDZ domains can also 
interact via PDZ-PDZ interactions in a head to tail oligomerization, thereby forming 
homo- and hetero-oligomers, examples include GRIP (Dong et al., 1999), ZO-1 (Fanning 
et al., 1998a) and InaD (Xu et al., 1998). PDZ domains can also bind to internal S/TXV 
motifs that are conformationally constrained and structurally mimic a free C-terminus 
(Brenman et al., 1996; Gee et al., 1998). Furthermore, PDZ domains can bind to lipids or 
interact with other protein–binding motifs such as ankyrin repeats (Maekawa et al., 
1999), spectrin repeats (Xia et al., 1997) and LIM domains (Cuppen et al., 1998), 
although the structural basis of these interactions are still unclear (Fig.14). 
 PDZ domain containing proteins can contain multiple PDZ domains. In the case 
of MUPP1 protein, up to 13 PDZ domains (hence, its name Multi-PDZ domain 1) are 






Fig. 14: Possible modes of interaction of PDZ containing proteins. PDZ proteins can 
bind to C-terminal motifs of ligands or to an internal peptide motif. They can also hetero- 
or homo-dimerize with another PDZ protein and interact with lipids.  
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1.4.2.4: Roles of PDZ domains 
Several fundamental roles of PDZ domains have been established and these include: 
1. To localize ligands to the appropriate plasma membrane domain. This function can 
be observed in polarized cells like epithelial cells where PDZ domains have been found 
to localize specifically at apical, basolateral or junctional domains. For example, PDZ 
containing protein NHERF interacts and co-localizes with CFTR and Na+/H+ exchanger 
in the apical surface (Short et al., 1998).  
2. To cluster and anchor transmembrane proteins in specific domains. For example, 
deletion of the C-terminal PDZ binding motif in Shaker K+ channel eliminated co-
clustering and its interaction with PSD-95 and channel clustering (Kim et al., 1995). PDZ 
domains can also function in the recruitment of cytosolic ligands to the plasma membrane 
or specific subcellular domains. For example, the PDZ containing proteins syntrophin 
and nNOS interact via their PDZ domains and this interaction is important for plasma 
membrane localization. nNOS isoforms lacking PDZ domains fail to localize to the 
plasma membrane (Brenman et al., 1996) and nNOS is diffusely distributed throughout 
the cytosol in cells of syntrophin null mice (Kameya et al., 1999).  
3. To organize signaling pathways. PDZ domains proteins act as scaffolds or adaptors 
and can recruit different components of a signal transduction pathway. PDZ domains can 
couple membrane proteins with downstream signaling targets. For example, InaD has 
five PDZ domains and is a component of the Rhabdomere of Drosophila photoreceptors 
required for the phototransduction signal cascade. InaD interacts with and organizes 
several components of this cascade, which involve transmembrane proteins rhodopsin (a 
G protein), the TRP Ca2+ channel, protein kinase C and phospholipase C-β via one or 
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more of its five PDZ domains. This clustering creates a signaling complex, called 
transducisome that is important for the efficient phototransduction (Tsunoda et al., 1997).  
4. To oligomerize PDZ proteins. Several PDZ domain-containing proteins have more 
than one PDZ domain and some PDZ domains can specifically interact with the PDZ 
domains of a different protein. For example, while ZO proteins can interact with C-
terminal motifs of ligands, they can also heterodimerize. ZO-1 can form a complex with 
either ZO-2 or ZO-3 via PDZ-PDZ domain interaction (Wittchen et al., 1999). 
 
1.4.2.5: SH3 and GUK domains 
 SH3 domains are 50-70 amino acid domains that bind to PXXP sequences in 
other proteins. More recently, the SH3 domain in MAGUKs has been shown to interact 
with the guanylate kinase (GK) domains. The GUK domain is homologous to the enzyme 
guanylate kinase that catalyses the conversion of GMP to GDP at the expense of ATP. 
However, the GUK domains in MAGUK proteins are enzymatically inactive and rather 
appear to acts as protein-binding motifs (Kim et al., 1997). The SH3 domain can engage 
in inter- and intramolecular interactions with the GUK domain via a mechanism that does 
not involve the usual proline rich recognition sequence (Nix et al., 2000). 
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1.4.2.6: The ZO protein family 
1. ZO-1 protein 
 ZO-1 is a 225 kDa protein that localizes at TJs in epithelial, endothelial and 
neuronal cells such as Schwann cells. ZO-1 is also expressed in cells lacking TJs such as 
cardiac myocytes and fibroblasts (Itoh et al., 1991). ZO-1 is found in the cytoplasm or 
colocalizes with cadherins in non-epithelial cells that lack TJs like fibroblasts (Itoh et al., 
1991). The plasma membrane localization of ZO-1 is dependent on extracellular calcium 
and cell-cell contact (Siliciano and Goodenough, 1988).  
 At TJ, ZO-1 directly interacts with several TJ integral membrane proteins; its first 
PDZ domain associates with the C-termini of claudins (Itoh et al., 1999a) and its second 
and third PDZ domains interact with C-termini of JAMs (Ebnet et al., 2000). ZO-1 can 
also interact with occludin via its GUK domain (Fanning et al., 1998b; Schmidt et al., 
2001). Furthermore, ZO-1 interacts with ZO-2 and -3 via PDZ-PDZ domain interactions 
(Wittchen et al., 1999). Other TJ plaque proteins such as AF-6 (ALL-1 fusion partner at 
chromosome 6) and cingulin have also been shown to bind ZO-1 (Cordenonsi et al., 
1999; Yamamoto et al., 1999). The C-terminal proline rich domain binds to the actin 
cytoskeleton (Fanning et al., 1998a; Itoh et al., 1997; Wittchen et al., 1999). Thus, ZO-1 
appears to be a scaffolding protein that on one hand links transmembrane TJ proteins to 
the actin cytoskeleton and, on the other hand, recruits other scaffolding proteins as well 
as proteins involved in signaling.   
    
 52
ZO-1 was demonstrated to be a phosphoprotein (Anderson et al., 1988; Stevenson 
et al., 1989; Van Itallie et al., 1995); however the role of phosphorylated ZO-1 remains 
unclear. Sequence analysis of ZO-1 shows that it contains two lysine-rich stretches of 
amino acids, which might serve as putative nuclear localization signals (NLS): 95-
RRKKK99 and 490-KKKDVYRR497. Expression of a cDNA encoding only the first 200 
amino acids (which contain the first NLS) fails to localize to sites of cell-cell contact and 
accumulates exclusively within the nucleus (Anderson et al., unpublished; Kausalya and 
Hunziker, unpublished). ZO-1 also has three putative nuclear export signals (NES) 
(Gonzalez-Mariscal et al., 1999), suggesting that ZO-1 shuttles between the nucleus and 
the plasma membrane (Islas et al., 2002). Moreover, in cells with decreased cell-cell 
contact, ZO-1 is predominantly present in the nuclei (Gottardi et al., 1996). In addition, 
ZO-1 was found at process interdigitations of neighbouring cells and also in the nuclei in 
differentiated podocytes (Reiser et al., 2000). ZO-1 was also reported to translocate from 
the cell-cell junctions to the nuclei in podocytes following treatment with puromycin 
aminonucleoside (PAN), which causes podocyte injury and proteinuria in animal models 
(Rico et al., 2005). The PAN-induced podocyte injury stimulates ZO-1 shuttling to the 
nucleus suggesting that ZO-1 may transmit signals to the nucleus and regulate cellular 
responses to extracellular stresses (Rico et al., 2005). Furthermore, ZO-1 has been found 
to associate with a Y-box transcription factor, ZONAB, which, in a cell-adhesion 
dependent manner negatively, regulates Erb-B2 expression (Balda and Matter, 2000). 
This suggests a role for ZO-1 in a signaling pathway that, in response to cell-cell 
adhesion regulates epithelial cell differentiation and growth. 
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Several studies have correlated ZO-1 protein expression with the degree of 
tightness of the TJ. Entamoeba hystolytica toxin induces ZO-1 degradation and 
concomitantly increases TER and the paracellular flow across enterocyte monolayers 
(Leroy et al., 2000). Increased expression of ZO-1 stimulated by dexamethsone has been 
correlated with increased paracellular resistance (Singer et al., 1994; Zettl et al., 1992). In 
contrast, TER measurements in ZO-1 depleted EpH4 mammary epithelial cell-line did not 
yield any significant differences when compared with wild type cells, which could be due 
to the low TER values inherent to EpH4 cells as compared to MDCK cells. However, the 
establishment of a TJ barrier as measured by Ca2+ switch and tracer permeability 
experiments, was retarded to some extent and could be overcome by exogenous 
expression of ZO-1 in the ZO-1 depleted EpH4 cells (Umeda et al., 2004).    
 Three alternative splice variants of ZO-1, α, β, and γ have been identified, which 
are all located in the C-terminus. The spliced sequence in the α-form is an 80 amino acid 
domain. Although both the α+ and α− isoforms are expressed in endothelial and epithelial 
cells, the α+ isoform is more abundant in epithelial cells and the α− isoform is more 
predominant in endothelial cells. Expression of the two isoforms appears to correlate with 
the degree of TER since cells that express the α− isoform, such as podocytes and in 
Sertoli cells show low TER, whereas cells expressing the α+ isoforms normally show a 
higher degree to TJ tightness. Other splice variants including β1, β2 and γ are expressed in 
many tissues and their functional differences are largely unknown. 
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2. ZO-2 protein 
 ZO-2, a second member of the ZO family, was originally identified as a TJ 
protein that co- precipitates with ZO-1, an interaction later shown to occur via PDZ 2 
domain in both ZO-1 and ZO-2 proteins (Gumbiner et al., 1991; Wittchen et al., 1999). 
Like ZO-1, ZO-2 binds to TJ integral membrane proteins, including claudins (Itoh et al., 
1999b) and occludin (Itoh et al., 1999b) as well as to other peripheral TJ proteins like 
cingulin (Cordenonsi et al., 1999; D'Atri et al., 2002), α-catenin (Itoh et al., 1999b), 
protein 4.1 (Mattagajasingh et al., 1999) and to the actin cytoskeleton (Wittchen et al., 
1999). ZO-2 has the ability to shuttle between the nucleus and the plasma membrane. 
ZO-2 contains functional NLS (Jaramillo et al., 2004) and NES (Islas et al., 2002). In 
sparse MDCK cell monolayers, ZO-2 is present in the nuclei and co-localizes with the 
splicing factor SC-35 (Islas et al., 2002). Additionally, ZO-2 has been found to associate 
with the transcription factors Fos, Jun and C/EBP (Betanzos et al., 2004).  
 
3. ZO-3 protein 
 ZO-3 was identified as a 130 kDa protein that is present with the ZO-1/ZO-2 
complex (Haskins et al., 1998). The interaction with this complex occurs between the 
second PDZ domains of ZO-1 and ZO-3 and there is no direct binding between ZO-2 and 
ZO-3 (Wittchen et al., 1999). Like ZO-1 and -2, ZO-3 directly interacts via its PDZ 1 
domain with claudins (Itoh et al., 1999a) and via both its the amino and carboxyl halves 
to occludin (Haskins et al., 1998). The C-terminus of ZO-3 contains a class I PDZ-
binding motif that binds to the PDZ domain of PATJ (Roh et al., 2003) (Fig. 15). PATJ is 
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the mammalian homologue of Drosophila Disc-lost. PATJ knockdown results in 
mislocalization of ZO-3 to the lateral membrane (Michel et al., 2005).  
Unlike the other ZOs, the actin binding site of ZO-3 is located in the amino 
terminal half of the protein (Wittchen et al., 1999). ZO-3 also contains putative NLS 
(Gonzalez-Mariscal et al., 1999) and NES (Islas et al., 2002), although the presence of 
ZO-3 in nuclei has not been reported to date.  
 
 
Fig 15:  ZO-3 interacts with PATJ, which is part of the Crumbs-Pals-PATJ 
complex. PATJ also interacts with claudin-1, where it forms a link between the apical 
and tight junction components (Figure reproduced from Turksen and Troy, 2004 with 
permission from Company of Biologists Ltd). 
 
 56
1.4.3: Regulatory proteins 
Several regulatory molecules that localize at the TJ have been identified in recent 
years and are thought to play roles in TJ assembly and protein targeting. This also 
implicates TJs in signaling roles, in addition to their barrier and fence functions. Protein 
kinase C (PKC) has been suggested to be a major regulator of TJ formation (Balda et al., 
1991). Two atypical PKC isotypes, PKC ς and λ (Stuart and Nigam, 1995) and their 
interacting protein, ASIP (atypical PKC isotype specific interacting protein, the 
mammalian orthologue of C.elegans PAR-3) (Izumi et al., 1998) were shown to 
concentrate at TJs. 
Rabs are small GTPases generally thought to participate in the control of vesicular 
transport steps. Rab13 (Zahraoui et al., 1994) and Rab3B (Weber et al., 1994) are 
associated with TJs. Rab13 is recruited from cytoplasmic pool to cell-cell contacts at 
early stages of TJ assembly, suggesting that rab13 might be involved in regulating the 
assembly of cell-cell junctions (Zahraoui et al., 1994); (Sheth et al., 2000). In addition, 
overexpression of rab13 mutants impaired the cell-surface transport of claudin-1 but not 
LDLR and p75NTR, suggesting that rab13 specifically directs the cell surface transport 
of claudin-1 and possibly other TJ integral membrane proteins (Yamamoto et al., 2003). 
Mammalian homologues of the yeast Sec6/8 gene products were also found to be 
concentrated at the cytoplasmic face of TJs (Grindstaff et al., 1998). The Sec6/8 complex 
is part of the exocyst and is required for specific vesicle targeting to the bud in yeast or 
for different forms of secretion in mammalian cells, including transport to the basolateral 
surface in epithelial cells (Huber et al., 1993).  
 57
AF-6 (ALL-1 fusion partner at chromosome 6) is another regulatory protein 
localized at the TJs. The PDZ domain containing AF-6/afadin protein was originally 
identified as a Ras target (Kuriyama et al., 1996) and it has two Ras-binding domains. 
AF-6/afadin forms a complex with ZO-1 (Yamamoto et al., 1999) and JAM (Ebnet et al., 
2000) at TJs in epithelial cells.  AF-6/afadin is also recruited to nectin-based adherens 
junctions (Mandai et al., 1997), where a novel cell-cell adhesion complex containing 
nectin, AF6 and ponsin can be found (Asakura et al., 1999). Nectin is a member of the 
immunoglobin superfamily and associates with AF-6 through its C-terminal PDZ-binding 
motif (Takahashi et al., 1999). Ponsin binds to the proline rich region of AF-6 through its 
SH3 domain and ponsin connects this adhesion complex to the cadherin-catenin based 
adherens junction complex (Mandai et al., 1997). While the exact mechanisms of AF-
6/afadin signaling are still unclear, the AF-6/nectin complex is thought to be involved in 
the establishment of intercellular junctions (Zhadanov et al., 1999); Ikede et al., 1999). 
1.4.4: Transcriptional and post-transcriptional regulators 
Evidence for a role of TJ in the regulation of gene expression in response to cell-
cell adhesion cues came from the discovery of several transcription factors that localize 
to TJs.  
ZONAB (ZO-1 associated nuclei acid binding) binds to the SH3 domain of ZO-1 
and it is a Y-box TF that binds to inverted CCAAT box sequences. ZONAB localizes to 
the TJ of MDCK cell at high cell density, conditions where cells contain high ZO-1 and 
low ZONAB levels. In contrast, at low cell density with low ZO-1 and high ZONAB 
protein levels, ZONAB is found in the nuclei. ZONAB negatively regulates the 
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expression of a proto-oncogene Erb2, in a cell density dependent manner (Balda and 
Matter, 2000). 
Several other transcription factors have been detected at TJs. HuASH-1 is 
homologous to Drosophila Ash-1 (absent, small or homeotic disc-1), a transcription 
factor that is involved in regulating homeotic gene expression during development. 
HuASH co-localizes with TJ proteins at cell-cell junctions but it is not clear how TJs 
contribute to regulation of huASH-1 mediated transcription (Nakamura et al., 2000). As 
indicated above, Fos, Jun and C/EBP can localize to TJ through their interaction with 
ZO-2 (Betanzos et al., 2004), but the functional significance of this interaction is not 
known. 
1.5: Assembly of Tight Junctions 
The assembly of tight junctions requires the spatial cues and the coordination of 
several junctional proteins such as cadherins, Par3/6/aPKC complex and 
Crumbs/Stardust/PATJ complex.   
In the early stages of cell-cell contact formation, migrating cells protrude 
lamellipodia and filopodia at the leading edge of the cell (Fig 16A). The formation of 
adherens junctions appears to precede the formation of TJs (Mitic and Anderson, 1998). 
The initial cell-cell contact between two epithelial cells requires nectin or E-cadherin 
adhesion molecules. E-cadherin mediated adhesion is dependent on Ca2+, while nectin is 
a Ca2+-independent immunoglobin-like adhesion molecule (Takahashi et al., 1999). E-
cadherin or nectin molecules first bind to their respective partners on the adjacent cell 
surface in a homophilic manner, following which ZO-1 and JAM but not occludin are 
recruited to the spot-like primordial adherens junction at the tips of cellular protrusions 
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(Fig. 16) (Adams et al., 1996; Adams et al., 1998; Ando-Akatsuka et al., 1999; 
Yonemura et al., 1995). Other TJ proteins, in particular occludin and claudins, are 
gradually recruited to ZO-1 complexes. Par-3, -6 and aPKC are recruited by JAM-A, 
which might serve as a docking platform for the attachment of the Par-3-aPKC-Par-6 
complex (Fig. 16), where overexpression of this complex results in delay in tight junction 
assembly (Nagai-Tamai et al., 2002; Suzuki et al., 2001; Yamanaka et al., 2001). As 
polarization matures, ZO-1 and associated proteins segregate from AJs to the newly 
developing tight junctions (Asakura et al., 1999; Yonemura et al., 1995). Apical cues 
provided by the Crumbs-Pals-PATJ complex are said to play a critical role in building 
tight junctions. Overexpression of Crumb-3 results in a delay in TJ assembly much like 
the case with overexpression of Par3-Par6-aPKC complex (Lemmers et al., 2004).  
However, PATJ is thought to play a predominant role as overexpression of PATJ results 
in mislocalization of Pals, ZO-1 and also the Par3-Par6-aPKC complex (Hurd et al., 
2003), indicating that PATJ could play a general role in building to tight junctions. In 
PATJ knockdown, Pals1 no longer associates with TJ and ZO-3 and occludin are 
mislocalized to the lateral membrane (Michel et al., 2005). These results suggest that 
PATJ might acts as a stabilizer to localize occludin and ZO-3 to the basal side of tight 
junction.  
In fully polarized epithelial cells, TJs and AJs can be distinguished at the 








Fig.16: Stages of cell-cell contact and polarization. (A) Cells with no cell contact have 
lamellipodial and filopodial protrusions at the leading edge of the cell. (B) Initial cell 
contacts at the tips of protrusions result in the formation of primodial, spot-like adherens 
junctions or puncta and these structures are positive for E-cadherin, ZO-1 and JAM-A. 
(C) Cell-cell contacts mature and cell polarizes with more proteins specifically enriched 
at adherens junction (E-cadherin) and TJs (ZO-1, JAM-A). Occludin, claudins and Par-3 
and other proteins might appear at these later stages. The junctions start to segregate. 
Crumbs-Pals-PATJ complex are also involved in the building of tight junctions. (D) Cells 
are fully polarized with TJ and AJ (Figure reproduced from Ebnet et al., 2004 with 







1.6: Diseases linked to the TJ function 
A compromised TJ integrity has been implicated in a large number of different 
human diseases. In addition, a wealth of information can be obtained on the functions of 
TJ proteins based on knockout mice and mutations in genes of TJ proteins that are linked 
to human diseases. The myriad of diseases and abnormalities due to defects in various TJ 
proteins illustrates the importance of TJ, both during development as well as for the 
maintenance of normal physiological functions.  
 
1.6.1: Diseases associated with TJ peripheral proteins 
 Most of the TJ peripheral proteins have functions in scaffolding, regulation and 
gene expression. In recent years, several of these proteins has been identified as targets of 
viral oncoproteins or associated with tumor progression. 
 Table 3 summaries some of the diseases associated with TJ peripheral proteins. 
Briefly, ZO-1 has been shown to be down-regulated in poorly differentiated, highly 
invasive breast cancer lines (Sommers et al., 1994) and the gene encoding ZO-1, tpj-1, is 
found near a genomic interval showing frequent loss of heterozygosity (LOH) in 70% of 
metastaic tumors (Mohandas et al., 1995; Wick et al., 1996).  
Other peripheral proteins like MUPP1 and MAGI proteins are targets of viral 
oncoproteins of human papillomavirus (HPV) and adenovirus (Glaunsinger et al., 2000); 
(Thomas et al., 2001); (Lee et al., 2000). c-kit, another oncoprotein, binds to MUPP1 
(Mancini et al., 2000), while MAGI-1 is a substrate of Ras (Dobrosotskaya et al., 1997). 
AF-6/afadin is also a substrate of Ras and it is involved in acute myeloid leukemia as an 
ALL-1 fusion partner (Yamamoto et al., 1999).  
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1.6.2: Diseases associated with TJ integral membrane proteins 
 Table 4 highlights the diseases associated with TJ integral membrane proteins. 
Mutations in claudins were the cause of at least two human diseases. Based on knockout 
and transgenic mice studies other TJ integral membrane proteins may also be potential 
candidates in human diseases. Claudin-16 (Paracellin-1) was identified by positional 
cloning of a mutated gene linked to familial hypomagnesaemia with hypercalciuria and 
nephrocalcinosis (FHHNC), a disease characterized by severe renal magnesium and 
calcium loss (Simon et al., 1999). Mutations in claudin-14 have been found to be a cause 
of deafness (Wilcox et al., 2001). 
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Overexpression and deletions of claudins demonstrate the importance of claudins 
in the TJ structure and permeability barrier. Claudin-11 expression is restricted to the 
myelin sheath of oligodentrocytes in the CNS and to Sertoli cells in the testis, the organ 
of Corti and collecting ducts in the kidney. Claudin-11 knockout mice show a complete 
loss of TJ fibrils in Sertoli and CNS myelin cells (Gow et al., 1999). Claudin-1 null mice 
died within 1 day of birth exhibiting wrinkled skin. The epidermal permeability barrier 
was severely compromised in these mice as determined by dehydration and trans-
epidermal water-loss assays (Furuse et al., 2002). Transgenic mice over expressing 
claudin-6 died within 2 days of birth due to the apparent lack of an intact epidermal 
permeability barrier. The deregulated expression of claudin-6 resulted in disturbances in 
epidermal differentiation genes, which might be the cause of retarded or disrupted 
epidermal differentiation (Turksen and Troy, 2002). Claudin-5 expression is restricted to 
endothelial cells and claudin-5 deficient mice had a selective increase in the permeability 
barrier for small molecules (Nitta et al., 2003). Several studies have suggested that 
expression of claudins is modulated in tumorigenesis, implicating them in tumor 
suppression (reviewed by Turksen and Troy, 2004). For example, claudin-23 is 
downregulated in gastric and breast cancers, while claudin-7 is downregulated in head 
and neck squamous cell carcinoma cell-lines (Kominsky et al., 2003).   
Some of the integral membrane proteins in TJs have also been reported to be 
targets of viral proteins. JAM is a receptor for reovirus (Barton et al., 2001), while CAR 
is a receptor for coxsackievirus and adenovirus (Cohen et al., 2001). Claudin-3 and -4 are 
receptors for the enterotoxin of Clostridium perfringens (CPE), which is a common cause 
for food poisoning (Fujita et al., 2000; Katahira et al., 1997).  
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    Table 4: Summary on diseases associated with TJ integral membrane proteins. 
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1.7: Model systems to study junction assembly and function 
1.7.1: General techniques 
1.7.1.1: Epithelial cells as a model cell system 
Epithelial cells were classically favoured in the study of TJs and AJs since they 
enable the analysis of polarity and junctional functions. Epithelial cell lines, in particular 
Madin Darby Canine kidney (MDCK) cells, are often used since when grown on 
permeable supports the cells form epithelial monolayers in culture that resemble a simple 
epithelium. The cells in these monolayers establish intact TJs and the polarized 
distribution of apical and basolateral membrane proteins is similar to that observed in 
cells in tissues in situ (Gonzalez-Mariscal et al., 1985). Furthermore, the cells mediate 
complex intracellular transport pathways characteristic for epithelial cells such as 
transcytosis, for example of polymeric Ig (Apodaca et al., 1994; Tamer et al., 1995). Two 
strains of MDCK cells have been established with functional and biochemical 
differences. Monolayers of strain I cells have a resistance of ~3000 Ω/cm2, while strain II 
cell monolayers are more ‘leaky’ with 50-100Ω/cm2 resistance. These differences in TER 
can be attributed to differences in the claudin repertoire, which however, does not affect 
the number and density of TJ fibrils (Stevenson et al., 1988). MDCK cells are easy to 
grow on permeable polycarbonate filters and can be transfected stably or transiently with 





1.7.1.2:  Permeable supports  
As indicated above, studies on junctional assembly and function are generally 
performed with epithelial cells grown on permeable supports such as Costar Transwell 
(Corning) filters or Cyclopore cell culture inserts (Falcon) (Fig. 17A and B). Epithelial 
cells cultured on these permeable supports polarize and differentiate better than on 
plastic. Nutrients and growth factors have access to the basolateral surface through the 
permeable membrane. Once a confluent monolayer is established (usually within 3-4 
days), apical and basolateral plasma membrane domains and functional TJs are 
established. TJ and epithelial monolayer integrity can be monitored by measuring the 
TER to electric currents or using tracer flux experiments. Furthermore, antibodies or 
ligands specific to integral membrane proteins can be added to either the apical or 
basolateral compartments to study the distribution and transport of membrane proteins. 
By chelating calcium, the integrity of TJs can be compromised in situ, whereas adding 


























Fig. 17: Permeable supports use in the study of polarity. (A) Permeable supports such 
as Costar Transwell filters can be used to grow epithelial cell monolayers. (B) 
Monolayers of epithelial cells form a tight monolayers to create two distinct 
compartments: apical (luminal) and basolateral (serosal), allowing the analysis of 
polarity, paracellular and transcellular transport (red arrows) across the monolayers. (C) 
Epithelial voltohmmeter allows transepithelial electrical resistance (TER) measurements 




1.7.1.3: Immunofluorescence analysis for TJ protein localization 
Immuno-fluorescence analysis is often the method of choice for the rapid 
localization of junction-proteins and junction-associated proteins. In MDCK cells, TJs 
localize as discrete punctate structures to the apical end of lateral membrane in 
perpendicular (xz plane) sections. Given this distinct localization of TJs at the apex of 
lateral plasma membrane, immunofluorescence labeling and colocalization of a particular 
proteins with a well-established TJ marker using confocal microscopy is usually taken as 
good evidence for whether the protein in question localizes to TJs. ZO-1 is an excellent 
marker for TJs, while other TJ proteins such as JAMs and claudins are often also found to 
some extent on the lateral membrane (Hashizume et al., 2004). AJ proteins such as E-
cadherin usually run along the entire length of the lateral membrane. Real time imaging 
of fluorescently tagged proteins is also used in live-cell imaging of TJ dynamics. Green- 
or red- fluorescent protein fused to tight junction proteins have shown that TJ strands 
undergo dynamic breaking and re-sealing within minutes (Sasaki et al., 2003).  
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1.7.2: Analysis of TJ function 
1.7.2.1: Analysis of fence function  
Integrity of the junctional fence is normally monitored by visualization or 
measurement of lipid or protein diffusion from one cell surface domain to the other. This 
can be accomplished by labeling one side of the monolayers (e.g. the apical or basolateral 
plasma membrane) with either a fluorescent lipid probe or lipid, for example BODIPY 
FL C5-spingomyelin (Balda et al., 1996) and monitoring if it can diffuse into the opposite 
domain. As a control, TJs can be compromised by chelating calcium, which will allow 




Fig. 18: TJ Barrier analysis. Diffusion barrier to BODIPY FL C5-spingomyelin added 
to the apical side of filter grown MDCK cells. Addition of EDTA disrupts the integrity of 
TJ, allowing BODIPY FL C5-spingomyelin to diffuse into lateral membrane (Figure 






1.7.2.2: Analysis of gate function  
Several techniques can be employed to analyze the gate function of TJ and the ion 
and charge selectivity of the paracellular transport.  
Ion permeability of TJs is generally determined by measuring the transepithelial 
electrical resistance (TER). This can be done on epithelial cells monolayer grown on 
permeable filters/supports using a hand-held voltohmmeter with chopstick-like electrodes 
(Fig.17C). Alternatively, polarized cultures can be mounted on Ussing chambers 
interfaced to a voltohmmeter, which permits the continuous measurements of 
transepithelial potential difference and TER. However, the major drawback in TER 
measurements is that both the transcellular and paracellular pathways are reflected. This 
can be overcome by blocking the transcellular ion transport across the apical membrane 
with specific inhibitors. Hydrophilic tracers can also be used to measure paracellular 
permeability. Tracers such as dextrans of different sizes (~4-400 kDa) can be 
fluorescently or radioactively labelled and their diffusion from the upper to the lower 




CHAPTER 2: Identification and characterization of proteins that 
interact with ZO-1 PDZ domains using yeast-two-hybrid 
 ZO-1 is said to be a tumor suppressor. Several studies have reported that a 
reduction of ZO-1 expression correlates with tumor dedifferentiation and a progression in 
breast and colon carcinomas where ZO-1 was found to be localized in the cytosol in 
breast carcinomas (Hoover et al., 1998; Kaihara et al., 2003; Martin et al., 2004). In 
addition, ZO-1 has been found to be over-expressed in primary and metastatic cancers. 
Expression of a ZO-1 construct lacking the GUK domain no longer localizes to the 
plasma membrane and induced a dramatic epithelial to mescenchymal transition (EMT) 
of MDCK-I cells (Reichert et al., 2000). This EMT is characterized by the repression of 
epithelial (i.e. E-cadherin) and induction of mesenchymal (i.e. fibronectin) marker genes, 
increased tumorigenicity in nude mice and an activation of β-catenin/Tcf/Lcf 
transcriptional activity. Furthermore, ZO-1 has been reported shuttle between the plasma 
membrane and nucleus under specific conditions (Gottardi et al., 1996).  Given these 
observations, ZO-1 might be involved in signaling pathways where de-localized ZO-1 
from TJs might give rise to tumor progression.  
In order to understand the functions of ZO-1, I sought to identify PDZ domain 
interacting proteins. The PDZ 1-3 domains of ZO-1 were used as bait in a yeast-two 
hybrid screen. One of the problems encountered in this approach was that a number of 
out-of frame cDNAs with prematurely terminated PDZ-binding motifs were isolated. 
Hence, only in-frame clones were followed up and putative interacting proteins were 
confirmed for interaction by immunoprecipitation, pull-down and immunofluorescence 
experiments. Two of the confirmed interacting clones code for a gap junction protein, 
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Cx45 (Connexin-45), and an adherens junction associated protein, ARVCF (Armadillo 
repeat gene deleted in velo-cardio facial syndrome) and were chosen for further analysis 
and characterization of their binding to ZO-1 as well as possible functional significances 






















Section 2.1: Connexin45 directly binds to the PDZ domains of ZO-1 and 
localizes to the tight junction region in epithelial MDCK cells 
2.1: Gap Junction and Connexins 
 
Intercellular communication is vital for individual cells to function in a 
coordinated manner in multicellular tissues and organisms. Gap junctions mediate 
intercellular communication by allowing the exchange of small molecules and ions 
without having to pass through the gaps that connect the cytoplasm of two adjoining 
cells. Gap junctions allow the movement of molecules < 1000 Da, such as glucose, 
nucleotides and second messengers (including cAMP and calcium) but not protein or 
nucleic acids (as reviewed by Kumar and Gilula, 1996) (Fig. 19). 
 Gap junctions exist in almost all cell types of multi-cellular organisms with the 
exception of skeletal muscles, and circulating cells (i.e. red blood cells and lymphocytes) 
(reviewed by Kumar and Gilula, 1996). 
 For a long time, gap junctions were considered to be passive conduits; however 
they are regulated by complex mechanisms that are currently being identified. These 
regulatory mechanisms include changes in the level of intracellular Ca2+, pH as well as 





Fig. 19: Gap junctions between neighouring cells where ions and cAMP molecules 
are transferred. Molecules such as proteins and nucleic acids > 1000 Da are not 




Gap junction proteins are composed of connexins (Cx). Cxs form a multi-gene 
family and at least 20 members have been identified in humans (Willecke et al., 2002). 
Two nomenclature systems are in usage, one commonly favored is based on the 
molecular mass of the connexin, the other based on evolutionary considerations (Kumar 
and Gilula, 1996). The importance of gap junctions can be observed in several 
physiological processes such as the rapid transmission of action potentials in the heart 
and in neuronal tissue, where the rapid and coordinated intercellular diffusion of 
metabolites and nutrients such as nucleotides, glucose and second messengers such as 
Ca2+ and inositol-triphosphate (IP3) play an important role.   
Connexins span the transmembrane four times, with both N- and C-termini facing 
the cytosol (Milks et al., 1988; Yeager et al., 1998).  In mammalian cells, six connexins 
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form a hemi-channel or a connexon and two connexons on adjacent cells assemble in 
register into a channel (Fig. 20). Even though a gap occurs between adjacent cell 
membranes, two connexons interact and dock in the extracellular space to form a tightly 
sealed, continuous aqueous pathway for the movement of ions and molecules. A few to 
more than 105 connexons aggregate into tightly packed plaques to form gap junctions. 
Connexons may contain six identical connexins (homomeric connexon) or contain 
different connexin subtypes (heteromeric connexon). The ability to form homotypic or 
heterotypic channels that consist of 2 identical connexins and 2 different connexons 
generates diversity in terms of subunit composition, stiochiometry and the physiological 
properties of individual gap junctions. Several studies indicate that many connexins 
follow the general secretory pathway for their synthesis, assembly and trafficking (Falk et 
al., 1994); (Falk et al., 1997; Musil and Goodenough, 1991). Connexins have relatively 
short half-lives of 1-3h in cultured cells (Laird et al., 1995).  
 
 
Fig.20: Gap Junction Structure. Six connexin molecules form one connexon that docks 




 In the yeast-two hybrid screen to identify proteins that associate with the PDZ 
domains of ZO-1, a member of the connexin family, Cx45 was identified as a binding 
partner of ZO-1. Previously, another gap junction protein, Cx43 has been shown to 
associate with ZO-1 (Giepmans and Moolenaar, 1998; Toyofuku et al., 1998) 
 
Section 2.2: Results 
Section 2.2.1: The C-terminus of Cx45 interacts with the PDZ domains of 
ZO-1 and ZO-3 in a yeast two-hybrid assay 
To identify proteins that interact with the PDZ domains of ZO-1, a yeast two-
hybrid screen was carried out using a mouse 17-day embryo cDNA library. Sequencing 
of positive clones revealed cDNAs encoding the C-terminal coding region of connexin 
45. One Cx45 clone encoding amino acids 315-396 fused in frame to the Gal4 
transactivator domain was selected for further characterization. In addition to the PDZ 
domains of ZO-1, the Cx45 construct interacted with the PDZ domains of ZO-3, but not 
with those of ZO-2 (Table 5), indicating that Cx45 did not indiscriminately interact with 
PDZ domains in general. No interactions were detected between the Cx45 construct and 
laminin, nor with an empty library vector encoding the Gal4 DNA binding domain.  
PDZ domains often interact via C-terminal amino acids motifs in transmembrane 
proteins and the C-terminal SVWI in Cx45 is reminiscent of type-1 PDZ binding motifs 
(Sudol, 1998). To test whether this motif was required for the interaction with the ZO-1 
PDZ domains, the four C-terminal residues were mutated to alanine. The mutant Cx45 no 
longer interacted with the ZO-1 PDZ domains in the two-hybrid assay (Table 5), 
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confirming the importance of the C-terminal SVWI in mediating the association. 
Together, these results show that in a yeast two-hybrid assay, the PDZ domains in ZO-1 
and ZO-3, but not those in ZO-2, interact with Cx45 via a C-terminal SVWI PDZ binding 
motif.  
 
Table 5: Interaction of the PDZ domains of ZO-1, ZO-2 and ZO-3 with a construct 
encoding a C-terminal region of Cx45 or a Cx45 mutant in which the SVWI amino acids 
encoding a putative PDZ-binding motif were mutated to alanine. Interactions were 
determined by monitoring growth of co-transformed yeast on selective media and β-
galactosidase activity. Similar results were obtained under low and high stringency 
conditions. Empty bait (pGBKT7) and library (pACT2) plasmids and a laminin construct 
served as negative controls. T-antigen (T-Ag) and p53, known to interact, were used as a 





 Cx45 Cx45 mutant Library vector Laminin  T-Ag 
ZO-1 PDZ +++ - - - nd 
ZO-2 PDZ - - - - nd 
ZO-3 PDZ +++ - - - nd 
Bait vector  - - - - - 
p53 - - - - +++ 
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2.2.2: Characterization of epithelial MDCK cells transfected with Cx45 
cDNA 
To confirm the two-hybrid results, I determined if full length ZO-1 was able to 
bind to full length Cx45 and whether this interaction occurred in vivo. For this purpose, 
epithelial MDCK cells, which endogenously express ZO-1, were stably transfected with 
either mouse Cx45 or the Cx45 mutant carrying an inactivated C-terminal PDZ-binding 
motif. Expression of the transfected Cx45 was characterized by Western blot analysis and 
immunofluorescence using an antibody to mouse Cx45. As shown in Fig. 21A, a 45 kDa 
band, corresponding to the apparent molecular weight of Cx45, was detected in cells 
transfected with the wild type (lane 2) or the mutant Cx45 (lane 3), but not in control 
MDCK cells (lane 1). The expression of Cx45 was confirmed by immunofluorescence 
microscopy (Fig. 21B). Cells expressing the wild type or the mutant Cx45 showed a 
punctate staining typical of connexons. Interestingly, the wild type, but not the mutant, 
Cx45 was concentrated at sites of cell-cell contact (Fig. 21B, arrows). 
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Fig.21: Characterization of MDCK cells expressing wild type or mutant Cx45. (A) 
Western blot analysis. Lysates of control MDCK cells (lane 1), or cells transfected with a 
mouse Cx45 cDNA (lane 2) or Cx45 mutant with an inactivated PDZ-binding motif in 
which the C-terminal SWVI residues were mutated to alanines (lane 3) analyzed in 
Western blot using a monoclonal Cx45 antibody. (B) Immunofluorescence analysis. 
Control cells or cells stably expressing wild type or mutant Cx45 were grown on 
coverslips and fixed, permeabilized and stained with Cx45 antibody. Arrows show the 




2.2.3: Cx45 directly associates with ZO-1 in vivo 
To confirm the two-hybrid interaction and to analyze if full-length Cx45 and ZO-
1 can also interact in vivo, co-immunoprecipitation experiments were carried out. MDCK 
cells expressing either wild type or mutant Cx45 were lysed and endogenous ZO-1 
precipitated using a polyclonal antibody. Immunoprecipitates were then analyzed by 
Western blot using an antibody to Cx45. 
As shown in Fig. 22, Cx45 did co-precipitate with ZO-1 from cells expressing 
wild type Cx45 (lane 2) but not from untransfected control cells (lane 1). Co-precipitation 
from two clones expressing different amounts of the mutant Cx45 was greatly reduced as 
compared to wild type Cx45 (lane 3 and 4), even though expression levels for mutant 
Cx45 were 3-4-fold higher than for the wild type protein (compare lanes 7 and 8 to lane 
6). Quantification of the co-precipitation experiments, taking into account the differences 
in expression levels, showed that the inactivation of the PDZ-binding motif in Cx45 
resulted to a ~20-fold reduction of the Cx45 that was associated with ZO-1. 
 While Cx45 readily co-precipitated with ZO-1, ZO-1 was not detected in Cx45 
immunoprecipitates, possibly due to a masking of the antibody epitope at the C-terminus 
of Cx45 by bound ZO-1. 
Thus, full length Cx45 and ZO-1 bind in vivo through a direct interaction, which 
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Fig.22: Cx45 directly interacts with ZO-1 via the C-terminal SWVI. Control MDCK 
cells (lane 1and 5) or cells expressing wild type (lanes 2 and 6) or mutant (lanes 3, 4, 7 
and 8) Cx45 were lysed and equal amounts of total protein we used to immunoprecipitate 
ZO-1 using a polyclonal antibody (lanes 1-4). Immunoprecipitates were then analyzed by 
Western blot using a monoclonal anti-Cx45 to detect Cx45 that was bound to ZO-1. An 
aliquot of the cell lysate was directly blotted (lanes 5-8) to determine the amount of wild 




2.2.4: Cx45 co-localizes with ZO-1 in the tight junction region in polarized 
MDCK cells 
Next, I determined if Cx45 and ZO-1 co-localize in fully polarized MDCK cell 
monolayers. MDCK were grown on permeable polycarbonate filters to obtain polarized 
cell monolayers with well-established tight junctions. Cell monolayers were fixed, 
permeabilized, stained with rabbit anti-ZO-1 and monoclonal mouse anti-Cx45 antibodies 
and further stained with suitable labeled secondary antibodies and visualized by confocal 
microscopy. Images for horizontal sections at the height of the tight junctions (Fig. 23, 
panels A-C) and vertical sections along the apico-basolateral axis (panels D-F) of the 
monolayer were acquired. 
 82
As shown in Fig. 23, control cells (panels A and D) as well as cells transfected 
with wild type (panels B and E) or mutant (panels C and F) Cx45 showed the typical 
localization of ZO-1 (red color) to tight junctions. No staining for Cx45 (green color) was 
observed in control cells (panels A and D), whereas cells transfected with wild type 
(panels B and E) or mutant (panels C and F) Cx45 showed a punctate staining. A 
significant degree of co-localization (yellow color) of Cx45 and ZO-1 was observed in 
cells transfected with wild type Cx45, whereas the co-localization of the Cx45 mutant 
lacking the PDZ-binding motif was strongly decreased. Nevertheless, mutation of the 
PDZ-binding motif in Cx45 did not completely abolish its co-localization with ZO-1 (see 
panel C, arrows). This suggests that localization of Cx45 to the tight junction area could 
be mediated by other mechanisms besides a direct association with ZO proteins (see 
discussion pg103). 
In conclusion, Cx45 was present with ZO-1 in the tight junction region of MDCK 









Fig.23: Cx45 co-localizes with ZO-1 to the tight junction region in MDCK cells. 
Control cells (panels A and D) and cells transfected with wild type (panels B and E) or 
mutant (panels C and F) Cx45 were grown on polycarbonate filters to obtain polarized 
cell monolayers. Cells were fixed, permeabilized and stained for Cx45 (green) and ZO-1 
(red). Confocal images were taken of horizontal sections at the height of tight junctions 
(panels A-C) or of vertical sections along the apico-basal axis of the monolayer (panels 
D-F). Cx45 extensively co-localizes with ZO-1 (yellow) at the level of tight junctions 
(panels B and E). Although the co-localization of the mutant Cx45 with ZO-1 is strongly 























Section 2.3: Discussion 
Using a yeast-hybrid assay, the C-terminus of Cx45 was shown to interact with 
the PDZ domains of ZO-1 and ZO-3, but not those of ZO-2. Full length Cx45 and ZO-1 
interact in vivo in MDCK cells based on co-immunoprecipitation and co-localization 
experiments. MDCK cells were chosen since, in contrast to the broad distribution 
throughout the area of cell-cell contact in osteoblasts or cardiac myocytes, ZO-1 is 
restricted to the discrete tight junction area, facilitating the interpretation of co-
localization experiments. The C-terminus of Cx45 encodes a classical PDZ-binding 
motifs and mutational analysis confirmed the requirement of the SWVI motif for the 
interaction between Cx45 and PDZ domains of ZO-1 and ZO-3.  
Although mutation of the SWVI sequence dramatically reduced the fraction of 
Cx45 that co-precipitated with ZO-1, the interaction was not completely abolished, 
suggesting that the mutant Cx45 might be able to associate with ZO-1 via an alternative 
mechanism. Since different connexins can assemble into a single connexon, Cx45 may be 
incorporated into heteromeric connexins containing a second connexin able to bind to 
ZO-1. Indeed, MDCK cells express Cx43 (Berthoud et al., 1992), which is known to 
form heteromeric connexons with Cx45 (Kanter et al., 1993) and to interact with ZO-1 
(Giepmans and Moolenaar, 1998; Toyofuku et al., 1998). Thus, although mutant Cx45 
can no longer bind ZO-1 directly, it may still associate indirectly via Cx43. Mixed 
Cx43/Cx45 connexons likely also account for the occasional, albeit significantly reduced, 
detection of mutant Cx45 in the tight junction region. The findings obtained in this study 
were confirmed by a second study, where Cx45 was shown to interact with the PDZ2 
domain of ZO-1 and with Cx43 in osteoblast cells (Laing et al., 2001). 
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Several other members of the connexin family also encode putative PDZ-binding 
motifs at their C-termini and recently Cx31.9 (Nielsen et al., 2002), Cx32 (Kojima et al., 
2001), Cx36 (Li et al., 2004), Cx46 and Cx50 (Nielsen et al., 2003) were also shown to 
interact with ZO-1 in various cell lines.  
The functional relevance of the association between ZO-1 and connexins remains 
poorly understood, but the growing number of connexins that interact with ZO-1 suggests 
that the interaction plays an important role, possibly in targeting or localizing connexins 
to specialized plasma membrane domains. Indeed, different connexins are restricted to 
specialized plasma membrane domains in different cell types, including granulosa cells 
(Simon et al., 1997), Schwann cells (Bergoffen et al., 1993; Scherer et al., 1998) and 
cardiac myocytes (Toyofuku et al., 1998). Interestingly, Cx45 is expressed in endothelial 
cells, which often form ZO-1-containing tight junctions, and mice deficient for Cx45 
show severe defects in blood vessel maturation (Kojima et al., 1999).  
ZO proteins may also play a role in connexon assembly, targeting and/or stability. 
The close opposition of the plasma membranes of adjacent epithelial cells at tight 
junctions, for example, may facilitate the formation of gap junctions between neighboring 
cells. While overexpression of a ZO-1 mutant that is unable to localize to cell-cell 
boundaries interfered with the transport of Cx43-FLAG to the target site (Toyofuku et al., 
2001), a truncated Cx43 lacking C-terminal phosphorylation sites and ZO-1 binding 
motif was still incorporated into channels (Dunham et al., 1992; Fishman et al., 1991). 
However, in the latter study, the mutant Cx43 might have been incorporated into gap 
junctions through its associations with endogenous connexins. Overexpression of ZO-1 in 
ROS cells increased gap junctional communication and punctate appositional membrane 
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staining for Cx43. On the other hand, overexpression of ZO-17-444 mutant led to a 
disruption between endogenous Cx43 and ZO-1 interaction. In addition, Cx43 had a 
perinuclear staining pattern and Lucifer Yellow dye transfer was significantly reduced in 
cells expressing ZO-17-444 mutant. ZO-17-444 expression also altered the mobility of Cx43 
on sucrose flotation gradients, where 40% of the Cx43 floated into these sucrose 
gradients while none of the Cx43 entered these gradients in untransfected ROS cell 
lysates. This suggests that more Cx43 is associated with lipid rafts in the ZO-17-444 
mutant transfected ROS cells than untransfected cells. The authors suggested that ZO-1 
might regulate Cx43-mediated gap junctional communication in ROS cells and mediate 
delivery of Cx43 from a lipid raft domain to gap junctional plaques (Laing et al., 2005).    
Alternatively, binding to ZO proteins could determine which connexin types co-
assemble into a particular connexon. Interestingly, the over-expression in hepatocytes of 
Cx32, which directly associates with ZO-1 increases the number and complexity of tight 
junction strands and small gap junction plaques were observed between TJ strands 
(Kojima et al., 1999; Kojima et al., 2001). 
ZO proteins could also have a role in connexin turnover. Lindane-induced 
interruption of junctional communication between Sertoli cells (Defamie et al., 2001) and 
increased association of ZO-1 and Cx43 during remodeling of myocyte intercellular 
contacts led to suggest a role of ZO-1 in Cx43 turnover during or after gap junctional 
endocytosis (Barker et al., 2001). An increased turnover rate was indeed observed for a 
Cx43 mutant that no longer binds ZO-1 (Toyofuku et al., 2001), supporting a role of ZO 
proteins in stabilizing connexons, possibly by tethering them to the actin cytoskeleton.  
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The observation that ZO-1 only co-localizes with a subset of a particular connexin 
implicates the presence of distinct connexons populations in a given cell, which could 
differ in function or mode of regulation. Recent evidence supports a role for ZO proteins 
in signal transduction events, possibly as platforms to assemble signaling molecules 
(Zahraoui et al., 2000). Thus, ZO proteins associated with gap junctions could mediate 
the recruitment of signaling molecules involved in the regulation of intercellular 
communication. Fig. 24 summarizes the implicated roles of ZO-1 in connexin assembly, 





Fig. 24: Main steps involved in connexin synthesis, assembly and turnover. Several 
proteins are involved in these processes with ZO proteins possibly playing important 
roles in the assembly, targeting and degradation of connexins. ZOs highlighted as red 
box. ER, endoplasmic reticulum; CGN, cis Golgi network; L, lysosomes; P, proteosomes; 
TGN, Trans Golgi network; AJ, annular gap junction (Figure reproduced from Herve et 












Section 2.4: Association of ARVCF with ZO-1 and ZO-2: binding 
to PDZ-domain proteins and cell-cell adhesion regulate plasma 
membrane and nuclear localization of ARVCF 
2.4.1: Cadherins and Catenins 
Many epithelial cells are of columnar or cuboidal in shape, with the nuclei 
localized at the base of the cell and have apical and basolateral domains with distinct 
proteins and lipids compositions (Fig. 1). Cytoskeleton and adhesion complexes maintain 
the typical epithelial morphology. AJs and desmosomes are particularly important in 
providing mechanical strength between neighboring cells in a tissue. 
 Cadherins are glycoproteins that mediate calcium-dependent cell adhesion 
(Grunwald, 1993). Cadherins belong to an evolutionally diverse cadherin protein 
superfamily with about 80 members. This superfamily can be divided into (1) classical or 
type I cadherins, (2) classical type II cadherins, (3) desmosomal cadherins, (4) 
protocadherins, (5) Flamingo cadherins and (6) FAT-like cadherins (reviewed by 
(Gooding et al., 2004). 
 The classical or type I cadherins are the best characterized and they mediate 
adhesion at the AJs. Classical cadherins are single pass integral membrane proteins, and 
require calcium for their homophilic binding through their five extracellular binding 
repeats (Fig. 25). Many tissue-specific cadherins have been identified, including E-
cadherin (epithelial), N-cadherin (neuronal), P-cadherin (placental), VE-cadherin 
(vascular endothelial) and others (Vleminckx and Kemler, 1999). E-cadherin and N-










Fig. 25: Schematic diagram of cadherin molecule showing its functional domains. 
Cadherin molecules have five extracellular domains (EC1- EC5). The HAV domain, 
which contains the His-Ala-Val (HAV) sequence, is required for homotypic interaction 
and these single-pass transmembrane proteins are anchored in the membrane by a 
hydrophobic transmembrane domain (TM). The cytosolic region interacts with armadillo 
proteins whereby the juxtamembrane domain (JMD) binds to members of the p120 





 The cytosolic tail of cadherin binds to catenins, which carry characteristic 
armadillo repeats and are thus members of the armadillo family of proteins. Fig. 28 
shows two subfamilies of catenins. The β-catenin subfamily consists of β-catenin and 
phakoglobin (γ-catenin) with 12 armadillo (arm) repeats each. The p120 subfamily is 
composed of p120, ARVCF (Armadillo gene deleted in Velo-cardio facial syndrome), 
NPRAP/δ-catenin, p0071 and phakophillins and these proteins contain 10 arm repeats 
each. Both subfamilies are able to directly interact via the armadillo repeats with the 









Fig. 26: The armadillo family. The domain structure of the two subfamilies namely β-
catenin and p120 subfamilies is shown (Figure reproduced from Vincent et al., 2004 with 
permission from The American Physiological Society). 
 
 
Besides differing in the number of arm repeats the two subfamilies interact with 
different sub-regions of cadherin cytosolic tail, with the p120 family proteins binding at 
the juxtamembrane domain (JMD) and β-catenin or phakoglobin binding the most C-
terminally located domain (Fig. 27). β-catenin is a well-studied member of the catenin 
family due to  its dual role in the regulation of AJ and as a transcriptional co-activator of 
the T-cell factor/lymphoid enhancer factor (TCF/LEF) transcriptional factors of the Wnt 
pathway which are involved in the modulating embryonic development and 
tumorigenesis (Cadigan and Nusse, 1997).  
α-catenin on the other hand does not associate directly with cadherins but binds 
either to β-catenin or phakoglobin and, through its direct or indirect interaction with F-
actin links the adhesion complex to the actin cytoskeleton (Fig. 27) (Gumbiner, 1996). 
However, recent findings indicate that α-catenin does not simultaneously interact with 
both cadherin-β-catenin and the actin cytoskeleton (Drees et al., 2005) but rather ZO-1 or 
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vinculin act to link the cadherin-catenin complex to the actin cytoskeleton. α-catenin may 
have a new role as a regulator of actin dynamics (Drees et al., 2005). 
 
Fig. 27: Cadherin-catenin complexes. Classical cadherins like VE-cadherin form at 
least three complexes with armadillo proteins. α-catenin indirectly links cadherin to the 
actin cytoskeleton by interacting with either β-catenin or phakoglobin, which in turn 
directly associates with cadherins. A third complex can be found with the p120 family of 
proteins and they bind to the juxtamembrane region of the cadherins (Figure reproduced 






2.4.2: The p120 family  
p120 is a well-characterized member and the most abundant of the p120 
subfamily. p120 (also known as p120ctn) was identified as a prominent substrate for the 
Src oncoprotein (Reynolds et al., 1989). cDNA cloning and sequence analysis revealed 
that it has armadillo repeats like β-catenin (Reynolds et al., 1992) and was later shown to 
interact directly with cadherins (Reynolds et al., 1994; Shibamoto et al., 1995; Staddon et 
al., 1995).  
The p120 subfamily can be further divided into two groups based on their 
interaction with classical cadherins or desmosomal cadherins. Group 1 members bind to 
classical cadherins and include p120, ARVCF and NPRAP/δ-catenin. Group 2 is 
composed of phakophillin-1, -2 and -3 and they bind to desmosomal cadherins.  
p120 has emerged as a key regulator of cadherin function. p120 affects cadherin 
adhesiveness, although conflicting data exists as to whether p120 strengthens (Davis et 
al., 2003; Ireton et al., 2002; Thoreson et al., 2000; Yap et al., 1998) or weakens 
adhesion (Aono et al., 1999; Ohkubo and Ozawa, 1999; Ozawa and Kemler, 1998). p120 
knock-down using siRNA technology led to the loss of  E-cadherin and resulted in the 
loss of cell-cell adhesion (Davis et al., 2003). However, the roles of other members of 
p120 subfamily are less well-understood in part due to their low abundance, as compared 
to p120 and the apparent redundant functions that they might share with p120 (Davis et 






Sirotkin et al., 1997 identified ARVCF as a candidate gene for Velo-cardio facial 
syndrome (VCFS), a relatively common human disorder with an estimated incidence of 
1/4000 newborns (Burns and Goodship, 1996). ARVCF is an autosomal dominant 
disorder (Williams et al., 1985) with typical phenotypic features that include cleft palate, 
velopharyngeal insufficiency resulting in hypernasal speech, conotruncal heart defects 
and facial dysmorphology (Shprintzen et al., 1978; Shprintzen et al., 1981; Shprintzen et 
al., 1985; Young et al., 1980). VCFS is phenotypically related to DiGeorge syndrome 
(DGS). ARVCF gene maps to chromosome 21q11 (Bonne et al., 1998; Sirotkin et al., 
1997); however other genes also map to this region and genes other than ARVCF have 
been implicated in VCFS. 
Sequence comparison of ARVCF revealed high similarity to p120 catenin family 
of proteins with 65% similarity to p120. ARVCF contains a coiled coil domain in the C-
terminus and 10 armadillo (arm) repeats in the central portion of the protein and both 
domains are capable of promoting protein-protein interactions. Each arm repeat is 
approximately 42 amino acids long (Fig. 28). Sequence analysis revealed that ARVCF 
has a putative nuclear localization signal, a feature also found in other catenins (Sirotkin 
et al., 1997). ARVCF mRNA is expressed in a ubiquitous manner as shown in a Northern 
analysis (Sirotkin et al., 1997); however it is present in very low amounts at the protein 
level (Mariner et al., 2000). ARVCF is also expressed in multiple isoforms (Mariner et 
al., 2000; Waibler et al., 2001).  Like p120, ARVCF has a dual localization to both AJs 
and the nuclei. ARVCF and p120 bind E-cadherin in a mutually exclusive manner 
(Mariner et al., 2000). Loss of E-cadherin and cell-cell adhesion observed in siRNA 
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knock-down of p120, could be overcome by exogenous expression of other members 
such as ARVCF and δ-catenin, indicating some degree of functional redundancy (Davis 
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Fig. 28: Schematic diagram of the domain structure of ARVCF. ARVCF like p120 
has coiled-coil domains and ten armadillo repeats. 
 
 
Despite structural similarities with p120 and the possible functional redundancy, 
ARVCF is likely to have specific functions. Endogenous levels of ARVCF are far too 
low for ARVCF to act as a competitor to p120. However, it is possible that ARVCF 
expression is developmentally regulated. In addition, overexpression of ARVCF and 
p120 in several cell lines showed that ARVCF has a more pronounced propensity to 
localize to the nuclei. This suggests that ARVCF might have specific functions in the 
nucleus or shuttle between the membrane and nucleus in response to signals sensing cell-
cell contact. ARVCF also lacks the branching activity of p120 (Mariner et al., 2000) 
consistent with ARVCF exerting functions that are non-redundant with p120. However, 
these results contradict those obtained for Xenopus ARVCF and p120 (Fang et al., 2004).  
Depletion of xARVCF and xp120 generated gastrulation defects, which were rescued 
with exogenous xARVCF and xp120 expression, respectively. Interestingly, the defects 
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were partially cross-rescued with xp120 exogenous expression in xARVCF-depleted 
embryos and vice versa. In addition, xARVCF exogenous expression in NIH3T3 cells 
resulted in branching phenotype similar to that observed after p120 overexpression, 
indicating that xARVCF and xp120 may have roles in vertebrate development and share 
significant overlapping functions (Fang et al., 2004).     
Using PDZ domains of ZO-1 as bait, the C-terminus of ARVCF was isolated as 
an interacting protein. The following sections verify the interaction and explore the 
functional significance of this interaction.  
 
2.5: Results 
2.5.1: ARVCF interacts with ZO-1 and ZO-2 but not ZO-3 
 The three PDZ domains of human ZO-1 were used as bait in a yeast-two-hybrid 
screen of a mouse 17-day embryo cDNA library to identify interacting proteins. 
Sequencing of positive clones identified cDNA encoding the C-terminus of ARVCF. The 
cDNA clone encoding amino acids 670-893 was further characterized using different ZO 
proteins by using yeast-two-hybrid (Table 6). In addition, to interact with the PDZ 
domains of ZO-1, ARVCF also interacted with PDZ domains of ZO-2 but not ZO-3. The 
interaction with C-terminus of Cx-45 with ZO-1 and ZO-3 and p53 with T-Ag served as 
positive controls, whereas laminin with p53 or library vector were used as negative 
controls, confirming the specificity of the observed interaction. PDZ domains generally 
interact with short C-terminal amino acid sequences and the C-terminal serine-
tryptophane-valine (SWV) in ARVCF conforms to a class I PDZ-binding motif (Sheng 
and Sala, 2001). Mutation of the S, W and V amino acids to alanine (A) abolished the 
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interaction with the PDZ domains of ZO-1 and ZO-2 (Table 6), showing that the SWV 




Table 6: Interaction of the PDZ domains of ZO-1 and ZO-2 with a construct encoding 
the C-terminal region of ARVCF (amino acids 670-893) or a mutant thereof (ARVCF∆P) 








Interactions were determined by monitoring growth of cotransformed yeast on selective media and β-
galactosidase activity. Similar results were obtained under low and high stringency conditions. Empty bait 
(pGBKT7) and library (pACT2) plasmids and a lamin construct served as negative controls. T-antigen (T-
Ag) and p53, two known interaction partners, were used as a positive control. Growth on dropout media 
and β-galactosidase activities for yeast coexpressing T-Ag and p53 (positive control) were similar for 
clones coexpressing the C-terminus of ARVCF and the PDZ-domains of ZO-1 and ZO-2. Since the ZO-3 
bait can interact with the PDZ-motif in Cx-45, the lack of an interaction with ARVCF was not due to the 
experimental set up. +++, interaction; -, no interaction; nd, not determined. 
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Fig. 29 shows a schematic diagram of the constructs used in this study. Since 
ARVCF was initially identified using the PDZ domains of ZO-1 as bait, subsequent 
experiments focused on the characterization of the binding between ARVCF and ZO-1. A 
GST fusion protein carrying the three PDZ domains of ZO-1 was analyzed for its ability 
to bind full-length in vitro translated ARVCF or a mutant with a destroyed PDZ-binding 
motif (ARVCF(∆P)). Confirming the yeast two-hybrid results, the GST-ZO-1 PDZ bound 
to ARVCF but not ARVCF(∆P) (Fig. 30A). To further establish that the association was 
direct, in vitro translated ARVCF and ARVCF(∆P) were fractionated by SDS-PAGE, 
transferred to PVDF membranes and the blot overlaid with GST-ZO-1 PDZ. As shown in 
Fig. 30B, GST-ZO-1 PDZ bound to ARVCF but not ARVCF(∆P), consistent with a 
direct interaction. ARVCF binds to PDZ1 domain of ZO-1 significantly (Fig. 30C). 
These results thus establish a direct association between the PDZ-domains of ZO-





















































Fig. 29: Schematic diagrams of ARVCF, ZO-1 and ZO-2.  A. Domain structure of 
ARVCF. The amino acid substitutions that abolish binding to PDZ-domains 
(ARVCF(∆P); black diamond) and the deletion of the armadillo domains (ARVCF(∆A) 
are indicated. B. Domain organization of ZO-1. Truncated ZO-1 and ZO-2 proteins 
carrying only the three PDZ domains (ZO-1 PDZ, ZO-2 PDZ) are depicted and amino 
acid substitutions in the PDZ domains of ZO-1 that abolish binding to C-terminal peptide 
(ZO-1 PDZ(mut), white diamonds) and the deletion of the nuclear localization signal in 


































































Fig. 30: Binding of ARVCF and ZO-1. A. In vitro translated ARVCF binds to a 
GST fusion protein containing the PDZ domains of ZO-1. GST or GST-ZO-1 PDZ 
fusion proteins were coupled to glutathione beads and incubated with in vitro translated, 
radioactively labeled, ARVCF or ARVCF(∆P). Protein bound to the beads (Pull-down) 
was analyzed by SDS-PAGE and autoradiography. An aliquot (5%) of the in vitro 
translated material was directly analyzed to confirm that similar amounts of the in vitro 
translated proteins were added to the binding reaction. B. ZO-1 PDZ domains bind 
directly to ARVCF in blot overlays. In vitro translated ARVCF or ARVCF(∆P) were 
fractionated by SDS-PAGE, transferred to PVDF membranes and incubated with ZO-1 
PDZ domains fused to GST. Bound GST-ZO-1 PDZ was detected with a labeled anti-
GST antibody. C. ARVCF significantly binds to PDZ1 domain of ZO-1. GST or GST-
fused to PDZ1, 2, 3 of ZO-1 were incubated with in vitro translated ARVCF or 
ARVCF(∆P) and bound translated products were analyzed by Western blot using HA 




















2.5.2: ARVCF and ZO-1 interact in vivo and partially co-localize in MDCK 
cells 
To determine if full length ZO-1 and ARVCF interact in vivo, epithelial MDCK 
cells, which endogenously express ZO-1 and low levels of ARVCF (see Fig. 33A), were 
stably transfected with cDNAs coding for wild type or mutant human ARVCF constructs 
carrying an N-terminal HA-tag.  
To analyze if ZO-1 and ARVCF associate in vivo, endogenous ZO-1 was 
immunoprecipitated and precipitates blotted with antibodies to HA or, as a control, 
ARVCF. ARVCF but not ARVCF(∆P) coprecipitated with ZO-1 (Fig. 31A). Similarly, 
an ARVCF mutant lacking the armadillo repeats (ARVCF(∆A)) co-precipitated with ZO-
1, but the association was lost if the PDZ-binding motif was mutated (ARVCF(∆A∆P)). 
Furthermore, endogenous ARVCF coprecipitated with ZO-1 from MDCK cells (Fig. 
31B), which express low levels of ARVCF (Fig. 33A and (Kaufmann et al., 2000), 
validating the coprecipitation experiments from cells overexpressing the tagged protein. 
To determine if ZO-1 and ARVCF colocalize, MDCK cells expressing wild type 
or mutant ARVCF were stained with antibodies to ZO-1 and HA and analyzed by 
confocal immunofluorescence microscopy (Fig. 32). In cells grown on cover slips, 
ARVCF was present at the plasma membrane at sites of cell-cell contact, where it 
extensively colocalized with ZO-1 (panels a-c). In contrast, ARVCF(∆P) was 
cytoplasmic and absent from the plasma membrane and the nucleus (panels d-f). 
Compared to wild-type ARVCF, the amount of ARVCF(∆A) at the plasma membrane 
was reduced but still detectable, with an increased fraction found in the cytoplasm and 
nucleus (panels g-h). The fraction of ARVCF(∆A) present on the plasma membrane 
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extensively colocalized with ZO-1. Similar to ARVCF(∆P), ARVCF(∆A∆P) was absent 




























Fig. 31: A. ARVCF co-precipitates with ZO-1 from transfected MDCK cells. Control 
cells (MDCK) or cells expressing ARVCF, ARVCF(∆P), ARVCF(∆A) or 
ARVCF(∆A∆P) were lysed and equal amounts of total protein used to immunoprecipitate 
ZO-1. Precipitates were blotted to detect ARVCF (anti-HA and anti-ARVCF) that was 
bound to ZO-1. An aliquot of the cell lysate (5%) was directly blotted to determine the 
amount of wild type and mutant ARVCF present in the lysates. Untransfected cells 
served as a control for the specificity of the precipitation; nd, not determined. B. 
Endogenous ARVCF and ZO-1 coprecipitate from MDCK cells. Endogenous ZO-1 
was immunoprecipitated from lysates of MDCK cells and precipitates were analyzed by 
Western blot using an anti-ARVCF antibody to detect associated ARVCF. An aliquot of 
the lysate (5%) was directly blotted. Beads coated with an irrelevant antibody (IgG) 
failed to precipitate ARVCF. An aliquot of the MDCK cell lysate (5%), or for 
comparison cells transfected with ARVCF, was directly blotted. ~20x the amount of cell 




















Fig. 32: Colocalization of ARVCF and ZO-1 in transfected MDCK cells. MDCK cells 
transfected with wild type ARVCF (panels a-c) or mutant ARVCF(∆P) (panels d-f), 
ARVCF(∆A) (panels g-i ) or ARVCF(∆A∆P) (panels j-l) were grown on glass coverslips 
fixed, permeabilized and stained for ZO-1 (red color; panels a, d, g and j) and ARVCF 
(green; panels b, e, h, and k). Confocal images of the ZO-1 and ARVCF labeling were 





The co-localization of ARVCF and ZO-1 was confirmed in polarized MDCK cell 
monolayers grown on permeable polycarbonate filters (Fig. 33). Cells were stained for 
ZO-1 and ARVCF and images of horizontal sections at the height of the TJ (Fig. 33A and 
B) or vertical sections along the apico-basal axis panels C and D) of the cell monolayer 
were acquired. While ARVCF (green color, panels A and C) predominantly localized to 
the lateral plasma membrane, ARVCF(∆P) was absent from the plasma membrane 
(panels B and C), consistent with the results for cells grown on cover slips (Fig. 33). 
Although ARVCF was found along the length of the lateral membrane, a significant 
degree of colocalization with ZO-1 (red color) was observed only in the apical region of 
the lateral membrane (yellow color). In contrast, ARVCF(∆P) did not colocalize with 
ZO-1. Interestingly, in contrast to the characteristic and well localized punctuate staining 
for ZO-1 in control cells (our unpublished results) or cells expressing ARVCF(∆P) (panel 
D), the ZO-1 staining extended further down into the lateral membrane in cells 
expressing ARVCF (panel C). Expression levels of endogenous ARVCF in MDCK cells 
were too low to be detected by immunostaining (Mariner et al., 1999).  
In conclusion, ARVCF and ZO-1 associate and partially colocalize in vivo, with 
both the interaction and colocalization being dependent on the presence of an intact PDZ-



































Fig. 33: ARVCF partially colocalizes with ZO-1 to a discrete region between the 
lateral plasma membrane and TJ of polarized MDCK cells. MDCK cells transfected 
with ARVCF (panels A and C) or ARVCF(∆P) (panels B and D) were grown on 
polycarbonate filters to obtain polarized cell monolayers. Cells were fixed, permeabilized 
and stained for ARVCF (green color) and ZO-1 (red color). Confocal images 
corresponding to horizontal sections at the height of TJ (panels a and b) or to vertical 
sections along the apico-basal axis of the monolayer (panels C and D) were acquired and 





















2.5.3: Colocalization and association of ARVCF with ZO-1 does not require an intact 
actin cytoskeleton 
Since ZO-1 and ARVCF are found in adhesion complexes that link to F-actin, I 
analyzed whether compromising the integrity of the actin cytoskeleton using cytochalasin 
D altered the colocalization and association of the two proteins. Cytochalasin D severely 
disrupted the normal organization of the actin cytoskeleton in MDCK cells (our 
unpublished results) and the contiguous localization of ZO-1 and ARVCF to areas of 
cell-cell contact (see Fig. 32) was broken up into strings of patches where ZO-1 and 
ARVCF extensively colocalized (Fig. 34, panels a-c). The cytoplasmic localization of 
ARVCF(∆P) was not altered by the drug (panels d-f). ARVCF(∆A) showed a punctate 
staining pattern similar to ARVCF,  but the fraction present in the cytosol was increased 
in drug treated cells (panels g-i). 
As expected from their known association, also ARVCF and E-cadherin 
extensively colocalized in cytochalasin D treated cells (panels j-l). While ARCVF(∆P) 
did not colocalize with E-cadherin (panels m-o), a detectable fraction of ARVCF(∆A) 
was present in E-cadherin containing patches (p-r). As expected from the colocalization 
of ARVCF with ZO-1 as well as with E-cadherin, also ZO-1 and E-cadherin colocalized 
in cytochalasin D treated cells (panels s-u). Furthermore, ZO-1 and ARVCF but not 
ARVCF(∆P) coprecipitated from cytochalasin D treated cells (panel v). 
Thus, the colocalization and interaction of ZO-1 with ARVCF does not require an 



































































Fig. 34: Colocalization and coprecipitation of ARVCF and ZO-1 or E-cadherin in 
transfected MDCK cells treated with cytochalasin D. a-u. Colocalization of ZO-1, E-
cadherin and ARVCF. MDCK cells transfected with wild type ARVCF (panels a-c and j-
l) or mutant ARVCF(∆P) (panels d-f and m-o) or ARVCF(∆A) (panels g-i or p-r) were 
fixed, permeabilized and stained for ZO-1 (red color; panels a, d, and g), E-cadherin (red 
color; panel j, m, and p) and wild type or mutant ARVCF  (green colors; panels b, e, h, k, 
n and q). Confocal images of the ZO-1 or E-cadherin and ARVCF labeling were merged 
to show regions of colocalization (yellow color; panels c, f, i, l, o, r). Colocalization of E-
cadherin (red color, panel s) and ZO-1 (green color; panel t) in cytochalasin treated cells 
is shown in yellow (panel u). v. ARVCF coprecipitates with ZO-1 from cytochalasin D 
treated MDCK cells. Control cells (MDCK) or cells expressing ARVCF or ARVCF(∆P) 
were lysed and equal amounts of total protein used to immunoprecipitate ZO-1. 
Precipitates were blotted to detect ARVCF that was bound to ZO-1. An aliquot of the cell 
lysate (5%) was directly blotted to determine the amount of wild type and mutant 
ARVCF present in the lysates. Untransfected cells served as a control for the specificity 




2.5.4: ARVCF can associate with E-cadherin via its armadillo domains or 
through binding to PDZ domains proteins 
Intriguingly, the PDZ binding motif appeared to be critical for plasma membrane 
localization of ARVCF in MDCK (Figure 31-34), 293T (our unpublished results) and 
MCF7 (see below) cells, whereas deletion of the armadillo repeats, which have been 
shown to mediate the interaction between ARVCF and M-cadherin (Kaufmann et al., 
2000), only partially affected plasma membrane localization (Fig. 33 and 34). I therefore 
analyzed the contributions of the armadillo repeats in binding of ARVCF to E-cadherin, 
both in vitro and in vivo. 
An immobilized GST-fusion protein carrying the cytosolic domain of E-cadherin 
bound in vitro translated ARVCF (Fig. 35A), confirming the direct interaction of ARVCF 
with cadherins (Kaufmann et al., 2000; Mariner et al., 2000). Deletion of the armadillo 
domains in ARVCF abolished the interaction, similar to the results obtained for M-
cadherin (Kaufmann et al., 2000). The interaction of ARVCF(∆P) with the GST-E-
cadherin fusion protein was comparable to that of wild-type ARVCF, indicating that the 
PDZ-binding motif is dispensable for E-cadherin binding in vitro. 
 However in vivo, the association of ARVCF(∆P) with endogenous E-cadherin 
was severely impaired when compared to wild-type ARVCF (Fig. 35B). ARVCF(∆A), on 
the other hand, retained E-cadherin binding activity, which was abolished only if the 
PDZ-binding motif was also mutated. The ability of the different ARVCF constructs to 
coprecipitate with E-cadherin in vivo therefore correlated with the extent of their 
colocalization with E-cadherin (Fig. 33) and their presence at the plasma membrane 
(Figs. 30-32). Thus, in vivo, the armadillo domains as well as the C-terminal PDZ-
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binding motif contribute to the plasma membrane localization of ARVCF and its 
association with E-cadherin. Given the interaction of ARVCF with cadherins and ZO-1, I 
next analyzed if E-cadherin coprecipitated with ZO-1 and if the association was affected 
by overexpressing ARVCF. E-cadherin was detected in ZO-1 precipitates from control 
cells or cells expressing ARVCF or ARVCF(∆P) (Fig. 35C). Interestingly, however, 
significantly more E-cadherin coprecipitated with ZO-1 from cells expressing ARVCF as 
compared to either control cells or cells expressing ARVCF(∆P) (Fig. 35D), suggesting 
that ARVCF can link ZO-1 to E-cadherin. Basal levels of E-cadherin present in the ZO-1 
precipitates from control cells or cells expressing ARVCF(∆P) likely reflect the known 
association of ZO-1 with E-cadherin via α-catenin (Ando-Akatsuka et al., 1999; 
Rajasekaran et al., 1996).  
To confirm complex formation between E-cadherin, ARVCF and ZO-1 in vitro, 
ARVCF and the cytosolic domain of E-cadherin were translated in vitro and incubated 
with immobilized GST-ZO-1 PDZ. ARVCF and the E-cadherin tail bound to the ZO-1 
PDZ domains (Fig. 35E) and binding of either protein required an intact PDZ-binding 
motif in ARVCF. This experiment confirms the ability of ARVCF to link E-cadherin to 
ZO-1 and shows that a complex containing the three proteins can assemble in vitro. 
In conclusion, ARVCF can link ZO-1 to E-cadherin and, in vivo, the armadillo 
domains of ARVCF as well as its interaction with PDZ domain proteins contribute to the 
























































Fig. 35: Binding of ARVCF and E-cadherin. A. Binding of in vitro translated wild 
type and mutant ARVCF to a GST fusion protein containing the cytosolic domain of 
E-cadherin. GST or GST-E-cadherin tail fusion proteins were coupled to glutathione 
beads and incubated with in vitro translated, radioactively labeled, ARVCF, 
ARVCF(∆P), ARVCF(∆A) or ARVCF(∆A∆P). Protein bound to the beads (Pull-down) 
was analyzed by SDS-PAGE and autoradiography. An aliquot (5%) of the in vitro 
translated material was directly analyzed to confirm that similar amounts of the in vitro 
translated proteins were added to the binding reaction. B. Coprecipitation of wild type 
or mutant ARVCF with E-cadherin. Control cells (MDCK) or cells expressing 
ARVCF, ARVCF(∆P), ARVCF(∆A) or ARVCF(∆A∆P) were lysed and equal amounts 
of total protein used to immunoprecipitate E-cadherin. Precipitates were blotted to detect 
ARVCF (anti-HA) that was bound to E-cadherin. Alternatively, wild type or mutant 
ARVCF was precipitated with the anti-HA antibody and precipitates blotted to detect 
bound E-cadherin. An aliquot of the cell lysate (5%) was directly blotted to determine the 
total amount of ARVCF or E-cadherin, respectively, present in the lysates. Untransfected 
cells served as a control for the specificity of the precipitations. C. Coprecipitation of 
ZO-1 and E-cadherin. Control cells (MDCK) or cells expressing ARVCF or 
ARVCF(∆P) were lysed and equal amounts of total protein we used to immunoprecipitate 
ZO-1. Precipitates were then analyzed by Western blot to detect E-cadherin that was 
bound to ZO-1. An aliquot of the cell lysate (5%) was directly blotted to determine the 
amount of E-cadherin present in the lysate. D. Quantification. The relative amounts of 
E-cadherin that coprecipitated with ZO-1 from control cells or those expressing wild type 
or mutant ARVCF was quantified. E. In vitro association of ZO-PDZ, ARVCF and E-
cadherin. Immobilized GST or GST-ZO-1 PDZ domain fusion proteins were incubated 
with in vitro translated ARVCF or ARVCF(∆P) and E-cadherin. Proteins bound to the 
beads were then identified by Western blot. An aliquot of the in vitro translation reaction 
was directly blotted (i; input) to monitor the amount of ARVCF, ARVCF(∆P) and E-
cadherin added to the reaction. 
E 
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2.5.5: Plasma membrane and nuclear localization of ARVCF require the 
interaction with PDZ domain proteins and are regulated by cell-cell adhesion 
Variable degrees of nuclear localization have been reported for ARVCF in 
different cell types (Kaufmann et al., 2000; Lawrence et al., 2002; Mariner et al., 2000). 
Briefly, filter grown MDCK cells expressing ARVCF were treated with EDTA to break 
down cell- cell adhesion and the subcellular distribution of ARVCF and ZO proteins was 
analyzed, either immediately following the EDTA treatment or after recovery to allow 
the cells to reestablish cell-cell contact. 
Calcium depletion resulted in the loss of ARVCF and ZO-1 from the plasma 
membrane (Fig. 36A, panels a-c). While ARVCF was observed in both the cytoplasm and 
the nucleus, ARVCF(∆P) was excluded from the nucleus (panels g-i). ZO-1 remained in 
the cytosol showing a punctuate staining similar to that previously reported under these 
conditions (Ivanov et al., 2004). After a 60 min recovery, ARVCF and ZO-1 were 
recruited to sites of initial cell-cell contact, where they extensively colocalized (panels d-
f). The amount of ARVCF present in the nucleus was notably reduced after recovery. 
Although ZO-1 relocalized to sites of cell-cell adhesion in cells expressing ARVCF(∆P), 
the latter remained cytosolic (panels j-l). 
ZO-1 released from the plasma membrane was excluded from the nucleus after 
calcium depletion, whereas ZO-2 efficiently accumulated in the nucleus (panel m). 
Redistribution of ZO-2 from the nucleus back to sites of cell-cell contact lagged behind 
that of ZO-1 or ARVCF (panels n-o) and required a longer recovery (our unpublished 
results and (Islas et al., 2002). 
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Thus, disruption of cell-cell adhesion results in the release of ARVCF from the 
plasma membrane and increased appearance in the nucleus. Furthermore, nuclear 


























Fig. 36: Plasma membrane recruitment and nuclear localization of ARVCF require the 
PDZ-binding motif and are regulated by cell-cell adhesion using calcium switch assay. 
MDCK cells grown on filters and expressing either ARVCF (panels a-f) or ARVCF(∆P) (panels 
g-l) were incubated with EDTA to deplete calcium and disrupt cell-cell adhesion. The distribution 
of ARVCF (green color) and ZO-1 (red color) was analyzed after EDTA-treatment or following 
the incubation for 60 min in calcium-containing media to allow re-establishment of cell-cell 
adhesion, by staining with suitable antibodies and visualization by confocal microscopy. In panels 
where staining for ARVCF and ZO-1 was merged, the yellow color indicates colocalization of the 
two proteins. In panels m-p, ZO-2 (red color) was colocalized with ZO-1 (green color, panels m 
and n), or ARVCF or ARVCF(∆P) (green color, panel o and p, respectively), either following 
calcium depletion or a 60 min recovery. 
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2.5.6: ARVCF, ZO-1 and E-cadherin are recruited to sites of initial cell-cell 
contact  
Given the presence of ARVCF at sites of cell-cell contact following recovery 
from calcium depletion, the recruitment of ARVCF, ZO-1 and E-cadherin to sites of 
initial cell-cell adhesion in sparse cultures of transiently transfected MCF7 cells was 
further characterized.   
As shown in Fig. 37I and similar to MDCK cells, ARVCF and E-cadherin (panels 
a-c), ZO-1 and E-cadherin (panels g-h), as well as ARVCF and ZO-1 (panels j-l) 
extensively colocalized to sites of cell-cell contact. In cells expressing ARVCF(∆P), 
which remained cytoplasmic, E-cadherin (panels d-f) and ZO-1 (panels m-o) were still 
recruited to contact sites. 
Since plasma membrane localization of ARVCF required an intact PDZ-binding 
motif and thus the ability to interact with ZO-1 (or other PDZ-domain proteins), I 
analyzed if over expressing ZO-1 mutants affects the recruitment of ARVCF to regions 
of cell-cell adhesion. Over expressing an N-terminal portion of ZO-1 encoding the three 
PDZ domains (ZO-1 PDZ, Fig. 37II panel b) interfered with the recruitment of ARVCF 
to sites of cell-cell contact (Fig. 37II, panels a-c). As observed in MDCKI cells (Reichert 
et al., 2000) the ZO-1 PDZ domains remained mostly cytoplasmic, highlighting that the 
C-terminal domains are required for ZO-1 to be localized to the plasma membrane. Most 
importantly, this mutant presumably prevented recruitment of ARVCF to the plasma 
membrane by competing for its interaction with wild-type ZO-1 and/or other PDZ-
domain proteins. In contrast, overexpression of a ZO-1 PDZ construct in which the 
ability of the PDZ domains to interact with ligand had been obliterated (ZO-1 PDZ(mut)), 
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did not interfere with plasma membrane recruitment of ARVCF (Fig. 39II panels g-i). As 
expected, neither ZO-1 PDZ nor ZO-1 PDZ(mut) altered the cytoplasmic distribution of 
ARVCF(∆P) (panels d-f and j-l), nor was membrane localization of ARVCF affected by 
overexpressing wild-type ZO-1 (Fig.37II panels m-o).  Coimmunoprecipitation 
experiments confirmed that in vitro translated 35S-methionine labeled ARVCF and ZO-1 
PDZ domains associated with each other and that the binding was abolished by mutation 
of either the PDZ-binding motif in ARVCF (ARVCF(∆P)) or the PDZ domains in ZO-1 
PDZ (ZO-1 PDZ(mut)) (Fig. 38, panel v). 
Thus, E-cadherin, ZO-1 and ARVCF are recruited to sites of initial cell-cell 
contact. Membrane recruitment of ARVCF requires an intact ZO-1 at the plasma 
membrane, where possibly ZO-1 association with membrane proteins and/or the 






















































Fig. 37: I. Recruitment of ARVCF to sites of cell-cell contact in MCF7 cells. Sparsely 
plated MCF7 cells either transfected with cDNAs for ARVCF (panels a-c and j-l), 
ARVCF (∆P) (panels d-f and m-o) or not transfected (panels g-i) were processed for 
immunofluorescence staining and the localization of ARVCF, ARVCF(∆P) and 
endogenous E-cadherin and ZO-1 visualized by confocal microscopy. Colocalization of 
the respective proteins appears yellow in the merged images. II. Effect of ZO-1 mutants 
on ARVCF localization in MCF7 cells. Sparse MCF7 cells coexpressing ARVCF or 
ARVCF(∆P) (panels a-c, g-i and d-f, j-l, respectively) and either ZO-1 PDZ domains 
(panels a-f), a ZO-1 PDZ carrying inactivated PDZ-domains (PDZ(mut); panels g-l) or a 
full length ZO-1 construct were analyzed by immunofluorescence staining and confocal 
microscopy. ZO-1 constructs carried an N-terminal FLAG tag. Colocalization of the 
respective proteins appears yellow in the merged images. 
II 
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2.5.7: The PDZ domains of ZO-2 mediate the efficient nuclear localization 
of ARVCF 
Given the interaction between the ZO-2 PDZ domains and ARVCF (Table 6) and 
the nuclear localization of the two proteins following disruption of cell-cell adhesion 
(Fig. 36), the possible role for ZO-2 in nuclear localization of ARVCF was explored. ZO-
2 has several nuclear localization signals (NLS) within its N-terminal part (Jaramillo et 
al., 2004) and therefore the subcellular distribution of ARVCF was analyzed in MCF7 
cells cotransfected with cDNAs for ARVCF and ZO-2 PDZ (Fig. 29B) or a mutant with 
impaired nuclear localization capacity (ZO-2 PDZ(∆NLS)), Fig. 29B). 
Overexpression of ZO-2 PDZ displaced ARVCF from the plasma membrane into 
punctate cytoplasmic structures and strongly enhanced nuclear accumulation of ARVCF 
(Fig. 38, panels a-c). ARVCF and ZO-2 PDZ colocalized not only in the nucleus, but also 
in the cytoplasmic structures.  The ZO-2 PDZ induced displacement of ARVCF from the 
plasma membrane as well as the colocalization support the interaction between the two 
proteins. ARVCF(∆P) was excluded from the nucleus (panels d-e), showing that nuclear 
localization of ARVCF required its ability to interact with ZO-2 PDZ. 
ZO-2 PDZ(∆NLS) was still able to relocalize ARVCF from the plasma membrane 
to the cytoplasmic structures (panels g-l), indicating that deletion of the NLS did not 
affect the interaction with ARVCF (see below). ARVCF, however, was effectively 
excluded from the nucleus in cells expressing ZO-2 PDZ(∆NLS), directly implicating 




Interestingly, the ZO-2 PDZ domains also partially relocalized endogenous ZO-1 
from sites of cell-cell contact to the nucleus (panels m-o), likely reflecting association 
between ZO-1 and ZO-2 through PDZ domain interactions (Wittchen et al., 1999). 
Consistent with previous observations (Jaramillo et al., 2004), endogenous ZO-2 
accumulated in the nucleus of sparse cell cultures (panels p-r). The plasma membrane 
localization of E-cadherin, in contrast, was not altered by the expression of ZO-2 PDZ 
(panels s-u). As expected from the functional effect of ZO-2 PDZ(∆NLS) on ARVCF 
localization and its codistribution with ARVCF, coimmunoprecipitation experiments 
using vitro translated 35S-methionine labeled ARVCF and ZO-2 PDZ(∆NLS) confirmed 
the interaction between the two proteins (Fig. 38, panel w). 
In conclusion, the ZO-2 PDZ domains mediate nuclear accumulation of ARVCF 
in a process that requires both a PDZ based interaction and the NLS of ZO-2, consistent 































Fig. 38: Role of ZO-2 in nuclear localization of ARVCF. MDCK cells expressing 
ARVCF (panels a-c and g-i) or ARVCF(DP) (panels d-f and j-l) were transfected with 
cDNAs encoding the ZO-2 PDZ domains (panels a-f) or ZO-2 PDZ domains with an 
inactivated NLS (ZO-2 PDZ(∆NLS), panels g-l) and analyzed by immunofluorescence 
staining and confocal microscopy. Colocalization of the respective proteins appears 
yellow in the merged images. In panels m-u, the distribution of endogenous ZO-1, ZO-2 
and E-cadherin was analyzed in MDCK cells transfected with a plasmid encoding the 
ZO-2 PDZ domains. ZO-2 constructs carried an N-terminal Xpress tag. Colocalization of 
the respective proteins appears yellow in the merged images. Panel v. Mutation of the 
PDZ domains in ZO-1 PDZ abolished interaction with ARVCF. ARVCF or ARVCF(∆P) 
and ZO-1 PDZ or ZO-1 PDZ(mut) were in vitro cotranslated in the presence of 35S-
methionine. ARVCF or ARVCF(∆P) was then immunoprecipitated, the precipitates 
fractionated by SDS-PAGE and the dried gels used for autoradiography. Panel w. 
Deletion of the NLS in ZO-2 PDZ(∆NLS) does not affect the interaction with ARVCF. 
ARVCF and ZO-2 PDZ(∆NLS) were in vitro cotranslated in the presence of 35S-
methionine, ARVCF was then immunoprecipitated, the precipitates fractionated by SDS-
PAGE and the dried gels used for autoradiography. An aliquot of the in vitro translation 
reaction was directly analyzed to monitor the amount of protein added to the reaction. 






Section 2.6: Discussion 
In this study, ARVCF is identified as a binding partner of ZO-1 and ZO-2 and the 
role of PDZ-domain proteins in plasma membrane and nuclear localization of ARVCF 
are characterized. Based on several assays, including yeast two hybrid, pull-down and 
ligand overlay, ARVCF was shown to bind directly to ZO-1 through the interaction of a 
C-terminal type 1 PDZ-binding motif (SWV) in ARVCF and PDZ domains in ZO-1. 
ARVCF also interacts with PDZ domains of ZO-2, but not ZO-3, confirming the notion 
that different ZO proteins recruit distinct partners to TJ. 
Co-precipitation and co-localization experiments showed that ARVCF and ZO-1 
also interact in vivo. Interestingly, the two proteins only colocalized in the apical most 
region of the lateral plasma membrane of fully polarized MDCK cells, thus defining two 
distinct pools of plasma membrane associated ARVCF, one in the region of the apical 
junctional complex, the second along the length of the lateral domain. Since inactivation 
of the PDZ-binding motif led to the loss of the bulk of ARVCF from the plasma 
membrane, PDZ-domain proteins other than ZO-1 such as Erbin (Laura et al., 2002) are 
likely to be involved in localizing ARVCF to the lateral plasma membrane. Cell type 
specific expression of different PDZ-domain proteins promoting the interaction of 
ARVCF with cadherins or other membrane associated proteins may thus explain why co-
localization of ARVCF and cadherins is often dependent on the cellular context (Waibler 
et al., 2001). Interestingly, overexpression of ARVCF, but not ARVCF(∆P), resulted in a 
more lateral distribution of ZO-1, consistent with the two proteins interacting. Since 
endogenous ARVCF levels are too low to be detected in MDCK cells (see also (Mariner 
et al., 2000)), it is not clear if the endogenous protein preferentially localizes to the more 
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apical or basal region, or if it is distributed along the length of the lateral plasma 
membrane. In any case, since the bulk of the overexpressed ARVCF localized to the 
plasma membrane, the mechanism(s) that recruit ARVCF were not saturated in the 
transfected MDCK cells. 
ARVCF can directly interact through its armadillo repeats with cadherins 
(Kaufmann et al., 2000; Waibler et al., 2001) and it has been proposed that membrane 
localization of ARVCF is mediated through this association. It was therefore surprising 
that inactivation of the PDZ-binding motif resulted in the loss of ARVCF from the 
plasma membrane, in particular since cadherins do not contain PDZ domains. I confirmed 
that in vitro, the armadillo repeats are indeed required for binding ARVCF to the 
cytosolic tail of E-cadherin. Under these conditions, inactivation of the PDZ-binding 
motif does not affect the association of the two proteins. In vivo, however, ARVCF 
lacking the armadillo domains was still present at the plasma membrane, albeit at reduced 
levels. A fraction of the mutant lacking the armadillo repeats also coprecipitated with E-
cadherin and only the inactivation of the PDZ-binding motif in ARVCF(∆A) led to the 
complete loss of membrane localization and E-cadherin coprecipitation. This suggests 
that ARVCF can bind to E-cadherin via different mechanisms (see Figure 39A). On one 
hand, ARVCF may associate with cadherins via the armadillo repeats and with ZO-1 via 
the PDZ-binding motif, thereby linking ZO-1 to E-cadherin. Indeed, a complex between 
ZO-1 PDZ domains, E-cadherin and ARVCF could form in vitro and overexpression of 
ARVCF increased the amount of ZO-1 that coprecipitated with E-cadherin. Such a 
complex may also explain the redistribution of ZO-1 from TJ to a more lateral location. 
Alternatively, based on the known association of ZO-1 with the cadherin complex via α-
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catenin (Ando-Akatsuka et al., 1999; Itoh et al., 1997; Rajasekaran et al., 1996), ZO-1 
could link ARVCF indirectly to E-cadherin. Such an interaction could explain the 
displacement of ARVCF from the plasma membrane following overexpression of the 
ZO-1 (or ZO-2) PDZ domains. In addition, it is also possible that a fraction of ARVCF is 
recruited to tight junctions by directly binding to ZO-1. 
Plasma membrane localization of ARVCF not only required a functional PDZ-
binding motif but also cell-cell adhesion. Dissociation of cell-cell adhesion or sparse 
culture conditions led to the release of ARVCF from the plasma membrane into the 
cytoplasm and the nucleus. Although a presence of ARVCF in the nucleus has been 
reported (Mariner et al., 2000; Waibler et al., 2001), a cell-cell adhesion dependent 
shuttling between plasma membrane and nuclear localizations has not been documented. 
Even without affecting cell-cell adhesion, nuclear localization of ARVCF(∆A) was 
increased, correlating with the less efficient membrane localization of ARVCF following 
deletion of the armadillo repeats. Under any condition, mutation of the PDZ-binding 
motif resulted in the effective exclusion of ARVCF from the nucleus, showing that 
nuclear translocation and/or retention requires a functional PDZ-binding motif and hence 
the interaction with a PDZ-domain containing protein. 
ZO-1 remained cytoplasmic in sparse cell cultures or following disruption of cell-
cell adhesion, suggesting that it does not participate in nuclear localization of ARVCF. 
ZO-2, in contrast, relocated to the nucleus with ARVCF and, given the interaction 
between the ZO-2 PDZ domains and ARVCF, raised the possibility that ZO-2 may play a 
role in nuclear localization of ARVCF. Such a role for ZO-2 is indeed supported by the 
ability of the ZO-2 PDZ domain to efficiently relocate ARVCF from the plasma 
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membrane to the nucleus in a process that required the ability of the two proteins to 
interact and the presence of a functional NLS in the ZO-2 PDZ domains. Thus, ZO-2 
could be involved in nuclear translocation and/or retention of ARVCF and play a role in 
regulating postulated functions of ARVCF in gene expression. Interestingly, in addition 
to the nuclear relocalization, the PDZ domains of ZO-2 induced cytosolic patches that 
contained ARVCF. While the nature of these patches remains to be elucidated, they did 
not contain E-cadherin nor did they colocalize with a lysosomal marker (our unpublished 
results). 
Little is known about the role of ARVCF in cell-cell adhesion. Members of the 
p120ctn family bind laterally to cadherins and have been postulated to regulate, positively 
or negatively, the lateral clustering of adhesion complexes (Ozawa and Kemler, 1998) 
and thus adhesive strength (Ozawa and Kemler, 1998; Yap et al., 1998). More recently, 
several p120ctn family members, including ARVCF, have been implicated in cadherin 
turnover (Davis et al., 2003). Despite a common role in cadherin turnover, ARVCF lacks 
the cellular branching activity associated with the expression of p120ctn in fibroblasts 
(Mariner et al., 2000; Reynolds et al., 1996), or the induction of a fibroblastoid 
phenotype observed for δ-catenin in MDCK cells (Lu et al., 1999). Consistent with these 
studies, I did not observe morphological changes by overexpressing wild-type or mutant 
ARVCF in several cell lines including 3T3 adipocytes, where Xenopus laevis ARVCF 
has been reported to induce branching (Fang et al., 2004). This apparently contradictory 
result may reflect the fact that Xenopus ARVCF is structurally more closely related to 
mammalian p120ctn than to mammalian ARVCF. Although E-cadherin, ZO-1 and 
ARVCF may play a role in initial stages of cell-cell adhesion, assembly of junctional 
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components was not visibly altered by the overexpression of wild-type or mutant 
ARVCF. Also other functional parameters, such as transepithelial resistance, cyst 
formation in Matrigel and wound healing were not significantly altered, possibly 
reflecting an extensive functional redundancy between ARVCF and the more abundant 
p120ctn (Davis et al., 2003; Fang et al., 2004). Since ZO-1 links to the actin cytoskeleton 
(Fanning et al., 1998b; Wittchen et al., 1999), one function of the interaction of ARVCF 
with ZO-1 may be to anchor cadherins, possibly in the vicinity of the apical adhesion 
complex, to F-actin. 
In conclusion, although the precise cellular functions of ARVCF remain to be 
elucidated, its recruitment to either the plasma membrane or the nucleus, and hence 
postulated functions in adhesion and transcription, respectively, appear to be tightly 
regulated by interactions with PDZ-domain proteins. The C-terminal PDZ-binding motif 
in ARVCF is conserved among the different alternative splice variants and, with the 
exception of p120ctnitself, is also found in the other p120ctn family members (see Figure 
39B), suggesting that they may also bind ZO-1, ZO-2, or other PDZ-domain proteins. 
Whether these interactions regulate the subcellular localization of other members of the 





Fig. 39: Putative E-cadherin/ARVCF/ZO-1 associations and C-terminal PDZ 
binding motifs in members of the p120ctn protein family. A. Schematic model of 
possible E-cadherin complexes. Cadherins may associate directly with the armadillo 
repeats of ARVCF, which in turn may bind to the ZO-1 PDZ domains via its PDZ-
binding motif. Alternatively, cadherins may bind ARVCF indirectly via their known 
interaction with β- or γ-catenin, α-catenin and ZO-1. ZO-2 may also associate with 
ARVCF. B. Alignment of the C-terminus of different members of the p120ctn protein 
family. The C-terminal ten amino acids of ARVCF splice variants and the different 
members of the p120ctn family are aligned. Identical amino acids are boxed and shaded. 
With the exception of p120ctn itself, the C-terminal PDZ-binding SWV motif identified in 
ARVCF is conserved, indicating that other members of the p120ctn family may also bind 
to ZO-1, ZO-2 and possibly other PDZ-domain proteins. 
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CHAPTER 3: Characterization of Claudin-16/Paracellin-1 and 
mutants associated with familial hypomagnesaemia with 
hypercalciuria and nephrocalcinosis (FHHNC) 
 
Section 3.1: Claudin-16 
3.1.1: Magnesium Homeostasis and Reabsorption 
The kidney plays a central role in magnesium homeostasis. Approximately 80% 
of the total plasma magnesium is filtered through the glomerulus and then reabsorbed in 
the nephron. The permeability of the nephron changes throughout development and 
decreases with age (Lelievre-Pegorier et al., 1983). In adults, 15-20% of the magnesium 
is reabsorbed by the proximal convoluted tubule while 70% of magnesium is reabsorbed 
by the cortical segment of the thick ascending limb of Henle (cTALH) (Fig. 40). 
However, in neonates much of the magnesium resorption occurs in the proximal tubule. 
The medullary segment (mTAL) does not absorb magnesium and the distal convoluted 
tubule reabsorbs the remaining 5-10% of the magnesium. Only less than 5% of the 
initially filtered magnesium is normally excreted in the urine.   
A number of renal magnesium wasting diseases arising from genetic disorders 
have been identified in the past decade. These disorders arise with different modes of 
inheritance and are linked to genes encoding proteins involved in different aspects of 








Fig. 40: Magnesium resorption in nephron segments. Up to 70% of the filtered 
magnesium is reabsorbed by the cortical segment of the thick ascending limb (cTAL), 
while the medullary segment (mTAL) does not reabsorb magnesium. While the distal 
convoluted tubule reabsorbs the remaining 5-10% magnesium (Figure obtained from 
Cole and Quamme, 2000).   
 
3.1.2: Claudin-16/Paracellin-1 and renal magnesium wasting disorder 
Using positional cloning, Simon et al., 1999 identified mutations in Paracellin-
1/Claudin-16 gene where the protein specifically localizes to the TAL, as being 
responsible for the recessive renal disorder, familial hypomagnesaemia with 
hypercalciuria and nephrocalcinosis (FHHNC). Based on the excessive excretion of 
magnesium and calcium in FHHNC, they proposed that claudin-16 forms a paracellular 
pore selective for Mg2+ and Ca2+ ions (Simon et al., 1999).  
Claudin-16 gene encodes a 233 amino acid protein. Claudin-16 has four 
transmembrane domains and has sequence and structural similarity to other claudin 
members and is most closely related to claudin-12 (Loh et al., 2004). However, claudin-
16 has only 10-18% similarity to each claudin member with the highest homology in the 
first extracellular loop, which is thought to form the bridge in the intercellular space. Like 
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other claudins, claudin-16 also has a PDZ binding motif in its C-terminus, but its Thr-
Arg-Val motif differs from that present in all other mammalian claudins. 
 
 
Fig.41: Sequence, structure and expression of claudin-16. (A) The amino acid 
sequence of claudin-16 with two putative ATG start sites. Genomic sequence analysis has 
revealed that the Met in position 71 is the start site. (B) Dendrogram of claudin-16 and 
other members. (C) Northern blot analysis of claudin-16 from human tissues. (D) 
Genomic organization of claudin-16 where it is encoded by five exons. (E) Claudin-16 
expression in the TAL segments and distal convoluted tubule, where a rabbit nephron 
segment is used for mRNA extraction and RT-PCR. mTAL and cTAL- medullary and 
cortical thick ascending limb respectively; DCT- distal convoluted tubule; CNT- 
connecting tubule; CCD- cortical connecting duct; OMCD and IMCD- outer and inner 
medullary collecting duct, respectively (Figure reprinted from Simon et al., 1999 with 






Northern analysis revealed that claudin-16 (CLDN-16) is exclusively expressed in the 
kidney and RT-PCR from nephron segments shows that it is expressed in the TAL 
segments and distal convoluted tubules (Fig 41), which are the main segments of the 
kidney involved in Mg2+ resorption. Localization of CLDN-16 was detected at 
intercellular junctions of a subset of renal tubules in kidney sections, were it co-localized 
with another tight junction protein, occludin (Simon et al., 1999). 
3.1.3: Magnesium Resorption Mechanism  
 De Rouffignac and colleagues in 1998 reported the passive transepithelial 
magnesium resorption, with the ions being transported from the lumen to the interstitial 
space through the paracellular pathway (Fig. 42). The main driving force of this transport 
is the transepithelial electrochemical gradient, which is generated by the Na+-K+-Cl- co-
transport and the active Na+ absorption. Any changes that influence the transport of Na+-
K+-Cl- and sodium active transport and /or the transepithelial electrochemical gradient 
will affect the permeability of the paracellular pathway and Mg2+ resorption. Thus, in 
addition to CLDN-16, mutations in other genes, including those mentioned above (i.e. 
Na+ transporter and Na+-K+-Cl- co-transporter or the Mg2+ sensing receptor), will lead to 
an imbalance in Mg2+ homeostasis. Although the paracellular pathway of Mg2+ is driven 
by an electrochemical gradient, transport is selective for Mg2+ and Ca2+ ions, probably 
due to the role of CLDN-16 in facilitating passage for these cations across the TJ in the 
TALH. Consistent with a role of CLDN-16 in cation transport is the observation that 
claudin-16 carries the most negative charges in the extracellular loops (in particular the 


























Fig.42: A schematic model of magnesium resorption in the cortical ascending limb 
(cTAL) of Loop of Henle. Magnesium reabsorption is passive process that occurs 
through the paracellular pathway, which involves TJ protein, claudin-16. The 
electrochemical gradient for Mg2+ transport is driven by Na+-K+-Cl- co-transport and the 











3.1.4: Familial hypomagnesaemia with hypercalciuria and nephrocalcinosis 
linked to mutations in CLDN16 gene  
 Familial hypomagnesaemia with hypercalciuria and nephrocalcinosis (FHHNC) 
is an autosomal recessive disorder that is characterized by renal magnesium wasting 
resulting in persistent hypomagnesaemia with hypercalciuria and nephrocalcinosis (Table 
7). Other symptoms include ocular abnormalities such as severe myopia, nystagmus and 
chorioretinitis (see pg13 for medical definitions). Hearing impairment, tenany, seizures, 
chondrocalcinosis, rickets and arterial hypertension have also been reported. 
Hypomagnesaemia is unresponsive to magnesium administration. The marked increase in 
urinary calcium predisposes to renal stone formation that in most cases leads to end-stage 
renal failure, requiring renal transplantation. In contrast, to primary hypomagnesaemia, 
FHHNC is complicated by chronic renal failure in early childhood or adolescence.  In 
addition to the reported mutations in CLDN16 in humans, a deletion mutation in bovine 
CLDN16 has also been documented to give rise to hypomagnesaemia and hypercalciuria 
in cattle (Ohba et al., 2000).  
 More than twenty CLDN16 mutations have been reported in affected 
individuals. Fig. 43 shows the topology of CLDN16 and highlights the mutations that 
have been reported to cause FHHNC (Simon et al., 1999; Weber et al., 2001b). Although, 
the precise molecular mechanism by which these mutations affect CLDN16 function is 
not known, it has been postulated that they may affect the paracellular cation transport 




































Fig.43: Predicted topology of CLDN16 and the location of the different mutations 









3.1.5: Objective of study 
 This study was initiated due to the identification in two families with idiopathic 
hypercalciuria of a novel mutation in CLDN16 that affects the putative C-terminal PDZ-
binding motif. Since, the C-terminus of CLDN16 varies considerably compared to that of 
other claudins, and since CLDN16 has not been reported to interact with ZO proteins, we 
analyzed if this interaction occurs and if is affected by the mutation associated with 
hypercalciuria. Furthermore, we sought to analyze the molecular mechanism by which 
this mutation results in a nonfunctional CLDN16 molecule. The analysis was then 
extended to an additional twenty mutations in the CLDN16 gene, which are linked to 
FHHNC. We analyzed the effect of the different mutations on the intracellular transport 
of CLDN16 and its paracellular magnesium transport function. This study was done in 
collaboration with Dr Dominik Muller (Charite Children’s Hospital, Dept of Pediatric 
Nephrology, Berlin, Germany) and co-workers, who identified the novel mutation in 
CLDN16 and provided the clinical data for the patients as well as Dr Michael Fromme 
and co-workers (Dept of Clinical Physiology, Benjamin Franklin Medical School, Freie 
Universitat Berlin, Germany), who carried out the electrophysiological analysis of 








Section 3.2:  Results on CLDN16 and mutations 
3.2.1: Characterization of an antibody to the first extracellular loop of 
CLDN16 
To monitor cell surface expression and intracellular trafficking of CLDN16, an 
antibody to the first extracellular loop was generated. To test if the antibody recognizes 
endogenous CLDN16 expressed in cells, parental MDCK or HeLa cells or cells 
expressing a HA-tagged CLDN16 construct were incubated with anti-loop antibody at 
4°C or 37°C and bound anti-loop antibody was subsequently detected by 
immunofluorescence staining. No bound anti-loop antibody could be detected in MDCK 
cells at 4°C (data not shown); however it was present at cell-cell contact as well as 
intracellular vesicles of cells, suggesting endocytosis of the antibody (Fig. 44a). In 
addition, the specificity of the antibody was tested with appropriate controls such as 
preimmune serum (Fig. 44a) and a competition binding experiment where 100 µM excess 
of peptide was pre-incubated with the antibody before adding to the surface of MDCK 
cells (Fig. 44a’’). This confirmed that the plasma membrane staining is specific and 
indicated that MDCK cells express CLDN16 endogenously. Furthermore, these two 
controls establish that the anti-CLDN16 loop antibody internalization did not occur via 
fluid-phase endocytosis, but most likely occurred following binding to CLDN16 
molecules exposed on the cell surface.  
A cell surface and vesicular staining was also observed in MDCK cells expressing 
exogenous HA-tagged CLDN16 incubated with the anti-loop antibody at 37°C. As 
expected, the labeling for the anti-loop antibody (Fig. 44b) and the HA antibody (Fig. 
44b’) partially overlapped (Fig. 44b”). CLDN16 molecules labeled by both antibodies 
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represent a subset that has been exposed on the cell surface and was thus able to bind the 
anti-loop antibody present in the media, whereas molecules only labeled with the anti-HA 
antibody are probably in transit in different compartments of the biosynthetic pathway. 
Interestingly, no staining was observed if either MDCK cells or transfected HeLa cells 
were incubated with the anti-loop antibody at 4°C, or if cells were fixed prior to staining, 
possibly reflecting a restricted accessibility of the epitope at low temperature and/or 
sensitivity to fixation.    
In conclusion, the anti-loop antibody is a sensitive tool to detect the appearance of 
CLDN16 at the cell surface and its vesicular localization indicates that CLDN16 can 
undergo endocytosis.  
   
3.2.2: Cldn16 internalizes via clathrin-dependent pathway 
 To confirm that Cldn16 is endocytosed, I analyzed if Cldn16 is delivered to early 
endosomes and if internalization occurs via clathrin- or caveolae-dependent mechanism. 
 HeLa cells expressing HA-Cldn16 were allowed to internalize anti-loop antibody 
at 37°C. The anti-loop antibody and early endosomes were then immunolabelled and 
visualized by confocal immunofluorescence microscopy. As shown in Fig. 44c-c”, the 
anti-loop antibody internalized via Cldn16 (panel c) extensively co-localized with early 
endosomal marker antigen 1 (EEA1) (panel c’). 
 To determine if Cldn16 internalizes via clathrin- or caveolae-dependent pathway, 
HeLa cells expressing HA-Cldn16 were incubated with anti-loop antibodies at 37°C and 
subjected to different experimental conditions that selectively affect clathrin- and 
caveolae-dependent pathway. Hypertonic media or cytosol acidification, which 
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selectively block clathrin-mediated endocytosis (Sandvig et al., 1987; Heuser et al., 
1989), resulted in the accumulation of Cldn16 on the plasma membrane (compare Fig. 
44d and e to f, b’ or c). In contrast, cholesterol oxidase, a selective inhibitor of caveolae 
mediated uptake (Smart et al., 1994; Coconnier et al., 2000), did not interfere with the 
internalization of Cldn16 to early endosomes (Fig. 44f).  

























































Fig. 44: Clathrin mediated endocytosis of Cldn16. a-a”. Characterization of an 
antibody to the first extracellular loop of Cldn16 and endogenous Cldn16 expression in 
MDCK cells. MDCK cells were incubated for 1 hr at 37°C in the presence of anti-loop 
antibody alone (a) or together with antigenic peptide (a’), or preimmune serum (a”). b-
b”. Detection of HA-tagged Cldn16 expressed in HeLa cells. HeLa cells expressing N-
terminally HA epitope tagged Cldn16 were incubated for 1 hr at 37°C with anti-loop 
antibody. HACldn16 (b) and the anti-loop antibody (b’) were then detected in 
permeabilized cells. Merging the HA and anti-loop antibody staining shows extensive 
colocalization in intracellular vesicles (b”). c-c”. Presence of Cldn16 in early endosomes. 
HeLa cells expressing HA-Cldn16 were incubated for 1 hr at 37°C with anti-loop 
antibody. The anti-loop antibody (c) and early endosomes (c’) were visualized by 
immunofluorescence microscopy and the two images merged (c”).  d-f. Clathrin 
mediated internalization of Cldn16. Hela cells expressing HA-Cldn16 were incubated for 
1 hr at 37°C with anti-loop antibody under either hypertonic (d) or cytosol acidified (e) 
conditions, or in the presence of cholesterol oxidase (f) to disrupt clathrin or caveolae 
function, respectively. The anti-loop antibody was then visualized by 
immunofluorescence microscopy. In (f), cells were stained with antibodies to the early 
endosome marker EEA1 and the merged image is shown. 2-3 independent experiments 
were performed and data from a representative experiment is shown. 
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3.2.3: Subcellular and surface expression of Cldn16 mutations 
 
To analyze the subcellular steady state localization of the Cldn16 mutants 
identified in patients with FHHNC (Fig. 43) Cldn16 mutants were expressed in HeLa 
cells as HA-tagged proteins. Cells expressing similar amounts of the different mutants 
were then incubated in the presence of the anti-loop antibody for 1 hr at 37°C, fixed, 
permeabilized, and the anti-loop antibody and the HA-tag stained and visualized by 
confocal immunofluorescence microscopy. 
Several Cldn16 mutants, in particular Cldn16 W47X (Fig. 45a), N53fs (Fig. 45b), 
R79X (Fig. 45g), L81F (Fig. 45h), L81W (Fig. 45i), G92V (Fig. 45j), L97P (Fig. 45k), 
G121R (Fig. 45l), G163D (Fig. 45q), S165F (Fig. 45r) and S165P (Fig. 45s), showed a 
predominant intracellular localization and could not be detected on the cell surface as 
evidenced by their inability to bind anti-loop antibodies. These mutants also failed to 
internalize the anti-loop antibody, indicating that they were not exposed, even transiently, 
on the cell surface. In contrast, Cldn16 A62V, H71D, L75P, R79L, G128A, A139T, 
R146T, F162C, G169R and T233R (Fig. 45) were able to bind and internalize the anti-
loop antibodies. 
In conclusion, several mutations linked to FHHNC affect the normal subcellular 
distribution of Cldn16, presumably reflecting defects in intracellular trafficking at the 






































Fig. 45: Cell surface expression of Cldn16 mutants linked to FHHNC. HeLa cells 
transiently expressing the indicated HA-Cldn16 mutants were incubated in the presence 
of anti-loop antibody for 1 hr at 37°C and then immunolabelled to detect the HA tag (red 
color) or the anti-loop antibody (green color). Merged images for the two labeling are 
shown. 2-3 independent experiments were performed and data from representative 
experiment is shown. 
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3.2.4: Cldn16 mutants that fail reach cell surface localize to the ER and 
Golgi 
To identify compartments to which Cldn16 mutants with a predominant 
intracellular steady-state distribution localize, we carried out colocalization experiments 
with markers for the ER (calreticulin), the Golgi complex (GM130) and lysosomes 
(CD63) in MDCK and HeLa cells. Selected mutants are represented in Fig. 46.   
 Cldn16 W47X, N53fs (Fig. 46a-a” and b-b”), R79L, R79X, L81F, L81W, G92V, 
L97P, G121R, G163D, S165F, S165P and G169R (data not shown) showed extensive 
colocalization with the ER marker. Since the ER and Golgi complex is often difficult to 
distinguish, cells were treated with nocodazole to alter the morphology of the Golgi 
complex and the different Cldn16 mutants then colocalized with the Golgi marker 
GM130. Of the mutants showing a predominant intracellular localization, Cldn16 R97X 
(Fig. 46c-c” and d-d”), L81F, L81W and G121R (data not shown) showed extensive 
colocalization with GM130. In addition, G121R extensively co-localized with lysosomes 
(Fig. 46e-e” and g-g”). 
In conclusion, Thus, Cldn16 mutants that fail to appear on the cell surface show 
















Fig. 46: Steady-state localization of Cldn16 mutants to different subcellular 
organelles. N53fs mutant has a predominant ER localization where it colocalizes with 
ER marker calreticulin in MDCK (a-a”) and HeLa (b-b”) cells. R79X localizes in the 
Golgi apparatus with Golgi marker GM130 in MDCK (c-c”) and HeLa cells (d-d”). 
G121R localizes to lysosomes in MDCK cells with Lamp2 (e-e”) and with CD63 in HeLa 
cells (g-g”). 2-3 independent experiments were performed and data from a representative 









3.2.5: Characterization of trafficking defects of Cldn16 mutants displaying a 
predominant intracellular steady-state localization 
In addition to the predominant localization to a particular intracellular 
compartment at equilibrium described above, several Cldn16 mutants were also detected, 
to varying extents, in other organelles.  For example, in addition to the ER, Cldn16 
G169R was also detected in the Golgi complex (data not shown) and the cell surface (see 
Fig. 45t). Cldn16 R79X, L81F and L81W, which predominantly localized to the Golgi 
complex, were also detected in lysosomes (data not shown). The mainly lysosomal 
Cldn16 G121R could also be detected in the ER and the Golgi complex (data not shown). 
To further characterize the trafficking defects associated with the different intracellular 
Cldn16 mutants we incubated cells at 20°C, conditions that block the exit of proteins 
from the Golgi complex and Trans-Golgi network (TGN) (VanSlyke et al., 2000; Matlin 
et al., 1983). Cldn16 mutants were then analyzed for their colocalization with GM130 
(Fig. 47; 20°C). Hence, if a particular Cldn16 mutant fails to exit the ER, it is expected to 
not colocalize with the Golgi marker under these conditions. Alternatively, following the 
20°C incubation protein synthesis and degradation were inhibited with cyclohexamide 
and N-acetyl–leu-leu-norleucinal (ALLN), respectively, and cells shifted to 37°C prior to 
stained for GM130 (Fig. 47; 20°C->1 hr 37°C) or CD63 (Fig. 47; 20°C -> 6 hrs 37°C). 
This experiment determines if a particular Cldn16 mutant is retained in the Golgi 
complex, or, if it exits the Golgi complex, is delivered to lysosomes. 
Cldn16 W47X (Fig. 47a-a”), N53fs (Fig. 47b-b”), R79L (Fig. 47d-d”), G92V 
(Fig. 47g-g”), L97P (Fig. 47h-h”), G163D (Fig. 47j-j”), S165F (Fig. 47k-k”) and S165P 
(Fig. 47l-l”), which all display a predominant ER equilibrium localization, did not 
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colocalize with GM130 following the 20°C incubation (20°C) and, as expected, neither 
colocalized with GM130 (20°C -> 1 hr 37°C) nor CD63 (20°C -> 6 hrs 37°C) after 
release from the 20°C block. These results strongly indicate that these mutants are unable 
to exit the ER.  
In contrast, Cldn16 R79X (Fig. 47c-c”), L81F (Fig. 47e-e”), L81W (Fig. 47f-f”) 
and G121R (Fig. 47i-i”), which show a predominant Golgi equilibrium localization, 
extensively colocalized with GM130 at 20°C (20°C). Interestingly, following release 
from the 20°C block, a significant fraction of these mutants no longer colocalized with 
GM130 (20°C -> 1 hr 37°C) and appeared in a vesicular compartment positive for CD63 
(20°C -> 1 hr 37°C). Thus, although at equilibrium these mutants show a predominant 
Golgi localization, they can exit the Golgi complex and reach lysosomes. 
In conclusion, Cldn16 mutants that display predominant intracellular equilibrium 








Fig. 47: Characterization of intracellular trafficking defects of different Cldn16 
mutants. Transfected HeLa cells expressing the indicated HA-Cldn16 mutants were 
incubated at 20°C for 3h to allow transport out of the ER but prevent exit from the Golgi 
complex and TGN.  Cells were then either processed for immunofluorescence staining 
(20°C) or transferred to 37°C for 1 hr (20°C -> 1 hr 37°C) or 6 hrs (20°C -> 6 hrs 37°C) 
in the presence of cycloheximide and ALLN to inhibit de novo protein synthesis and 
degradation, respectively. The cells were then immunostained with antibodies to HA to 
detect the tagged Cldn16 mutant (red color) and either the Golgi marker GM130 or the 
lysosomal membrane protein CD63 (green color). 2-3 independent experiments were 
performed and data from a representative experiment is shown. 
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3.2.5: Cldn16 mutants retained in the ER are subject to proteosomal 
degradation 
I next determined whether Cldn16 mutants that are retained in the ER are targeted 
for proteasomal degradation by the ER quality control machinery. HeLa cells expressing 
wt HA-Cldn16 or different mutants were incubated in the absence or presence of the 
proteasome inhibitor ALLN for 10 hr and then stained with antibodies to HA and 
ubiquitin (Fig. 48). Little ubiquitin was detected in cells expressing Cldn16 and, in the 
presence of ALLN, the ubiquitin staining did not increase significantly and also did not 
colocalize with Cldn16. In contrast, cells expressing Cldn16 W47X, N53fs, R79L, G92V, 
G163G and S165P/F, which are retained in the ER, showed increased ubiquitin labeling 
that was further enhanced in the presence of ALLN and extensively colocalized with the 
corresponding Cldn16 mutants. Mutants with a predominant Golgi and a partial ER 
localization (i.e. Cldn16 R79X, L81F, L81W and G121R) also showed an increased 
colocalization with ubiquitin in the presence of ALLN. Cldn16 T233R, which is 
predominantly found in lysosomes, did not colocalize with ubiquitin. 
These data, suggesting that Cldn16 mutants that are retained in the ER are 
ubiquitinated and degraded by the proteasome, was corroborated biochemically. HEK-
293T cells transiently expressing wt Cldn16 or selected mutants were incubated for 6 hrs 
in the presence or absence of ALLN and Cldn16 protein levels were determined by 
Western blot analysis. As shown in Fig. 49A, inhibiting proteasomal degradation did not 
significantly alter protein levels for wt Cldn16 or mutants that are transported to the cell 
surface (i.e. Cldn16 A139T) or lysosomes (i.e. T233R). In contrast, the ER retained 
Cldn16 G92V, R79L, L97P, G163D and S165P/F accumulated in the presence of ALLN, 
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consistent with these mutants being subject to proteasomal degradation under normal 
conditions. Cldn16 G121R, which is predominant in lysosomes at equilibrium but can 
also be detected in the ER, was moderately stabilized by ALLN. 
To further substantiate these data, 293T cells expressing Cldn16 or Cldn16 G92V 
were treated with cyclohexamide to inhibit de novo protein synthesis (Wettstein et al., 
1964) and Cldn16 protein levels monitored every 2 hrs by Western blot analysis. Only 
25% of the Cldn16 initially present was detected in cells treated for 10 hrs with 
cyclohexamide and the addition of ALLN only led to a modest stabilization. In contrast, 
the ER retained Cldn16 G92V turned over more rapidly than wt Cldn16 and its turnover 
was blocked by ALLN (Fig. 49B). 
 Taken together, these results show that Cldn16 mutants that are retained in the 















Fig. 48:  Colocalization of Cldn16 mutants with ubiquitin is increased in the 
presence of a proteasome inhibitor. Transfected HeLa cells expressing HA-Cldn16 or 
the HA-Cldn16 mutants indicated were incubated for 10 hrs in the absence (A-L) or 
presence (A’-L’) of the proteasome inhibitor ALLN. Cells were then immunostained with 
antibodies to detect the HA-tagged Cldn16 mutant (red color) or ubiquitin (green color). 
Colocalization of the different stainings is apparent in the merged images (yellow color). 







































Fig. 49: ER-retained Cldn16 mutants are subject to proteasomal degradation. A. ER 
retained Cldn16 mutants are stabilized by proteasome inhibitors. HEK-293T cells 
transiently expressing the indicated HA-Cldn16 mutants were incubated in the absence (-
) or presence (+) of the proteasome inhibitor ALLN. Cells were then lysed and Cldn16 
detected by SDS-PAGE and Western blot analysis. Blotting for actin served as a loading 
control (data not shown). B. Turnover of ER retained Cldn16 mutants are blocked by 
proteasome inhibitors. HEK-293T cells transiently expressing HA-Cldn16 or the ER 
retained HA-Cldn16 G92V were cultured in cycloheximide to block de novo protein 
synthesis for the periods of time indicated, either in the absence or presence of the 
proteasome inhibitor ALLN. Cells were then lysed and Cldn16 detected by SDS-PAGE 
and Western blot analysis. Blotting for actin served as a loading control. 2-3 independent 






3.2.6: T233R mutation disruption PDZ binding motif and is mistargeted to 
the lysosomes 
  T233 is part of the C-terminal threonine-arginine-valine (TRV) sequence that 
resembles a putative type I PDZ-binding motif (Hung and Sheng, 2002; Saras and 
Heldin, 1996), and some claudins have been reported to interact with PDZ-domains 
proteins in particular the ZO-1, ZO-2 and ZO-3 (Gonzalez-Mariscal et al., 2000; Itoh et 
al., 1999a).  I therefore determined whether CLDN16 interacts with ZO proteins and 
localizes to the TJ and whether T233R mutations affects its interaction or localization.  
 Immobilized peptides corresponding to the C-terminal 11 amino acids of wild-
type CLDN16 bound in vitro translated PDZ domains of ZO-1, showing that the TRV 
sequences codes for a functional PDZ binding motif. No specific interaction with PDZ 
domains of ZO-2 and ZO-3 were observed (Fig. 50A). The interaction between the 
T233R mutant peptide and the ZO-1 PDZ domains were eliminated. Binding to the 
immobilized wild-type CLDN16 peptide was abolished if the in vitro translated ZO-1 
PDZ domains were pre-incubated with soluble wild-type CLDN16 peptide, whereas the 
T233R peptide had no effect (Fig. 50B), confirming the specificity of the interaction. In 
addition, GST-PDZ-1 of ZO-1 interacted with immobilized CLDN16 peptides and not 
with PDZ -2 and -3, also T233R immobilized peptide did not interact with any of the 
GST fusion ZO-1 PDZ domains (Fig. 50C). Furthermore in MDCK cells stably 
expressing wild-type or T233R mutant CLDN16 carrying hemagglutinin epitope tag but 
not T233R mutant co-immunoprecipitated with endogenous ZO-1 (Fig. 50D), which is 
consistent with in vitro binding data.  In conclusion, CLDN16 specifically binds ZO-1 
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Fig. 50: Binding of wild type and mutant CLDN16 to ZO-1. a. Wild type CLDN16, 
but not the T233R mutant, binds to the ZO-1, but not the ZO-2 and ZO-3 PDZ 
domains. (A) In vitro translated and radioactively labelled ZO-1, ZO-2 or ZO-3 PDZ 
domains were incubated with peptides corresponding to the C-terminus of wild type 
(WT) or T233R mutant CLDN16 coupled to beads. Protein bound to the beads (Pull-
down) was analyzed by SDS-PAGE and autoradiography and an aliquot (5%) of the in 
vitro translated material was directly analyzed to confirm that similar amounts of the in 
vitro translated proteins were added to the binding reaction (Input). (B) Pre-incubation 
with wild type, but not T233R mutant peptides competes with ZO-1 PDZ binding to 
beads. In vitro translated and radioactively labelled ZO-1 PDZ domains were pre-
incubated with soluble wild type or mutant CLDN16 peptides prior to the incubation with 
the peptide-coupled beads. (C) CLDN16 or T233R peptide coupled to beads were 
incubated with GST fused PDZ-1, -2 or -3 or 1-3 domains of ZO-1. Bound fusion product 
was detected by staining with Ponceau red solution. (D) Wild type CLDN16, but not the 
T233R mutant, co-precipitates with ZO-1. Control cells (MDCK) or cells stably 
expressing wild type (CLDN16) or mutant (T233R) CLDN16 were lysed and equal 
amounts of total protein used to immunoprecipitate CLDN16. Precipitates were blotted 
with anti-ZO-1 antibody to detect ZO-1 bound to CLDN16. In the reverse experiment, 
wild type, but not mutant CLDN16 also associated with anti-ZO-1 precipitates (data not 
shown). Aliquots of the cell lysate were directly blotted to confirm that the cells 
expressed similar amounts of ZO-1, as well as wild type and mutant CLDN16 (Input).  
D 
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In agreement with TJ localization in kidney cells in human tissue (Simon et al., 
1999), wild-type CLDN16 was present at the height of TJ of transfected polarized 
MDCK cell monolayers where it colocalized with ZO-1 (Fig. 51A). In contrast, bulk of 
T233R mutant showed intracellular vesicular distribution and membrane localization was 
not apparent (Fig.51A). Vertical confocal sections along the apicobasal axis of the cell 
monolayer confirmed the colocalization of CLDN16 and ZO-1 and the mis-localization 
of T233R mutant (Fig.51B). ZO-1 localization however, was not affected in cells 
expressing T233R. Thus T233R mutation affects the association of CLDN16 with ZO-1 
as well as its correct TJ targeting.  
 To determine the nature of the intracellular compartment in which the T233R 
mutant accumulated CLDN16 and different organelles were labeled in cells expressing 
either the wild type or T233R mutant. Mutant, but not wild-type, CLDN16 extensively 
colocalized with lamp-2, a marker for late endosome or lysosomes (Hunziker and Geuze, 
1996; Nabi et al., 1991) (Fig.51C). In contrast, no colocalization with Golgi marker, 
GM130 was observed, a result indicative of normal transport of T233R in the secretory 
pathway. Thus, the T233R mutant CLDN16 is mistargeted to the lysosomes.     
 




Fig. 51: Subcellular localization of wild type and mutant CLDN16. a. Co-localization 
of CLDN16 and ZO-1 is abolished by the T233R mutation. MDCK cells stably 
expressing wild type (CLDN16) or mutant (T233R) CLDN16 grown as polarized cell 
monolayers on polycarbonate filters were stained for ZO-1 (red) and CLDN16 (green) 
and confocal images corresponding to horizontal sections at the height of TJ were 
acquired. The merged image shows regions where CLDN16 and ZO-1 co-localize 
(yellow). b. TJ localization of CLDN16 is abolished by the T233R mutation. Vertical 
confocal sections along the apico-basal axis of the cell monolayers expressing wild-type 
(CLDN16) or mutant (T233R) CLDN16 labelled for CLDN16 (green colour) or ZO-1 
(red colour). The position of the filter supporting the cells and the TJ are indicated. c. 
T233R localizes to lysosomes. MDCK cells transfected with wild type (CLDN16) or 
mutant (T233R) CLDN16 were stained to visualize lysosomes (anti-lamp-2) or the Golgi 
complex (anti-GM130) (red) and CLDN16 (green) and confocal images were acquired.  
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3.2.7: Cldn16 mutants delivered to lysosomes use different routes 
Cldn16 T233R and G121R showed extensive lysosomal steady state localization. 
Lysosomal delivery of newly synthesized membrane proteins can occur either directly 
from the Golgi complex via endosomes, or indirectly following delivery to the plasma 
membrane and internalization (Hunziker et al., 1996) To analyze by which of the two 
routes Cldn16 T233R and G121R reach lysosomes, it was determined if live cells 
expressing the two mutants were able to bind and internalize anti-loop antibodies added 
to the medium at 37°C. 
Cells expressing Cldn16 T233R efficiently internalized anti-loop antibodies and 
these extensively colocalized with the lysosomal marker CD63 (Fig. 52a-a”), indicating 
that Cldn16 T233R was exposed on the cell surface prior to being internalized and 
transported to lysosomes. In contrast, cells expressing G121R failed to internalize anti-
loop antibodies (Fig. 52c-c”). To exclude the possibility that Cldn16 G121R failed to 
bind anti-loop antibodies due to a shorter residence time on the cell surface as compared 
to Cldn16 T233R, endocytosis was blocked using cytosol acidification (see above). 
Under these conditions, the anti-loop antibody stained the cell surface of cells expressing 
Cldn16 T233R and it was no longer transferred to lysosomes (Fig. 52b-b”), confirming 
that Cldn16 T233R transits through the plasma membrane before reaching lysosomes. In 
contrast, no anti-loop antibody was detected on the surface of cells expressing Cldn16 
G121R, even if internalization was blocked (Fig. 52d-d”), consistent with its direct 
transport to lysosomes. 
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Thus, Cldn16 T233R is transported to the plasma membrane, endocytosed and 
delivered to lysosomes, whereas Cldn16 G121R does not transit via the cell surface en 































Fig. 52: Cldn16 mutants that localize to lysosomes follow different pathways. 
Transfected HeLa cells expressing HA-Cldn16 T233R (a and b) or G121R (c and d) were 
incubated in the presence of anti-loop antibodies at 37°C for 1 hr, either under normal 
conditions (a and c) or cytosol acidification to block endocytosis (b and d). The cells 
were then immunostained with antibodies to detect the anti-loop antibody (a’-d’; green 
color), the HA-tagged Cldn16 mutant (b and d; red color) or the lysosomal membrane 
protein CD63 (a and c; red color). Colocalization of the different stainings is apparent in 
the merged images (a”-d”; yellow color). 2-3 independent experiments were performed 
and data from a representative experiment is shown. 
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3.3.8: Pharmacological chaperones rescue cell surface expression of several 
Cldn16 mutants 
Cell permeable chemical compounds that facilitate the folding of membrane 
proteins (pharmacological chaperones) have been shown to rescue surface expression of 
some misfolded ER-retained proteins (Ulloa-Aguirre et al., 2004). To explore if these 
compounds facilitate surface transport of intracellularly retained Cldn16 mutants, their 
subcellular localization was monitored by immunofluorescence microscopy in cells 
treated with two commonly used pharmacological chaperones, thapsigargin and 4-
phenylbutyrate (4-PBA). 
Although Cldn16 R79L, G121R and G169R could not be detected at the plasma 
membrane of control cells at steady state (Fig. 53a-c), all three mutants were readily 
detected on the cell surface of thapsigargin treated cells (Fig. 53a’-c’). 4-PBA efficiently 
rescued surface expression of Cldn16 G121R and G169R (Fig. 58a” and b”), but the 
effect on R79L (Fig. 53c”) was less pronounced. After treating cells with 
pharmacological chaperones, quantification reveals an increase in surface staining as 
compared to intracellular staining per cell (Fig. 53d).   In addition, quantification also 
showed that 3-8 times as many cells treated with the pharmacological chaperones 
expressed Cldn16 R79L, G121R or G169R on the surface as compared to control cells 
(Fig. 53e). The effect of the two compounds on other ER-retained Cldn16 mutants was 
less pronounced (data not shown). 
 In conclusion, pharmacological chaperones such as thapsigargin and 4-PBA are 
able to rescue cell surface expression of intracellularly retained Cldn16 mutants, in 













































































Fig. 53: Chemical chaperones rescue cell surface expression of several Cldn16 
mutants. Transfected HeLa cells expressing HA-Cldn16 G121R (a-a”), G169R (b-b”) or 
R75L (c and c’) were incubated in the presence vehicle (a-c), thapsigargin (a’-c’) or 4-
PBA (a” and b”) and anti-loop antibodies at 37°C. The cells were then immunostained 
with antibodies to detect the anti-loop antibody (green color). (d) 50 randomly chosen 
cells expressing the Cldn16 mutant were analyzed and the % of the total cell showing 
surface and intracellular staining per cell in the presence of the pharmacological 
chaperones were quantitated. (e) 100 randomly chosen cells expressing the Cldn16 
mutant were analyzed and the % of the cells showing surface expression in the presence 
of the pharmacological chaperones was determined. Data from three independent 
experiments is shown. 2-3 independent experiments were performed and data from a 




3.3.9: Cldn16 mutants present in TJ are defective in paracellular Mg2+ 
transport 
Several Cldn16 mutants associated with FHHNC (i.e. Cldn16 A62V, H71D, 
L75P, G128A, A139T, R146T and F162C) were delivered to the cell surface (see above), 
suggesting that they either may not localize to TJ or may be present at TJ but defective in 
paracellular Mg2+ and Ca2+ transport.  
To determine if Cldn16 A62V, H71D, L75P, G128A, A139T, F162C and R146T 
are present in TJ, MDCK cells stably expressing these mutants were generated. As 
observed in HeLa cells and similar to wt Cldn16, these mutants were present on the cell 
surface of MDCK cells (data not shown). To obtain a polarized cells monolayer, MDCK 
cells were grown on Transwell filters and the different Cldn16 mutants analyzed for their 
colocalization with the TJ marker ZO-1. Confocal imaging was used to obtain vertical 
optical sections across cell monolayers. As shown in Fig. 54, the different Cldn16 
mutants showed a similar extent of colocalization with ZO-1 as observed for wt Cldn16, 
indicating that a significant fraction of these mutants is present at TJ. 
The above findings indicated that the pathological phenotype associated with 
Cldn16 A62V, H71D, L75P, G128A, A138T, F162C and R146T does not reflect a defect 
in cell surface expression or TJ localization. Since Cldn16 is thought to mediate the 
paracellular transport of Mg2+ and Ca2+ and patients suffering from FHHNC have 
impaired renal resorption of these divalent cations, the Mg2+ permeability properties of 
MDCK cells expressing several mutants using modified Ussing chambers combined with 
atomic absorption spectrometry (AAS) were analyzed.  
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Mg2+ permeability across monolayers of control MDCK C7 cells and two clones 
each expressing either wild type Cldn16 or Cldn16 H71D, L75P, G128A and R146T was 
analyzed by means of AAS. In addition, transepithelial resistance was measured. Basal 
Mg2+ permeability in controls was 3 ± 0.2 x 10-3 cm h-1 (n=16, Fig. 55A). Cldn16 
expressing clones showed an increased Mg2+ permeability of 23.1 ± 8.4 x 10-3 cm h-1 
(n=12, *p<0.05).  In contrast, none of the mutants analyzed showed an increase of Mg2+ 
permeability. Mg2+ permeability of monolayers expressing Cldn16 H71D, L75P, G128A 
and R146T were 3.3 ± 0.9 x 10-3 cm h-1 (n=12), 3.6 ± 0.6 x 10-3 cm h-1 (n=7), 4.1 ± 0.5 x 
10-3 cm h-1 (n=10) and 3.2 ± 0.5 x 10-3 cm h-1 (n=12) and in each case not significantly 
different from control MDCK cells. Transepithelial resistances varied between 673 ± 110 
(Cldn16 L75P) and 1494 ± 164 (Cldn16 H71D) and no correlation between Mg2+ 
permeability and Rt was observed (Fig. 55B). 
These data show that at least four of the Cldn16 mutants linked to FHHNC that 























































Fig. 54: TJ localization of Cldn16 mutants expressed on the cell surface. Transfected 
MDCK cells expressing Cldn16 mutants that are delivered to the cell surface were grown 
on permeable polycarbonate filters to obtain polarized cell monolayers. The cells were 
then fixed, permeabilized and stained with antibodies to HA detect the Cldn16 mutants 
(green color) or ZO-1 (red color) to visualize the TJ. 2-3 independent experiments were 













































Fig. 55: Measurements of Mg2+ permeability (A) and transepithelial resistance (B). 
A. Monolayers of stable transfected MDCK cells were grown on permeable supports and 
mounted in Ussing chambers. Mg2+ was added to the basolateral side, and net flux was 
measured by means of atomic absorption spectrometry (AAS). B. Transepithelial 
resistance of the clones ranged between 673 ± 110 (L75P) and 1493 ±163 Ω ⋅ cm2 
(H71D). No correlation of Mg2+ permeability and transepithelial resistance Rt was 
observed (n= 7-16, *significant difference from controls, p<0.05). 
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3.3.10: Clinical phenotypes 
More than 20 different mutations in CLDN-16 gene have been reported to date in 
patients suffering from FHHNC  (Asplin, 1984; Blanchard et al., 2001; Simon et al., 
1999; Wolf et al., 2001; Ikari et al., 2004). Of 15 individuals carrying the L81F mutation, 
11 were homozygous for the mutation, the remaining compound heterozygous (Weber et 
al., 2001). Homozygous individuals for this locus lack a phenotype-genotype correlation 
and at the time of the study, 5 individuals had a glomerular filtration rate (GFR) > 60 
ml/min per 1.73 m2 body surface area, another 5 individuals had a GFR below 60 ml/min 
per 1.73 m2 body surface area, one patient was on dialysis and one had undergone renal 
transplantation. There was no linear correlation between disease progression and age. 
Patients with the L75P mutation were all compound heterozygous carriers with various 
other mutations on the second allele. Renal function ranged from being unaffected to end 
stage renal failure and renal transplantation. So far, only two mutations, W47X/L81F and 
T233R, have shown a consistent clinical phenotype among different patients. Two 
patients from the same family carrying the W47X/L81F needed renal replacement 
therapy (Weber et al., 2001), whereas four patients from two different families with the 
T233R mutation presented a GFR > 80 ml/min per m2 body surface (Muller et al., 2003). 
However, the collective in either case is too small for a definite phenotype-genotype 









Section 3.4: Discussion on Cldn16 and mutations 
Although over twenty mutations in CLDN16 have been described in patients 
suffering from FHHNC (Blanchard et al., 2001; Simon et al., 1999; Weber et al., 2001b) 
little is known about the molecular mechanism by which these mutations affect the 
function of CLDN16. The course of FHHNC is highly variable and symptoms can be 
mild in the beginning of the disease. No obvious genotype-phenotype correlation could 
be observed among patients with the same type of mutation; however, a close 
intrafamilial concordance was found with respect to progression of renal failure (Weber 
et al., 2001b; Wolf et al., 2002). Therapeutic success is poor for FHHNC in general. 
Continuous administration of magnesium supplements does not increase serum 
magnesium levels. In order to reduce progression of nephrocalcinosis by correcting 
hypercalciuria, drugs such as thiazides and indomethacin have been administrated with 
little success. Since the defect primarily occurs in the kidney, the only cure is renal 
transplantation. Here, a systemic analysis of the various CLDN16 mutants reported to 
cause FHHNC, shows that many of these mutations affect the correct intracellular 
trafficking of CLDN16. 
During their synthesis and insertion into the ER membrane, proteins associate 
with chaperones that facilitate their correct folding. Misfolded proteins are subsequently 
removed from the ER, ubiquitinated and degraded by the proteosome machinery (Jarosch 
et al., 2002; Sitia and Braakman, 2003). This quality control mechanism ensures that only 
correctly folded and thus functional proteins exit the ER for delivery to their final 
destination. The cause of a disease can be often the result of mutations in a protein and its 
degradation. In general, mutations can prevent the transport of integral proteins to the 
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plasma membrane, leading to loss of protein function. These mutations can be classified 
into two types (Aridor and Balch, 1999). Class I mutants prevent the transport to the cell 
surface and efficiently degrade the mutant proteins. Class II mutants prevent both the 
transport and degradation of the mutant. This results in accumulation in insoluble 
aggresomes in the cytosol which triggers chronic and pathological ER stress signals 
((Johnston et al., 1998); and reviewed by Aridor and Balch, 1999).  
While wild type CLDN16 is efficiently transported to the cell surface, several 
mutant CLDN16 (i.e. W47X, N53fs, G92V, L97P, G163D, S165F and S165P) cannot be 
detected on the plasma membrane but are retained in the ER. These mutants failed to 
reach the Golgi complex in cells incubated at 20°C, which allows the exit of proteins 
from ER but blocks transport at the level of the Golgi complex (VanSlyke et al., 2000) 
and the TGN (Matlin and Simons, 1983), indicating that these mutants were efficiently 
prevented from leaving the ER. Cells expressing these mutants showed more ubiquitin 
staining which was increased if cells were incubated with a proteosomal inhibitor, 
correlating with an accumulation of these mutants in treated cells. These results suggest 
that W47X, N53fs, G92V, L97P, G163D, S165F and S165P are retained in the ER, 
probably due to defects in folding or topology, and subject to ubiquitination and 
proteosomal degradation in the context of the ER quality control mechanism. Taking into 
considerations the results, one can conclude that these intracellularly trapped FHHNC 
mutants fall under the class I category (for example, G92V). 
Three of the Cldn16 mutants analyzed (i.e. Cldn16 L81F, L81W and R79X) are 
competent to exit the ER and predominantly localize to the Golgi complex at steady state. 
Cells expressing these mutants fail to bind or internalize the anti-loop antibodies, 
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indicating that these mutants do not reach the cell surface. Accumulation of these mutants 
in the Golgi complex at 20°C and release from the 20°C block result in their detection in 
lysosomes; indicating that if accumulated in the Golgi beyond a particular threshold, they 
may be delivered to lysosomes. The exit of these mutants may be blocked or slowed as 
part of a quality control system operating in the Golgi complex or the TGN (Arvan et al., 
2002). 
In contrast to Cldn16 L81F, L81W and R79X, Cldn16 T233R and G121R showed 
a predominant lysosomal localization even at steady state, suggesting efficient transport 
out of the Golgi complex. The T233R mutation affects a PDZ binding motif that fails to 
interact with ZO-1. Furthermore, T233R was able to bind and internalize anti-loop 
antibodies at 37°C and accumulated at the cell surface if endocytosis was inhibited, 
showing that a significant fraction of this mutant transits via the plasma membrane and 
then reaches lysosomes following endocytosis. Thus, the mutation may not affect the 
formation of a functional paracellular ion channel per se but rather shorten the residence 
time of CLDN16 molecules present at the TJ, thus reducing the number of CLDN16 
molecules present at the TJ at any given time. In contrast, Cldn16 G121R does not appear 
to be routed via the cell surface and is probably delivered from the Golgi complex to 
lysosomes either directly or via endosomes. How the G121R mutation facilitates direct 
transport of Cldn16 G121R to lysosomes is not clear. G121 is located in proximity of the 
cytosolic face of the third transmembrane domain and the preceding cytosolic loop 
contains a tyrosine containing sequence (YIKV) reminiscent of lysosomal targeting 
signals. The G121R substitution may induce a conformational change that exposes and 
facilitates the recognition of this motif by the TGN sorting machinery. 
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The remaining mutants we analyzed (i.e. Cldn16 A62V, H71D, L75P, G128A, 
A139T, R146T and F162C) were delivered to the cell surface, where, similar to wt 
Cldn16, they extensively colocalized with the TJ marker ZO-1. To explore a direct effect 
of point mutations in Cldn16 on Mg2+ permeability, monolayers of stably transfected 
MDCK cells were used for Mg2+ flux analyses. Atomic absorption spectrometry emerged 
to be a suitable technique for direct measurement of Mg2+ permeability. These 
experiments demonstrated that, as expected, expression of Cldn16 results in an increased 
Mg2+ permeability of cell monolayers. In contrast, Cldn16 H71D, L75P, G128A, and 
R146T did not lead to an increased Mg2+ flux. This is the first direct evidence for a lack 
of paracellular Mg2+ transport in vitro by point mutations in Cldn16 linked to FHHNC. 
The extracellular loops of CLDN16 are rich in charged amino acids, negatively charged 
residues in particular being thought to be important for the paracellular transport of 
divalent cations (Simon et al., 1999). Interestingly, however, mutations found so far in 
patients with FHNNC do not affect negatively charged amino acids. Therefore, these 
mutations may alter the secondary or tertiary structure of Cldn16 and hence impede 
paracellular Mg2+ transport. For example, the H71D substitution may disrupt electrostatic 
interactions, L75P alter the protein conformation, and F162C induce the formation of 
aberrant disulfide bonds. Little is known about the structural requirements for 
oligomerizaiton, either in cis or in trans, of Cldn16, which may also be affected by some 
of these mutations.  
Interestingly, Cldn16 can internalize via a clathrin-mediated pathway. Similar to 
wt Cldn16, mutants transported to the cell surface were detected in small vesicles positive 
for the early endosome marker EEA1. Since Cldn16 was also present in early endosomes 
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in the absence of anti-loop antibodies, internalization was not induced by antibody 
crosslinking. Cldn16 encodes several putative internalization signals within the cytosolic 
loop (YIKV) and the C-terminal tail (YRLS, YSAA, YSAP AND YAVD), which could 
mediate clathrin dependent endocytosis by interacting with the AP-2 adaptor. Although 
endocytosis of endogenous Cldn16 was detected in MDCK cells, a larger fraction was 
present in endosomes of HeLa cells, possibly because in MDCK cells Cldn16 is more 
efficiently retained at the surface through its interaction with ZO-1.  This interpretation is 
consistent with the observation that the association between Cldn16 and ZO-1 increases 
the reabsorption of divalent cations in renal epithelial cells (Ikari et al., 2004). Indeed, 
Cldn16 T233R, which no longer interacts with ZO-1, is efficiently internalized, 
indicating that it may be retained less effectively at tight junctions as compared to wt 
Cldn16 and, as a consequence, be subject to a faster rate of lysosomal delivery. 
Alternatively, the T233R mutation could affect post-endocytic sorting by, for example, 
diverting the protein from a recycling into a lysosomal pathway, or ZO-1 bound to 
Cldn16 could prevent lysosomal delivery. Indeed, the ability of connexins to associate 
with ZO-1 has been correlated with a longer half-life of these gap junction proteins 
(Barker et al., 2001 and Toyufuku et al., 2001). 
No clear correlation between the location of a particular mutation and its effect on 
Cldn16 localization was observed, although mutations occurring in the vicinity of each 
other generally showed a similar defect. For example, mutations in the N-terminal half of 
the first extracellular loop (i.e. W47X and N52fs), the first transmembrane domain (i.e. 
L75P and G92V) or the C-terminal region of the second extracellular loop (i.e. G163D, 
S165P and S165F) lead to ER retention, whereas mutations affecting the C-terminus of 
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the first extracellular loop (i.e. R79L and L81F) result in Golgi localization. Furthermore, 
several mutations that lead to different substitutions of the same amino acid (i.e. R79P/L, 
L81W/F, and S165P/F) display a similar phenotype. Furthermore, there was no apparent 
correlation between a particular mutation or subcellular localization of Cldn16 and a 
clinical phenotype. Where a tendency for such a correlation could be suspected (i.e. 
T233R and W47X/L81F), the collective is too small for a definite genotype-phenotype 
analysis. 
Intriguingly, pharmacological chaperones such as thapsigargin or 4-PBA were 
able to rescue cell surface transport of some intracellularly retained Cldn16 mutants, in 
particular Cldn16 R79L, G121R and G169R. The exact mechanisms by which exogenous 
chaperones function are not fully understood and differ from one compound to the other, 
but they may stabilize misfolded proteins, prevent their aggregation or non-productive 
interaction with ER resident proteins, or affect the activity of chaperones, thus allowing 
the retained protein to exit the ER (reviewed in (Ulloa et al., 2004)). Stabilizing 
compounds such as glycerol or DMSO have been used to rescue conformationally 
defective mutants of the CFTR (Sato et al., 1996), aquaporin-2 (Tamarappoo et al., 1999) 
and the V2 vasopressin receptor (Tan et al., 2003). 4-PBA, which reduces mRNA and 
protein levels of the heat-shock protein Hsc70 (Yang et al., 1996; Rubenstein et al., 
2000), and thapsigarin, which depletes ER calcium stores (Booth et al., 1989), rescue ER 
retained mutants of the CFTR and K+ channels, respectively (Yang et al., 1996; 
Rubenstein et al., 2000; Rubenstein et al., 1997; Delisle et al., 2003). 4-PBA in particular 
shows low cytotoxicity and is in clinical trials for cystic fibrosis (Rubenstein et al., 1998; 
Zeitlin et al., 2002). 4-PBA and thapsigargin showed a dramatic increase in the surface 
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expression of Cldn16 G121R and G169R. Thapsigargin, in addition, rescued surface 
expression of Cldn16 R79L. Since the effectiveness of pharmacological chaperones 
likely depends on the severity of the conformational defect (Ulloa et al., 2004), Cldn16 
G169R, R79L and G121R may be less severely misfolded as compared to the other ER 
retained Cldn16 mutants. In addition to pharmaceutical chaperones, endocytosis 
inhibitors could provide a therapeutic means of increasing the amounts of Cldn16 present 
on the cell surface in patients carrying T233R or mutations with a similar defect. These 
findings open new therapeutic avenues for patients suffering from FHHNC. 
In conclusion, mutations in Cldn16 associated with FHHNC can be classified into 
two groups: i) mutations that affect intracellular trafficking of Cldn16 and result in either 
ER retention, Golgi accumulation or lysosomal mistargeting, and ii) mutations that do not 
interfere with surface expression or TJ localization of Cldn16 but abolish its ability to 
facilitate paracellular divalent cation transport. The benefits of therapeutic intervention in 
FHHNC are in general poor and most patients eventually require kidney replacement 
therapy (Asplin et al., 1984). Thus, the finding that several Cldn16 mutants associated 
with FHHNC are absent from the cell surface and that cell surface expression or retention 
of some of these mutants can be rescued using pharmacological chaperones or 
endocytosis inhibitors, respectively, opens new therapeutic possibilities. 
 Fig. 56 and Table 8 summarize the steady-state localization and defects of Cldn16 






























Fig. 56: Predicted topology of Cldn16 and location of the different mutations linked 
to FHHNC reported. Shown are the amino acid sequence in the one-letter code, with 
mutated residues in yellow and the arrow indicating the change introduced by the 
mutation. The effect of the corresponding mutation on the predominant steady state 
distribution of Cldn16 is highlighted in different colors. Green, cell surface; red, ER; dark 
blue, Golgi complex, light blue, lysosomes.  X, stop codon, fs, frame shift. The peptide 












































Table 8: Summary of steady-state localization and defects of Cldn16 mutants linked to FHHNNC 
 185
Chapter 4: Concluding Remarks 
ZO-1 was originally identified at the tight junctions and surprisingly later at the 
adherens junctions and the gap junctions by several laboratories. ZO-1 has important 
structural and possibly signaling roles in TJ, AJ and gap junction organizations as 
reflected by work in this thesis as well as the work done by others. Interestingly, loss of 
ZO-1 is strongly correlated with tumor progression where it is downregulated in 
gastrointestinal adenocarcinoma (Kimura et al., 1997), breast cancer (Hoover et al., 
1998) and colonrectal carcinoma (Kaihara et al., 2003). 
The work presented here shows that ZO-1 is involved in the recruitment and 
retention of junctional integral and peripheral proteins such as Cldn16, Cx45 and ARVCF 
to TJ, gap junction and AJ, respectively. ZO-1 possibly tethers these proteins to the actin 
cytoskeleton resulting in the stability of these proteins at the junctions. Lack of 
association with ZO-1 may result in mistargeting and instability of these proteins at the 
plasma membrane, leading to degradation, which in turn results in the lack of function. 
This is observed in T233R Cldn16 mutation, which no longer interacts with ZO-1, 
resulting in its failure to targeting to TJ and to transport Mg2+ and Ca2+. This mutant is 
instead mistargeted to the lysosomes and gives rise to hypercalciuria in patients. In the 
case of Cx45, the mutant lacking the PDZ-binding domain resulted in more Cx45 mutant 
localizing in intracellular vesicles than in the plasma membrane. ZO-1 is thought to 
mediate connexon assembly, targeting and stability at the gap junction (see review Herve 
et al., 2004). ARVCF∆P too fails to bind to ZO-1 and is not recruited to the plasma 
membrane or nucleus. The recent discovery that the α-catenin in AJ binds either to the 
cadherin-β-catenin complex or to the actin cytoskeleton and not to both simultaneously 
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(Drees et al., 2005) suggests that the ZO-1-ARVCF interaction may instead provide a 
stable link to the actin cytoskeleton.  Thus, the E-cadherin-ARVCF-ZO-1 complex link to 
actin cytoskeleton could be mediated directly by ZO-1, thereby strengthening the AJ.  
In addition to its structural role, ZO-1 may also be involved in signaling pathways 
via nuclear shuttling proteins such as ARVCF and ZONAB. Although the exact role of 
ARVCF in the nucleus is unclear, this process seems to depend on binding to ZO-2 and 
possibly other PDZ domain proteins. Hence, it would be of interest to analyze if there are 
any changes in expression of genes in cells transfected with both ZO-2 PDZ and ARVCF 
by performing microarray or chromatin immunoprecipitation (CHIP) assays. This could 
give an indication of what signaling pathways are regulated by ARVCF and ZO-2. 
 My findings highlight the emerging notion of crosstalk between different 
junctions mediated by ZO proteins (Fig. 57). Indeed, many TJ proteins co-localize with 
AJ components during early stages of cell-cell adhesion and ZO-1 has been implicated in 
regulating trafficking of connexins and gap junction function. Further work will be 













Fig. 57: Multiple roles of ZO proteins in the different adhesion junctional 
complexes. ZO proteins may have structural or signaling functions by interact with 
multiple proteins found at the different junctions. ZO proteins may stabilize the different 
protein complexes by tethering them to the actin cytoskeleton. In addition, ZO-2 is also 
able to shuttle between the nucleus and the plasma membrane (Figure reprinted from 







Chapter 5: Materials and Methods 
 
5.1 Antibodies and Reagents 
The following commercial antibodies were used: rabbit polyclonal anti-ZO-1 and ZO-2 
(Zymed Laboratories, South San Francisco, CA), rat monoclonal anti-HA (Roche), 
mouse monoclonal anti-E-cadherin (Transduction Laboratories), goat polyclonal anti-
ARVCF (Santa Cruz), monoclonal mouse anti-human Cx45 (Chemicon), GM130 and 
EEA1 (Transduction Laboratories), Ac17 (Nabi et al., 1991), rabbit polyclonal anti-
calreticulin (ABR), mouse monoclonal anti-CD63 (Developmental Studies Hybridoma 
bank) and monoclonal anti-Ubiquitin antibody (Santa cruz). Rabbit polyclonal anti-
CLDN16 loop antibody was raised against the 1st extracellular loop (amino acids 52-66) 
(Biogenes, Germany). HRP-labeled secondary antibodies were from Jackson 
Laboratories and Pierce, fluorescently labeled (Alexa 488 and 594) secondary antibodies 
were from Molecular Probes.  
Unless otherwise noted, all reagents were from Sigma (St. Louis, MO). Stock solutions of 
proteosomal inhibitors were prepared in DMSO at the following concentrations and 
stored at -20˚C: 26 mM N-acetyl–leu-leu-norleucinal (ALLN; Calbiochem). Stock 
solutions of lysosomal inhibitors: Leupeptin (10 mg/ml in ddH20) and NH4Cl (stored in 
4˚C, 1 M; prepared in H2O). Other reagents were stored as concentrated stocks in -20˚C: 
cyclohexamide (2 mg/ml in ddH2O) and nacodazole (10 mg/ml; prepared in DMSO), 
sodium 4-phenylbutyrate (100 mM; Calbiochem), thapsigarin (10 mM; A.G. Scientific, 
Inc.) and cholesterol oxidase. Final concentrations were as follows: 100 µM ALLN, 20 
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µg/ml cyclohexamide, 10 µg/ml nocodazole, 50 µg/ml leupeptin, 10 mM NH4Cl, 1 mM 
sodium 4-phenylbutyrate; 1 µM thapsigarin and 2 units/ml cholesterol oxidase.  
5.2: Plasmids constructions 
5.2.1: Cloning of ZO and mutants 
To generate GST-ZO-1 PDZ fusion protein, a cDNA encoding the N-terminal three PDZ 
domains of human ZO-1 (amino acids 1-507) was cloned into pGEX4 to obtain a C-
terminal in frame fusion to the GST cDNA. To inactivate the binding capacity of the PDZ 
domains, overlapping primer pairs were used to generate substitutions in PDZ1 (R16E, 
F23H, I24E and I26E), PDZ2 (K174E, G187H, L188E and L190E) and PDZ3 (K417E, 
G422H, L423E and L425E). The insert was cloned in to pcDNA3 expression vector with 
a FLAG tag in its N-terminus and also into pGEX4T-1 vector (Amersham Biosciences). 
ZO2 PDZ1-3 and ZO-2 PDZ ∆NLS mutant were obtained from Dr. Gonzalez-Mariscal 
(Jaramillo et al., 2004). An expression vector encoding the cytosolic tail of E-cadherin 
fused to GST was as described (Muller et al., 1999).  
5.2.2: Cloning of Connexin 45 and mutant constructs 
The full-length human Cx45 plasmid was kindly provided by Dr. K. Willecke, Bonn, 
Germany and was further subcloned into pcDNA3 expression vector. 
5.2.3: Cloning of ARVCF and mutant constructs 
The full-length human ARVCF cDNA was obtained by RT-PCR of testis cDNA library 
(Clontech) using suitable primers covering the 5’ and 3’ coding region of the cDNA. The 
primers were designed to introduce a 5’ EcoR I restriction site followed by an N-terminal 
HA-epitope tag and a 3’ Xho I restriction site. To generate a mutant ARVCF with an 
inactivated PDZ-binding motif (ARVCF (∆P)), the codons for the C-terminal SWV were 
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changed to code for alanines. Mutants lacking the armadillo repeats (amino acids 336-
782) were generated in the background of the wild-type (ARVCF (∆A)) or PDZ-binding 
motif mutant (ARVCF (∆A∆P)) constructs. The ARVCF constructs were subcloned into 
the pCDNA1 vector for expression in mammalian cells and for in vitro translation. 
 
5.2.4:  Cloning of Cld16 and mutants 
The full-length human CLDN16 was obtained from RT-PCR from a human kidney 
library (Clontech) using suitable primers. To generate wild type and FHHNC mutants 
(Fig.48), suitable overlapping primers were designed with a HA tag at the N terminus and 
introducing the restriction sites EcoR1 and Xba1 and ligated into the pcDNA 3 
expression vector.  
 
5.3: Yeast Two-Hybrid Screen 
A yeast two-hybrid screen was performed using the N-terminal three PDZ domains of 
human ZO-1 (amino acids 1-507) fused in frame to the GAL4 DNA binding domain of 
the yeast expression vector pGBKT7 (Clontech) as bait and a pre-transformed mouse 17 
day embryo cDNA library fused to the GAL4 transactivation domain in the yeast 
expression vector pACT2 (Clontech). All experimental procedures were carried out 
according to manufacturer’s instructions. Clones were selected under low and high 
stringency dropout media conditions and tested for β-galactosidase activity. Plasmids 
from positive clones were isolated and the cDNA inserts sequenced, resulting in the 
identification of cDNAs encoding the C-terminal region of Cx45 and ARVCF. The 
interactions were re-tested by transforming the library with library plasmid encoding 
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amino acids 315-396 of Cx45, or a mutant in which the four C-terminal amino acids 
(SVWI) were mutated to alanine and library plasmid encoding 378-963 amino acids of 
ARVCF, or mutant in which the last three amino acids (SWL) were mutated to alanine 
with bait vectors carrying human ZO-1, canine ZO-2 (amino acids 1-591) or ZO-3 
(amino acids 1-467). Empty pGBKT7 or bait plasmid with laminin cDNA (Clontech) 
served as negative controls.  
 
5.4: Cell Cuture and Transfection of cells 
Madin-Darby canine kidney (MDCK) strain II cells and HEK 293 cells were cultured in 
Dulbecco’s modified Eagles medium (DMEM) supplemented with 10% fetal bovine 
serum and grown on permeable Transwell polycarbonate filter units (Costar) to obtain 
polarized cell monolayers or on coverslips. MDCK cells were plated at 4 x 105 cells 
filters and grown for 3-5 days with media changes everyday. 
MCF7 and HeLa cells were grown on Roswell Park Memorial Institute medium (RPMI) 
supplemented with 10% fetal bovine serum (FBS). 293T cells were cultured in DMEM 
with 10% FBS. All cells were cultured in 5% CO2 and 95% humidity. 
cDNAs in mammalian expression vectors were transfected into cells using Lipofectamine 
(Invitrogen) and maintained for 24-48h for transient expression. For stable expression, 
cells were treated with G418 (Calbiochem) for selection for 3-4 weeks until clones 
appear. Clones were picked cloning rings and grown. Positive clones were screened 
either with Western blot or immunofluorescence labeling.  
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5.5: Co-immunoprecipitation assays 
5.5.1:Cx45 coimmunoprecipitations  
Control and transfected MDCK cells expressing either wild type or mutant Cx45 were 
incubated for 30 min at 37˚C with 2 µg/ml cytochalasin D (Sigma) and then cooled on ice 
for 30 min. After washing with cold phosphate-buffered saline (PBS), cells were lysed on 
ice in lysis buffer containing 0.5% Triton X-100 in PBS supplemented with protease 
inhibitor cocktail. The post-nuclear supernatant was precleared with protein G Sepharose 
and ZO-1 was immunoprecipitated with 3 µg/ml of rabbit anti-ZO-1 antibody and protein 
G Sepharose (Amersham Biosciences). Immunoprecipitates were washed with lysis 
buffer 3-4 times, fractionated with SDS-PAGE and blotted onto PVDF membrane. Cx 45 
was detected using a monoclonal mouse anti-human Cx45 antibody (1:1000), followed 
by horseradish peroxides-labeled goat-anti-mouse antibody (1:3000; Bio-Rad) and 
chemiluminescence (Super Signal West Pico, Pierce). Autoradiographs were quantitated 
by densitometry. 
5.5.2: ARVCF coimmunoprecipitation 
Control MDCK cells or transfected cells expressing either wild type or mutant ARVCF 
were washed with cold PBS and lysed on ice in lysis buffer (0.5% Triton X-100 in PBS 
supplemented with a protease inhibitor cocktail). The post-nuclear supernatant was pre-
cleared and immunoprecipitated either with anti-ZO-1, anti-HA, or anti-E-cadherin 
antibodies and protein G Sepharose. Immunoprecipitates were washed with lysis buffer, 
fractionated by SDS-PAGE (10% acrylamide), blotted onto PVDF membranes and 
probed with antibodies to HA, ARVCF, ZO-1 followed by suitable HRP-labeled 
secondary antibodies and chemiluminescence.  
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5.5.3: Cldn16 coimmunoprecipitation 
MDCK cells stably expressing CLDN16 and the T233R mutant were lysed (0.5% Triton 
X-100 in PBS supplemented with a protease inhibitor cocktail). Immunoprecipitates were 
washed with lysis buffer, fractionated by SDS-PAGE (10% acrylamide), blotted onto 
PVDF membranes and probed with antibodies to HA or ZO-1, respectively, followed by 
suitable HRP-labelled secondary antibodies and chemi-luminescence.3.5: GST Pull-down 
assay 
 
5.6: GST Fusion Purification 
GST fusion constructs were transformed into BL21 E.coli. Bacterial cultures were grown 
to an O.D600 of 0.5-1 before induction with 0.4mM IPTG (Invitrogen) at 37˚C following 
which bacterial cells were pelleted and resuspended in GST sonication buffer (50mM 
Tris-HCl, pH 7.5, 50mM NaCl, 1mM EDTA and Complete protease inhibitor cocktail) 
(Roche). Cell lysis was achieved by sonication and the resulting lysates were clarified by 
centrifugation and applied to a Glutathione Sepharose 4B column (Amersham 
Bioscience). The column was then washed with GST sonication buffer and the bound 
GST fusion protein was eluted with 10mM reduced Glutathione (Sigma) in elution buffer 
(Tris-HCl and NaCl). The elutant was then dialyzed in PBS overnight using a Slide-A-
Lyzer (Pierce). The purified GST fusion proteins were quantified by Bradford and 
Coomassie blue staining using BSA as standard. 
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5.7: Pull-down assay 
5.7.1: ARVCF GST pull down assays 
 
GST beads carrying 2-10 µg of GST or GST fusion proteins were incubated with 5-10 µl 
of in vitro translated (Quick coupled T7 TNT; Promega, Madison, WI) wild type or 
mutant proteins in binding buffer (25 mM Tris, pH 7.5, 50 mM NaCl, 0.1% Tween-20 or 
Triton X-100, 20 mM MgCl2, and 1 mM dithiothreitol (DTT) for GST ZO-1 PDZ fusion 
proteins or 20 mM HEPES, pH 7.9, 60 mM NaCl, 6 mM MgC12, 8.2% glyercine, 0.1 
mM EDTA, and 0.5% CHAPS for GST-E-cadherin tail fusions) for 2h at 4˚C. The beads 
were washed with washing buffer (25 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% 
Tween-20 or TritonX-100, 20 mM MgCl2, and 1 mM DTT for GST ZO-1 PDZ fusion 
proteins or 20 mM Tris-HCl, pH 8.8, 100 mM NaCl, 1mM EDTA, 0.5% NP-40 for GST-
E-cadherin tail fusions), resuspended in SDS-PAGE sample buffer, and bound proteins 
analyzed by SDS-PAGE, autoradiography, and densitometry  
5.7.2: Cldn16 pull down assays 
Peptides corresponding to the 11 C-terminal amino acids of wild type or T233R mutant 
CLDN16 were custom synthesized and coupled to Dynabeads (Dynal) by Biogenes. 
Labeled PDZ domains of ZO-1, ZO-2 and ZO-3 were generated by in vitro transcription 
and translation (Quick Coupled T7 TNT; Promega) in the presence of radioactive 
methionine. Between 5-10 µl of the in vitro translated products were incubated with 
peptide-coupled Dynabeads (2-10 µg peptide) for 2 h at 4˚C in binding buffer (25 mM 
Tris, pH 7.5, 50 mM NaCl, and 0.1 % Tween-20; or Triton X-100, 20 mM MgCl2, and 1 
mM DTT). Beads were then rinsed with washing buffer (25 mM Tris, pH 7.5, 150 mM 
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NaCl, and 0.1 % Tween-20; or Triton X-100, 20 mM MgCl2, and 1 mM DTT) and were 
resuspended in SDS-PAGE sample buffer. Bound PDZ domains were analyzed by SDS-
PAGE and autoradiography. For competition experiments, in vitro translated PDZ 
domains were pre-incubated with 100 mM uncoupled wild type or T233R peptides before 
addition to the beads. 
 
5.8: Immunofluorescence Labeling 
MDCK cells grown on glass cover slips or 0.4 µm Transwell filters (Costar) were fixed 
with either cold methanol (2.5 min; -20°C) or PFA (3.7%; 30 min) and, in the case of 
PFA fixation, permeabilized with Triton X-100 (0.2% in PBS). After blocking in 10% 
goat serum (GibcoBRL), cells were incubated with monoclonal mouse anti-human Cx45 
antibody (Chemicon) in the case of Cx45 experiments and rat anti-HA, rabbit anti-ZO-1 
or monoclonal mouse anti-E-cadherin antibodies (5µg/ml) for ARVCF-related 
experiments, followed by suitable, fluorescently labeled secondary antibodies (1:1000; 
Molecular Probes). Images were acquired using a confocal laser scanning microscope 
(BioRad) and IMARIS software (Bitplane). 
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5.9: Calcium-switch and cell-cell contact detection protocol 
Opening and resealing of TJs and AJs was essentially carried out as described (Lawrence 
et al., 2002). Briefly, filter grown MDCK cells were incubated for 45 min at 37°C in 2 
mM EDTA in PBS to chelate calcium. Cells were then washed and either fixed or 
incubated for 2 hrs at 37°C in complete media prior to fixation.  
Cell-cell adhesion analysis was carried out in MCF7 cells. A day after transient 
transfection, MCF7 cells were plated on coverslips and contact formation was observed. 
5.10: Blot overlay 
In vitro-translated ARVCF or ARVCF (∆P) (20-50 µl of TNT reaction) was fractionated 
by SDS-PAGE and transferred to PVDF membranes. Blots were incubated with purified 
GST-ZO-1 PDZ domain fusion proteins (75 nM), followed by mouse anti-GST antibody 
and HRP-labeled goat anti-mouse antibody in PBS with 0.2% Tween 20.  
5.11: Cytochalasin D treatment for ARVCF or mutant transfected 
cells 
Cells were incubated with 20 µg/ml cytochalasin D (Sigma) for 1h at 37˚C in DMEM 
culture media and then washed with ice cold PBS and processed for co-
immunoprecipitation or immunofluorescence labeling as described above. Actin 
cytoskeleton disruption was confirmed using rhodamine-phallodin labeling. 
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5.12: Endocytosis/ Internalization of CLDN16 and FHHNC 
mutants 
To monitor cell surface expression or internalization, HeLa or MDCK cells transiently 
transfected with wild type or mutated CLDN16 were incubated with rabbit anti-CLDN16 
loop antibody in RPMI or DMEM media for 1 h at 37˚C. For competition experiments, 
the rabbit anti-CLDN16 loop antibody was pre-incubated with peptides used to raise the 
antibody at 100 µM excess for 1h on ice before adding to untransfected or CLDN16 
transfected cells. These cells were later washed on ice with ice cold PBS containing 0.9 
mM CaCl2 and 0.5 mM MgCl2. Surface bound or internalized anti-CLDN16 loop 
antibody was visualized with labeled goat anti-rabbit Alexa 488 secondary antibodies. 
5.13: 20˚C block and cyclohexamide experiments 
Wild-type and mutated CLDN16 constructs were transiently transfected in HeLa cells 
and after 24h these cells were subjected to 20˚C incubation for 3hrs (VanSlyke et al., 
2000). The cells were then either fixed or transferred to 37˚C in the presence of 20 µg/ml 
cyclohexamide (Sigma) and ALLN (Sigma) for 3-6 h, before fixation and processing for 
immunofluorescence staining using antibodies to HA, GM130 or CD63.   
5.14: Nocodazole treatment 
HeLa cells transfected with cDNAs for wild-type or mutated CLDN16 were incubated 
with 10 µg/ml of nocodazole for 30 min and washed and stained using antibodies to HA 
and GM130.  
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5.15: Pharmacological inhibition of endocytosis 
To test for a role of clathrin-mediated endocytosis in the internalization of CLDN16, 
pharmacological inhibitors, hypertonic sucrose and cytosolic acidification treatments 
were used. HeLa cells transfected with CLDN16 were incubated with anti- CLDN16 loop 
antibody in RPMI or in RPMI containing 0.4 M sucrose and incubated for 1h at 37˚C. 
Cytosolic acidification was done with complete RPMI containing 20 mM MES and 
succinic acid, pH 5.5 incubated for 1 h. To inhibit cavaeloe-mediated endocytosis, cells 
were treated with anti-CLDN16 loop antibody and cholesterol oxidase (2 units/ml) in 
RPMI media. Treated cells were washed and processed for immunofluorescence. 
To test the effect of dynamin and the K44A mutant on CLDN16 endocytosis, HeLa cells 
were co-transfected with cDNAs for CLDN16 and wild type or K44A dynamin mutant.  
5.16: Proteosomal Degradation Western Analysis 
Transiently transfected 293T cells were incubated with proteosomal (ALLN or LLNL) 
inhibitors in the absence or presence of cyclohexamide. 293T cells were washed and 
harvested. The protein concentration of extracts were quantitated with Bradford assay and 
50-100 µg of the protein lysates were separated on SDS-PAGE analysis and blotted onto 
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